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Summary
Bunyamwera virus (BUNV) is the prototype of the family Bunyaviridae. It has a
tripartite genome consisting of negative sense RNA segments called large (L),
medium (M) and small (S). The S segment encodes the nucleocapsid protein (N) of
233 amino acids. The N protein encapsidates all three segments to form
transcriptionally active ribonucleoproteins (RNPs). The aim of this project was to
determine the domain map of BUNV N protein.
To investigate residues in BUNV N crucial for its functionality, random and site-
specific mutagenesis were performed on a cDNA clone encoding the BUNV N
protein. In total, 102 single amino acid substitutions were generated in the BUNV N
protein sequence.
All mutant N proteins were used in a BUNV minigenome system to compare their
activity to wt BUNV N. The mutant proteins displayed a wide-range of activity, from
parental-like to essentially inactive. The most disruptive mutations were R94A,
I118N, W134A, Y141C, L177A, K179I and W193A.
Sixty-four clones carrying single substitutions in the BUNV N protein were used in the
BUNV rescue system in an attempt to recover viable mutant viruses. Fifty
recombinant mutant viruses were rescued and 14 N genes were nonrescuable.
The 50 mutant viruses were characterized by: titration, protein labelling, western
blotting, temperature sensitivity and host-restriction. Mutant viruses displayed a wide-
range of titers between 103-108 pfu/ml, and three different plaque sizes large,
medium and small. Protein labelling and western blotting showed that mutations in
the N gene did not affect expression of the other viral genes as much as affecting N
protein expression. It was demonstrated that single amino acid substitutions could
alter N protein electrophoretic mobility in SDS- PAGE (e.g. P19Q and L53F).
Temperature sensitivity tests showed that recombinant viruses N74S, S96S, K228T
and G230R were ts, growing at 33˚C but not at 37˚C or 38˚C, while the parental virus
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grew at all temperatures. Using the northern blotting technique, mutant viruses N74S
and S96G were shown to have a ts defect in genome-synthesis (late replication
step), while mutant viruses K228T and G230R had a ts defect in antigenome-
synthesis (early replication step).
Host-restriction experiments were performed using 5 different cell lines (Vero-E6,
BHK-21, 2FTGH-V, A549-V and 293-V). Overall, the parental virus grew similarly in
all cell lines. Likewise, the majority of mutant viruses follow this pattern except mutant
virus Y23A. It showed a 100-fold reduction in titer in 2FTGH-V cells. Comparing the
ratios of intracellular and extracellular particles revealed that only 15% of the total
virus particles of mutant Y23A was released as extracellular particles compared to
30% of the parental virus.
Fourteen N genes were nonrescuable. They were characterized by (i) their activity in
the BUNV minigenome system, (ii) their activity in BUNV packaging assay, (iii) their
ability to form multimers, (iv) their ability to interact with L protein, and (v) their impact
on RNA synthesis.
In summary, BUNV N protein was shown to be multifunctional and involved in the
regulation of virus transcription and replication, RNA synthesis and assembly, via
interactions with the viral L polymerase, RNA backbone, itself or the viral
glycoproteins.
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Chapter 1. Introduction
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Chapter 1. Introduction
1.1. General introduction to bunyaviruses
The Bunyaviridae is one of the largest families of RNA viruses, containing more than
300 serotypes (Elliott et al., 2000). The genome consists of three segments of
negative sense RNA: the L (large), encodes L protein, the M (medium) encodes two
glycoproteins (Gn and Gc) and the S (small) expresses nucleocapsid (N). Viruses of
some genera also express non-structural proteins either on the M segment (called
NSm) or the S segment (called NSs). On the basis of serological and morphological
characteristics, bunyaviruses are classified into five genera, Orthobunyavirus,
Hantavirus, Nairovirus, Phlebovirus and Tospovirus (plant-infecting viruses)
(Table1.1).
The majority of these viruses are arthropod-borne with the exception of the
hantaviruses which are transmitted by rodents. Virions have a spherical or
pleomorphic shape, of 80-120 nm in diameter. On the outer surface are the two
glycoproteins, Gn and Gc, which are embedded in the lipid bilayer envelope. The
envelope, about 5nm thick, is usually derived from Golgi membranes of the host cell.
The L, M and S segments are found within this envelope. Each segment is
encapsidated by N protein and is associated with L polymerase to form
ribonucleocapsids (RNP). Hence, three RNPs are found inside the virion (Figure1.1).
Under the electron microscope, the RNPs are visualized as circular forms due to the
complementarity of the 3’ and 5’ ends of the genome RNA (Figure1.2) to form a pan-
handle structure (Hewlett et al., 1977). Typically, a bunyavirus virion (based on
Uukuniemi virus (UUKV) estimates) consists of 2% RNA, 7% carbohydrates, 58%
protein and 33% lipid. The virion density in sucrose is 1.16 - 1.18 g/cc, and in CsCl is
1.20 - 1.21 g/cc. Virions have sedimentation coefficients of 400 to 500 S (Obijeski
and Murphy, 1977).
The orthobunyavirus Bunyamwera virus (BUNV) is the prototype of its genus and the
entire Bunyaviridae family. BUNV is significantly an important tool for the study of
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Table 1.1. Classification of Bunyaviridae (Elliott et al., 2000).
Genus Serogroup Representative Virus
19 groups containing 177
viruses. Example groups :
Bunyamwera group (32)
Germiston and Bunyamwera viruses
(human pathogens) , and Cache Valley
virus (pathogen of cattle and sheep)
California group (14)
California encephalitis, La Crosse and
snowshoe hare viruses
(human pathogens)
Orthobunya-
virus
Simbu group (25)
Aino, Simbu and Oropouche Viruses
(humans and animals pathogens)
One group containing 10
viruses.
Hantavirus
Hantaan group
Hantaan, Puumala, Seoul and Sin Nombre
viruses (human pathogens)
7 groups containing 34
viruses Example groups :
CCHF group (3)
Crimean-Congo hemorrhagic fever virus
(human pathogenic)Nairovirus
Nairobi Sheep disease
group
(2)
Dugbe and Nairobi sheep disease viruses
(humans and animals pathogenic)
3 groups containing 51
viruses. Example groups :
Sandfly fever group (23)
Sandfly fever Naples , Punta Toro and Rift
Valley fever viruses
(human pathogenic)
Phlebovirus
Uukuniemi (12) Section 1.01 Uukuniemi virus
2 groups containing 4
viruses
Tomato Spotted Wilt (3)
Tomato spotted wilt virus
(plant pathogen)Tospovirus
Impatiens necrotic spot (1)
Impatiens necrotic spot virus
(plant pathogen)2
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Figure 1.1. Schematic of bunyavirus particle.
The bunyavirus virion is 80-120nm in diameter. The three segments (L, M and S)
within the viral envelope are encapsidated by the N protein and are associated with L
polymerase to form RNPs. The two glycoproteins (Gn and Gc) are inserted into the
viral envelope. Under the electron microscope, the RNPs are visualized as circular
forms due to the complementarity of the 3’ and 5’ ends of the genome RNAs to form
a pan-handle structure (Figure was provided by R.M.Elliott).
N Protein
L Protein
Gc Protein
Gn Protein
S
M
L
Lipid envelope
RNA
RNP
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Orthobunyavirus 3’ UCAUCACAU---
5’ AGUAGUGUG---
Hantavirus 3’ AUCAUCAUCUG---
5’ UAGUAGUAUGC---
Nairovirus 3’ AGAGUUUCU---
5’ UCUCAAAGA---
Phlebovirus 3’ UGUGUUUC---
5’ ACACAAAG---
Tospovirus 3’ UCUCGUUA---
5’ AGAGCAAU---
Figure 1.2. Consensus terminal sequences of the S, M, and L segments of
bunyaviruses (taken from Elliott, 1996).
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bunyaviruses for several reasons: it is relatively non-pathogenic, grows in many
different cell lines, and produces high titres. The emergence of bunyaviruses has
increased recently due to higher levels of travelling, animal transportation and
globalisation. Rift Valley fever virus (RVFV) was previously restricted to the African
continent, however, the recent outbreak of RVFV in Yemen and Saudi Arabia, is
strong evidence of the ability of bunyaviruses to spread into new geographical areas
(Balkhy and Memish, 2003).
1.2. Bunyaviruses and diseases
One of the most fascinating aspects of bunyaviruses is their ability to replicate in both
vertebrate and invertebrate cells, with different outcomes of infection. In mammalian
cells the infection is lytic and leads to cell death, whereas in invertebrate cells there is
no cytopathology, and while high titres of virus are released early in infection, later
the cells become persistently infected (Scallan and Elliott, 1992).
Members of the Bunyaviridae family cause several syndromes including:
hemorrhagic fever, encephalitis and fatal respiratory syndrome (Table1.2).
Hantaviruses are considered to be one of the most important among bunyaviruses
due to their ability to cause two types of human illnesses, hemorrhagic fever with
renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). Among adults
and children around 100 cases per year have been recorded for La Crosse virus
(LACV) since it was discovered in 1960. It causes encephalitis in children (Gonzalez-
Scarano et al., 1984). Another important disease is Crimean-Congo hemorrhagic
fever (CCHF) which is caused by a nairovirus via a tick vector (Whitehouse, 2004).
Bunyamwera virus causes a febrile illness with rash in children (Elliott, 1997).
Moreover, RVFV causes different diseases in human such as febrile, retinal and fatal
hemorrhagic diseases. It also causes abortion in domestic ruminants. RVFV is
transmitted to humans and animals by sandflies or mosquitoes.
Globally, several bunyavirus epidemics have been recorded. In Egypt, 200,000
patients suffered from RVFV infection in 1977 and more than 200 human deaths
were reported in Yemen and Saudi Arabia during a RVFV outbreak (Balkhy &
Memish, 2003). In Moravia more than 20% of febrile diseases diagnosed were due to
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GENUS/VIRUS HOST:DISEASE VECTOR DISTRIBUTION
Orthobunyavirus
Oropouche Human: fever Midge SA
La Crosse Human: encephalitis Mosquito NA
Tahyna Human: fever Mosquito Europe
Akabane Cattle: abortion Midge Africa, Asia
Cache Valley Sheep: congenital defects Mosquito NA
Hantavirus
Hantaan-like viruses Human: severe HFRS Rodent Eastern Europe
Asia
Seoul-like viruses Human: moderate HFRS Rodent Worldwide
Puumala-like viruses Human: mild HFRS Rodent Western Europe
Sin Nombre-like virus Human: HPS Rodent NA & SA
Nairovirus
Crimean-Congo
hemorrhagic fever
Human: hemorrhagic fever Tick Eastern Europe,
Africa, Asia
Nairobi sheep disease Sheep, goats fever,
hemorrhagic, gastroenteritis
Tick E. Africa
Phlebovirus
Rift Valley fever Human: encephalitis,
hemorrhagic fever, retinitis.
Domestic ruminants: necrotic
hepatitis, abortion
Mosquito Africa
Sandfly fever Naples Human: fever Phlebotomine
fly
Europe, Africa,
Tospovirus
Tomato spotted wilt virus Over 650 plant species Thrips Worldwide
Table1.2. The most important diseases due to members of the Bunyaviridae (taken
from Elliott, 1997). NA, North America; SA, South America. HFRS, hemorrhagic fever
with renal syndrome; HPS, hantavirus pulmonary syndrome.
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Tahyna bunyavirus (TAHV) infection (Gonzalez-Scarano et al., 1996). In Brazil,
Oropouche virus (OROV) infects thousands of people (Pinheiro et al., 1981). In
China about 100,000 patients are infected by hantaviruses annually (Elliott, 1997). In
plants, tomato spotted wilt virus (TSWV), a member of Tospovirus genus, infects
more than 650 plant species with different symptoms (Elliott et al., 2000).
1.3. Coding Strategies
1.3.1. The S segment
The S segment of viruses of the Bunyaviridae encodes the nucleocapsid N protein
(Figure1.3a). In addition to the N protein, the S segment of orthobunyaviruses,
phleboviruses and tospoviruses encodes a non-structural protein called NSs. In
orthobunyaviruses, NSs is expressed in an overlapping reading frame using an
alternative start codon to N from the same mRNA (Elliott, 1989b, Fuller and Bishop,
1982). In phleboviruses and tospoviruses, NSs is encoded by an ambisense strategy
(de Haan et al., 1990) (Figure1.4). The N protein is encoded within the negative-
sense half of the ambisense S RNA segment. The ambisense genomic segment
serves as a template for synthesis of antigenomic RNA that acts as a template for the
transcription of a second mRNA encoding non-structural protein NSs.
1.3.1.1. Nucleocapsid protein
The nucleocapsid protein of viruses of Bunyaviridae (size range 26-50 kDa) is the
most abundant protein in virions and infected cells. The primary function of N protein
is to encapsidate and protect the viral genome. The RNP of bunyaviruses is relatively
resistance to digestion by RNase (Hacker et al., 1989; Kolakofsky and Hacker, 1991;
Osborne and Elliott, 2000). The N protein is the major antigen, targeted by the
humoral immune response during infection of Dugbe virus (El-ghorr et al., 1990),
PUUV (Vapalahti et al., 1995) and TSWV (de Avila et al., 1990). Neither hantaviruses
nor nairoviruses encode NSs, but, they encode the largest N protein in Bunyaviridae
viruses 48 and 50kDa respectively.
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High homology of the N protein within viruses from the same genus was reported
whereas low homology was observed between the N proteins of viruses from
different genera. For example, Bunyamwera serogroup viruses showed
approximately 62% identity between N proteins and approximately 40% identity was
observed with viruses in the California serogroup (Dunn et al., 1994; Elliott, 1995).
Alignment of the N protein of 19 orthobunyaviruses from 3 serogroups (Bunyamwera,
California and Simbu) demonstrates highly conserved regions in the middle and in
the C-termini of the N proteins (Elliott, 1996) (Figure 1.5). Three phleboviruses
display 39.5% identity in the N protein (Marriott and Nuttall, 1992) and the N proteins
of five hantaviruses display 50% homology (Schmaljohn, 1996).The C-termini of
hantavirus N proteins showed identities of 85% (Schmaljohn, 1996b). The N protein
of some nairoviruses reveals 80% identity in the C-termini (Marriott and Nuttall,
1992).
1.3.1.2. NSs protein
Orthobunyaviruses, phleboviruses and tospoviruses are the only viruses of the family
which encode NSs protein. There is no homology between NSs proteins from
different genera and within viruses from the same genus, the similarity is lower than
N protein. The size of NSs protein ranges from 11 to 52 kDa. Using a bunyavirus
rescue system, a BUNV lacking NSs (BUNdelNSs) virus was generated (Bridgen et
al., 2001). BUNdelNSs virus showed reduced shut-off in mammalian cells compared
to wt BUNV. Furthermore, BUNdelNSs virus displayed a high induction of interferon
(IFN) whereas wt BUNV does not. Upon infection with BUNdelNSs, cellular mRNA
which encodes IFNβ was detected but not with wt BUNV. The NSs of BUNV was
found to postpone cell death by inhibiting interferon responsive factor-3 (IRF-3)
mediated apoptosis (Kohl et al., 2003). Thomas et al. (2004) found that BUNV NSs
protein inhibits phosphorylation of cellular RNA polymerase II. A nonfatal human
isolate of RVFV, designated clone 13, that expresses only 31% of the NSs ORF, was
characterized (Muller et al., 1995). In interferon-deficient Vero cells clone 13 grows
well, but grows poorly in interferon–competent cell lines. In mice lacking IFN
receptors clone 13 was highly virulent and caused death within 2 days. In common
with BUNdelNSs virus, clone 13 was a good inducer of INF, compared to wt virus.
RVFV NSs protein caused host transcription inhibition (Billecocq et al., 2004).
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Recently, the NSs of RVFV was shown to be disruptive to cellular RNA synthesis
through interaction with cellular transcription factor TFIIH (Le May et al., 2004).
TFIIH, one of the important transcription factors, consists of p44 and XPB proteins.
The NSs of RVFV interacts with both p44 and XPB, preventing the assembly of TFIIH
subunits which in return reduce concentration of TFIIH available for transcription.
Leonard et al. (2006) found that inhibition of both host transcription and interferon
response was linked to interaction of BUNV NSs protein with the MED8 protein (part
of Mediator, a multiprotein complex necessary for mRNA synthesis). The interaction
domain of MED8 mapped to the C-terminal aa 88-93 of the NSs protein. The NSs
protein of UUKV interacts with 40S ribosomal subunit but the mechanism of this
interaction has not yet been determined (Simons et al., 1992).
The inhibition of RNA silencing by NSs of LACV (Soldan et al., 2005) and TSWV
(Takeda et al., 2002) was reported. The cellular machinery of several eukaryotic
organisms such as mammals, plants and insects produces 21-25 nucleotides long
RNAs called small interfering RNAs (siRNA) which target degradation of viral RNAs
(Denli and Hannon, 2003). In the BUNV minigenome system, the NSs of BUNV,
Guaroa and Lumbo orthobunyaviruses inhibits the viral polymerase activity (Weber et
al., 2001). Similar BUNV minigenome utilizing mosquito cells was developed (Kohl et
al., 2004b). In the latter system NSs does not inhibit the viral polymerase.
Conversely, the NSs of RVFV was found to increase reporter gene activity (Ikegami
et al., 2005).
1.3.2. The M segment
The M segment encodes two glycoproteins Gn and Gc, based on their position in the
polyprotein precursor. The M segment of viruses from the Orthobunyavirus,
Phlebovirus (except UUKV (Calisher, 1996)) and Tospovirus genera encodes a non-
structural protein called NSm (Figure1.3b).
1.3.2.1. Glycoproteins
Bunyaviridae glycoproteins are type I membrane-spanning proteins, with the C-
terminus of each facing towards the cytoplasm and the N-terminus oriented toward
the ER (reviewed by Pettersson & Melin, 1996). The size of Gn ranges from 62-
Chapter 1. Introduction
10
110kD while the the Gc ranges from 32 to 67kD. Both glycoproteins are preceded by
a signal peptide for translocation through the endoplasmic reticulum (ER) membrane
(Eshita and Bishop, 1984; Lees et al., 1986; Schmaljohn et al., 1987; Arikawa et al.,
1990; Pettersson & Melin, 1996). The presence of highly conserved cysteine
residues in both Gn and Gc implies that disulfide bridge formation is a secondary
structure determinant in these glycoproteins. Both glycoproteins are glycosylated at
asparagine residues (at N60 in Gn and N624 and N1169 in Gc for BUNV) (Shi et al.,
2005). The Gn of most bunyaviruses contains a Golgi retention signal and co-
expression of both glycoprotiens is required for their transportation to the Golgi
(Pettersson and Melin, 1996; Shi et al., 2004). In other words, Gn can localize at the
Golgi apparatus by itself while Gc on its own is unable to, unless it is co-expressed
with Gn (Lappin et al., 1994). Interactions of both glycoproteins in some hantaviruses
are required for Golgi localisation. When both glycoproteins were expressed
individually, they were retained in the ER, but coexpression of both Gn and Gc from
separate plasmids resulted in localisation of both to the Golgi (Ruusala et al., 1992;
Shi and Elliott, 2002). The Gn retention sequences of different bunyaviruses have
been mapped. For example, the transmembrane domain of BUNV Gn protein (Shi et
al., 2004), the transmembrane domain and cytoplasmic tail of RVFV Gn protein
(Gerrard and Nichol, 2002), and the cytoplasmic domain of UUKV Gn protein
(Andersson et al., 1997). Heterodimerization of Gn and Gc of Hantaan, Uukuniemi
and Punta Toro viruses in the ER was observed (Chen and Compans, 1991; Persson
and Pettersson, 1991).
Although the polyprotein precursor has not been isolated from infected cells, the full
length precursor has been detected by in vitro translation systems (Suzich and
Collett, 1988). This observation can be explained as rapid co-translational cleavage
of the polyprotein precursor (Nakitare and Elliott, 1993). To date, only one enzyme
has been reported to be involved in processing CCHFV Gn protein, the cellular SK-1
protease (Vincent et al., 2003). Amino acids 860 -1442 of LACV Gc are crucial in
fusion and entry (Plassmeyer et al., 2006) and similar regions were found in the E1
fusion protein of two alphaviruses, Sindbis and Semliki Forrest viruses.
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1.3.2.2. NSm
The NSm protein of orthobunyaviruses is encoded from the middle of the genome,
while in phleboviruses is encoded from the 3` end (Figure 1.3b). The NSm of
tospoviruses is translated from mRNA transcribed from the antigenome RNA while
the glycoproteins are transcribed from mRNA encoded on the genome RNA as they
utilize an ambisense coding strategy. BUNV NSm is encoded as part of a precursor
polyprotein. Its localisation in the Golgi complex has been reported (Nakitare and
Elliott, 1993). The function of the NSm of orthobunyaviruses and phleboviruses is
unclear. Although the NSm protein of BUNV is targeted to the Golgi, BUNV and
LACV NSm proteins have no role in Gn and Gc localization in the Golgi (Bupp et al.,
1996, Lappin et al., 1994). The NSm protein of TSWV was shown to be involved in
the transport of RNPs via plant plasmodesmata (Storms et al., 1995). Significant
reduction in Gc protein glycosylation occurred when NSm protein was deleted from
the polyprotein (Shi and Elliott, 2004). The N-terminus (aa 300-350) of BUNV NSm is
required for virus assembly while the C-terminal region (aa 460-480) is an integral
signal for the Gc glycoprotein (Shi et al., 2006).
1.3.3. The L segment
The L segment of bunyaviruses encodes the RNA-dependent RNA polymerase or L
protein (Figure1.3c). The L segment of orthobunyaviruses, hantaviruses and
phleboviruses is about 6500 nucleotides (Elliott, 1989a, Elliott et al., 1992; Muller et
al., 1994, Schmaljohn, 1990). Tospoviruses L segment is 8897 nucleotides in length
and the longest L segment is 12225 nucleotides in Dugbe virus (DUGV) a nairovirus.
Although the L segment of bunyaviruses contains one open reading frame (ORF),
other smaller ORFs are predicted in the genome of orthobunyaviruses and
hantaviruses; however, no additional product has been reported (Elliott, 1989a,
Schmaljohn, 1990).
1.3.3.1. L protein
The RNA-dependent RNA polymerase is a structural protein involved in virus
transcription and replication in concert with nucleocapsid N protein (Dunn et al.,
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(a) S segment
5’3’
N26kDa
961nt
NSs11kDa
5’3’ 1696nt
N48kDA
Orthobunyavirus
BUNV
Hantavirus
HTNV
5’3’ 1712nt
N50kDA
Nairovirus
DUGV
5’3’ 1720nt
N28kDA
NSs 32kDA
Phlebovirus
RVFV
5’3’ 2916nt
N29kDA
NSs 52kDA
Tospovirus
TSWV
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(b) M segment
5’3’ 4458nt
5’3’ 3616nt
Orthobunyavirus
BUNV
Hantavirus
HTNV
5’3’ 4888nt
Nairovirus
DUGV
Phlebovirus
RVFV
5’
3’ 2916nt
Tospovirus
TSWV
Gc
32kDa
NSm
18kDa
Gn
110kDa
Gn
70kDa
Gc
55kDa
Gn
35kDa
Gc
73kDa
5’3’ 3884nt
Gc
55kDa
Gn
62kDa
NSm
14kDa
5’3’ 3231nt
Gn
72kDa
Gc
67kDa
Phlebovirus
UUKV
Gc
46kDa
Gn
75kDa NSm
37kDa
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(c) L segment
5’3’ 6875nt
5’3’ 6530nt
247kDA
Orthobunyavirus
BUNV
Hantavirus
HTNV
5’3’ 12225nt
459DA
Nairovirus
DUGV
Phlebovirus
RVFV
Tospovirus
TSWV
259kDa
5’3’ 6423nt
238kDA
5’3’ 8897nt
332kDA
Genomic RNA
3’ end of mRNA
5’ cap of mRNA
Protein product
Figure 1.3. The coding strategies of bunyavirus genome segments. The
S segment (a), M segment (b), and L segment (c) (adapted from Elliott,
1996).
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][ [ ]3`
3`5`
5`
NSs (+)N (-)
S genomic RNA
Replication3`
N
Cap
Cap
N mRNA
Transcription
NSs mRNA
3`
NSs
S antigenomic RNA
Figure 1.4. Ambisense strategy of phieboviruses and tospoviruses S
segment. Viruses utilizing an ambi-sense codon strategy produce two
mRNAs, one is transcribed from the viral genomic RNA and a second is
produced from the viral antigenomic RNA (adapted from Wagner and
Hewlett, 2004).
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Figure 1.15. Alignment of 19 orthobunyavirus N protein sequences (taken from
Elliott, 1996). “Con” indicates conserved amino acids.
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1995; Blakqori et al., 2003; Flick et al., 2003a; Flick et al., 2003b; Ikegami et al.,
2005). The L protein of orthobunyaviruses, hantaviruses and phleboviruses is about
250kD. The L proteins of tospoviruses and nairoviruses are 332 and 459 kD
respectively. The L polymerase cleaves the cap of cellular mRNAs (cap snatching) in
order to prime the synthesis of S, M and L mRNAs. The process is similar to that
which occurs in influenza virus (Krug et al., 1979, Plotch et al., 1981). Subsequently,
extensions of 8 to 15 nucleotides are found at the 5` ends of the viral mRNAs that are
not templated from the genomic RNA segments by the virus (Collett, 1986, Duijsings
et al., 2001, Garcin et al., 1995, Gro et al., 1992, Jin and Elliott,1993a, Patterson and
Kolakofsky, 1984). Alignment of bunyavirus L proteins showed the presence of four
consensus motifs, A, B, C and D (Poch et al., 1989). Site directed mutagensis of
BUNV L protein revealed consensus amino acids in motifs A and C are crucial for the
functionality of L protein. Mutation at residue N1119G which is conserved among
orthobuyaviruses, hantaviruses and tospoviruses generated impaired L protein (Jin
and Elliott, 1992). Two motifs conserved between bunyavirus and arenavirus L
proteins were observed (Muller et al., 1994). Honig et al., (2004) predicted protease
and homology sequence to helicase motifs in CCHFV L protein. Phylogenetic
analysis of the L protein sequences of bunyaviruses revealed that the
orthobunyaviruses and tospoviruses are more closely related (Roberts et al., 1995).
1.4. The role of N proteins in the virus replication cycle
The primary function of the N protein of many viruses is to protect the viral genome
and antigenome from physical and chemical injuries, to prevent the formation of
secondary structure, and to form ribonucleocapsids (RNPs) in negative-sense viruses
that are transcriptionaly active. Furthermore, the N protein is suggested to regulate
the activity of the viral polymerase, switching from mRNA synthesis to antigenome
RNA synthesis. Moreover, lack of a matrix protein in bunyaviruses suggests that the
RNPs interact with the C-tails of Gn or Gc to promote virus assembly underneath the
Golgi membrane.
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1.4.1. Positive-sense RNA viruses
The encapsidation process has been described best in tobacco mosaic virus (TMV)
assembly (Figure 1.6). The genome RNA contains a stem-loop called the origin of
assembly sequence (OAS) ≈ 1kb from the 3’ end. Encapsidation is initiated when a
two layered disc aggregate of 34 coat protein subunits binds to this site on the RNA.
The OAS is inserted into the middle of the disc and melts to promote the rest of
genome interacting with coat protein. As a result, a conformational change occurs in
the discs converting them to a locked washer. The RNA genome is buried in the
centre of the disc as more proteins are added to the helix. Encapsidation of the
genome at the 3’ end is slower as the travelling loop needs to be threaded through
the central hole of the disc (Cann, 2005).
The N protein NCp7 of HIV-1 is involved in the annealing of the primer (tRNA) to the
virus genome to initiate synthesis of (-) strand DNA, viral genome encapsidation and
viral RNA dimerzation (Darlix et al., 1995). Furthermore, Berat et al., (1993)
demonstrated that the reverse transcriptase of HIV was regulated by N protein. NCp7
interacts with encapsidation signal, a stem-loop designated SL3, triggering packaging
of heterogenous sequences into virus-like particles (Hayashi et al., 1992). The core
proteins of several positive-strand plant viruses have been reported to bind
specifically or non-specifically to the RNA. Specific-binding to a secondary structure
in the 3’ UTR was observed in brome mosaic virus (Duggal and Hall, 1993), turnip
crinkle virus (Wei & Morris, 1991) and alfafa mosaic virus (Reusken et al., 1994). The
RNA-binding activity of N and the infectivity of infectious bronchitis virus (IBV) were
dramatically reduced when either of R76 or Y94 in the N-terminus of N protein was
substituted to Alanine (Tan et al., 2006).
1.4.2. Nonsegmented negative-strand RNA viruses
Vesicular stomatitis virus (VSV) and rabies virus (RV) (Rhabdoviridae) are
nonsegmented NSVs. Their genomes contain leader RNA sequences at the 3’ end
thought to be an encapsidation signal. In both viruses, the N protein shows affinity for
binding leader RNA 10-fold higher than that for nonviral RNA (Blumberg et al., 1983;
Yang et al., 1998). The N protein of VSV (49kD) was thought to bind to a region of
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Figure 1.6. Assembly of TMV.
Assembly commences when the orgin of assembly sequence (OAS) interacts
with a disc causing the disc to convert to a locked washer structure. Further
discs add to this structure so RNA is buried in the centre of the discs (Taken
from Cann, 2005).
OAS
3’ 5’
Disc Locked
washer
3’ 5’
3’ 5’
Travelling loop
RNA binds to disc
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the positive-sense leader RNA (14 -17nt) possessing an adenine at every third
position. This region was implied to be the encapsidation initiation signal (Blumberg
et al., 1983; Moyer et al., 1991; Smallwood and Moyer, 1993). RV N protein was
suggested to bind adenine-rich sequences (20-30nt) on the leader RNA (Yang et al.,
1998). Sendai virus (SeV) (Paramixoviridae) nucleoprotein NP protein (58kD)
showed a similar pattern of encapsidation to that of VSV N protein. SeV NP binds to
the 54nt leader RNA sequence specifically, commencing the encapsidation of virus
RNA (Lamb and Kolakofsky, 1996). The RV, VSV and SeV RNPs are resistant to
digestion by ribonuclease.
1.4.3. Segmented negative-strand RNA viruses
Influenza virus nucleoprotein (NP) (56kD) binds non-specifically to the RNA with high
affinity to the 5’ end (Bauding et al., 1994). It has been reported that NP protein binds
RNA with a dissociation constant 2 × 10-8 M (Yamanaka et al., 1990; Bauding et al.,
1994; Digard et al., 1999). In vitro translated NP displayed self-association in the
absence of RNA with a dissociation constant of approximately 2 × 10-7M (Elton et al.,
1999a).This suggests that the NP binds RNA, triggering multimer formation.
However, the replication efficiency reached the highest levels when even numbers of
NP formed, suggesting that NP forms dimers. In infected cells dimeric and trimeric
forms of NP were observed (Prokudina-kantorovich and Semenova, 1996). In vitro,
multimerisation of NP was observed (Ruigrok and Bauding, 1995). Possessing a
large number of positively charged residues of the NP implies that electrostatic
interactions between the NP and RNA-back bone occur (Baudin et al., 1994). In
contrast to RV, VSV and SeV, influenza virus RNPs are susceptible to digestion by
ribonuclease, implying that the RNA is located on the outside of the NP (Duesberg,
1969; Pons et al., 1969; Baudin et al., 1994).
1.5. Encapsidation of bunyaviruses
In infected cells both the viral genome and antigenome but not the mRNA were found
to be encapsidated by nucleocapsid N protein. Bunyavirus mRNAs are truncated by
approximately 100nt at the 3’ end compared to the antigenome RNA (Bishop et al.,
1983; Jin and Elliott, 1993a; Patterson and Kolakofsky). The expression of BUNV N
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protein as a 6-histidine-tagged fusion protein in Echerichia coli was reported by
Osborne and Elliott (2000). Using metal chelate chromatography the 6-histidine-
tagged-N protein was purified. To investigate binding of N protein in vitro an RNA
probe containing the 5’ terminal 32 and 3’ terminal 33 nt of the S sgment was used.
Gel electrophoretic mobility shift assay (GEMSA) showed multiple bands (ladder-like
profile) on the protein gel when high concentration of N was added to the riboprobe.
On the other hand, addition of low amount of N caused the formation of a single
band. This suggests that the formation of multiple higher RNA-N complexes is due to
binding of discrete N molecules to the riboprobe. RNA-N complexes were resistant to
degradation with up to 1μg of RNase A per ml. Moreover, the N protein binds
selectively to a predicted stem-loop at the 5’ end of the S RNA, suggesting that the
encapsidation initiation signal is located within 3-18 nt of the the 5’ end. Likewise, the
N protein of PUUV was expressed as a His-tagged forn in bacteria and the formation
of complexes with ssRNA was confirmed. When the concentration of tagged-N
increased, the complexes shifted further up the gel, indicating an increase in the size
of the complexes. PUUV N protein binds preferentially to double-stranded RNA (Gott
et al., 1993), suggesting a sequence-specific (panhandle or internal stem-loop) is
involved in the encapsidation. The central conserved region (aa 175 -217) of HTNV N
protein was found to mediate the interaction with genomic RNA (Xu et al., 2002).
Trimeric forms of SNV N protein bound specifically with high affinity the 3’ and 5’
ends of the S genomic RNA.
In contrast, the monomeric and dimeric forms of SNV N protein bound
semispecifically and were sensitive to high salt concentrations (Mir and Panganiban,
2004). Moreover, the trimeric form of N protein from Andes, PUU, Prospect Hill, SEO
and SN viruses recognised both individual homologous and other hantavirus
panhandles with high affinity. Dramatic affinity reduction was observed when
panhandles from the Orthobunyavirus, Nairovirus, Phlebovirus or Tospovirus genera
were used (Mir et al., 2006). This is an indication of genus-specific recognition of the
viral RNA panhandle by HTNV N protein.
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1.6. Interaction of bunyavirus N protein molecules
Bunyavirus N protein shows the ability to multimerise in the presence or absent of
viral RNA. Using a bacculovirus system, recombinant hantavirus N protein expressed
in insect cells, showed a nucleocapsid-like structure with sedimentation and
morphological characteristics similar to the viral N protein (Betenbaugh et al., 1995).
The N proteins of three hantaviruses (Tula, PUU and Prospect Hill) were cross-linked
and showed trimer formation (Alfadhli et al., 2001; Kaukinen et al., 2001). Kaukinen
et al. (2004) suggested that the hantavirus N protein forms multimers by association
of preformed trimers.
The first 10 and the last 17 residues of the BUNV N protein were found to be involved
in N multimerisation and protein functionalty in the BUNV minigenome system
(Leonard et al., 2005). Two deletion mutants in the N-terminal region of BUNV N
protein were generated by PCR, BUNNdel1-10 and BUNNdel11-20. The latter
mutant N displayed no activity in the minigenome system while mutant BUNdel1-10
showed very low activity and did not efficiently multimerize into oligomers beyond
dimers compared to the native N protein. Furthermore, BUNNdel217-233 mutant and
a double mutant lacking the first and the last 17 aa (called BUNdel1-10 and 217-233)
were generated. Both mutant N proteins were inactive in the minigenome system. A
cross-linking experiment showed that mutant BUNNdel217-233 was able to form
dimers and weakly trimers but not higher multimers. In contrast, the double mutant
(BUNNdel1-10 and 217-233) failed to form any multimers. This study suggested two
possible interaction sites at the N-terminus and C-terminus of BUNV N protein, and
also that BUNV N protein forms multimers from monomers built molecule by
molecule. Likewise, TSWV N protein formed multimers by addition of one N molecule
at a time (Uhrig et al., 1999). Several bunyavirus N protein domain maps have been
determined (Figure1.7). Both Tula and SNV N proteins interact through the N-
terminus and the C-terminus (Alfadhli et al., 2001; Kaukinen et al., 2003a; Uhrig et
al., 1999). The central region and the C-terminal region of Seoul virus (SEOV) and
Hantaan virus (HTNV) N proteins are involved in N molecule interactions
(Yoshimatsu et al., 2003). Amino acids 100 -120 and 330 - 405 play a crucial role in
PUUV N-N protein interactions (Lindgren et al., 2006).
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Figure 1.7. Linear domain maps of bunyavirus N proteins.The interaction
domains are indicated by red boxes (adapted from Kaukinen et al., 2003a).
TulaV
SNV
HTNV
SEOV
TSWV
BUNV
1 43 393 398 429
1
1
1
1
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PUUV
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1.7. Interactions of N protein with L polymerase
It has been suggested that the N protein of many negative-strand RNA viruse (e.g.
SeV, measles) regulates viral transcription and replication through interactions with L
polymerase. Bankamp et al. (1996) demonstrated that the N protein of measles virus
binds the viral polymerase, regulating N protein assembly and replication. Influenza
virus replication requires soluble NP, implicating possible interactions between the
NP and the polymerase complex (Beaton and Krug, 1986; Shapiro and Krug, 1988).
In contrast, virus transcription requires the binding of NP to the RNA (Medcalf et al.,
1999). The 3D structure of recombinant influenza RNP showed that the viral
polymerase binds directly to two monomers of the N protein (Martin-Benito et al.,
2001).
Qanungo et al. (2004) reported that the L polymerase of VSV exists in two distinct
complexes. The first consists of viral L and P proteins, and cellular translation
elongation factor-1α, heat-shock protein 60 and guanylyltransferase, and is involved
in the early synthesis of mRNA. The second complex is composed of L, P and N
proteins, and is involved in the production of full-length antigenome and genome
RNA.
The N protein of Kairi bunyavirus (KRI) does not function in the BUNV minigenome
assay in concert with BUNV L protein and BUNV minigenome, whereas the N
proteins of other bunyaviruses function almost as well as that of BUNV N protein
(Dunn et al., 1995). Furthermore chimeras were made between these N proteins,
fused at residues 96/97 and showed chimeras with the N-terminal half derived from
KRI were non-functional, whereas chimeras with the KRI C-terminal half of N worked
(RM.Elliott, personal communication).
1.8. Interactions of N protein with the glycoproteins
It is believed that interactions of the N proteins with the glycoproteins of several
viruses promote virus budding and assembly. A Recombinant Semliki Forest virus
(SFV), an alphavirus genome which lacks the N protein or the glycoproteins genes
failed to be released from cells (Suomalainan et al., 1992). Using the mammalian
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Figure 1.8. The CT domain map of Gn and Gc glycoprotein of BUNV (a). Possible
interactions of the RNPs with the cytoplasmic tail of Gn or Gc underneath the Golgi
membrane enhances virus assembly (b).
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two-hybrid system, the interaction of severe acute respiratory syndrome, coronavirus
(SARS-CoV) N protein with the membrane (M) protein was found to be an essential
event for coronavirus assembly. Amino acids 168 -208 of SARS-CoV N protein were
predicted to be the most important in this interaction (He et al., 2004). Moreover, the
latter region is also involved in N multimerization.
Influenza virus matrix protein M1 interacts with the RNP structure and the viral
glycoproteins to serve as a bridge between the different components (Nayak et al.,
2004). Using the UUKV minigenome rescue system, which enables recovery of virus-
like particles, mutational analysis showed that four amino acids in the Gn cytoplasmic
tail, M76, L79, T80 and R81 are crucial for RNP packaging. These residues are
thought to be involved in interactions with the nucleoprotein (Overby et al., 2007).
Recently, the cytoplasmic tails (CT) of BUNV glycoproteins were identified (Gn is 78
residues and 25 residues for Gc) (Figure 1.8a). Deletion of the entire CT of either Gn
or Gc disrupted the formation of virus-like particles (VLPs) in the BUNV packaging
system. Alanine-scanning mutants were generated in both Gn and Gc CTs and were
also tested in the BUNV packaging assay. It seems that the Gn CT domain has
relatively more impact on virus assembly (Shi et al., 2007). Lack of a matrix protein in
the bunyavirus virion suggests that possible interactions between the RNPs and the
CT of the glycoproteins underneath the Golgi membrane promotes virus assembly
and budding at the Golgi (Figure1.8b). The yeast two-hybrid system was used to test
this hypothesis, however no obvious interactions between the N protein and Gn or
Gc were detected (Leonard, 2005).
1.9. Replication cycle
The bunyavirus replication cycle can be divided into 4 stages: (i) adsorption and
entry, (ii) transcription and translation, (iii) replication of viral genome, and (iv)
budding, assembly, maturation and release (Figure1.9).
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Figure 1.9. General schematic of a bunyavirus replication cycle.
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1.9.1. Adsorption and entry
Bunyaviruses attach to cellular receptors via the viral glycoproteins. The Gc protein
of LACV is thought to be involved in recognition of mammalian cells (Grady et al.,
1983, Kingsford and Hill, 1983, Najjar et al., 1985), while the Gn protein is involved in
recognition of mosquito cells (Ludwig et al., 1991). Protease-treated LACV displayed
a high reduction in virus infectivity in mammalian cells due to the loss of the
glycoprotein spikes, when compared to nontreated virus (Obijeski et al., 1976a). The
infectivity of LACV for mammalian cells was also impaired when reacted with
monoclonal antibodies raised against Gc glycoprotein indicating that Gc is crucial in
virus attachment (Hacker et al., 1995; Kingsford and Hill, 1983). Kingsford and Hill
(1983) confirmed the importance of Gc in virus attachment when LACV Gc was
digested proteolytically while Gn was still intact. The virus again was unable to infect
mammalian cells. On the other hand, the infectivity of LACV increased in insect cells
when the Gc was removed, implying the involvement of Gn in invertebrate cell entry
(Ludwing et al., 1989). So far, three cellular receptors, the β3 intgrins protein utilized
by SNV and New York hantaviruses (Gavrilovskaya et al., 1998), and the g1 and g3
integrins utilised by non-pathogenic and pathogenic hantaviruses respectively
(Gavrilovskaya et al., 2002), have been identified. After attachment, the virus particle
is endocytosed leading to fusion of the viral envelope with the cellular endosomal
membrane. Bunyavirus Gc proteins have been classified as a class II fusion protein
(Gary and Gary, 2004). Fusion of the viral envelope with the endosomal membrane
of the endosome relies on acidic pH 6.3 (Gonzalez-Scarano et al., 1984; Hacker and
Hardy, 1997).
1.9.2. Transcription and translation
After release of the virus genome into the cytoplasm, the viral RNA-dependent-RNA
polymerase starts transcription using the RNA genome as a template to produce
mRNAs. The synthezised mRNAs which are not encapsidated (Bouloy et al., 1984),
contain a methylated cap at the 5`end derived from cellular mRNA by the viral
polymerase and are shorter than viral antigenome by 50-100 nucleotides at the 3`end
(Bouloy et al., 1984, Cash et al., 1979, Eshita et al., 1985, Pattnaik and Abraham,
1983). The mechanism of bunyavirus mRNA synthesis is akin to that of influenza
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viruses but with several exceptions. While bunyavirus mRNAs synthesis occurs in the
cytoplasm, production of influenza virus mRNAs takes place in the nucleus.
Bunyaviruses utilize only one enzyme (L polymerase), whereas, influenza virus uses
three enzymes (PB1, PB2 and PA). Viral mRNAs contain non-templated RNA of 8-17
nt at the 5`end (Bishop et al., 1983; Eshita et al., 1985; Kormelink et al., 1992;
Patterson and Kolakofsky, 1984).
All bunyavirus mRNA transcripts, from all five genera, contain preferential specific
nucleotides at the 3` terminus of the non-viral sequence (Simons and Pettersson,
1991; Jin and Elliott, 1993a; Jin and Elliott, 1993b; Garcin et al., 1995a; Duijsings et
al., 2001). Predominantly, BUNV transcript primers end with the sequence AGU3’ or
GGU3’ that match the 5’ end of viral RNA 5’…G/AGU AGU….3’ where the primer
sequence is highlighted in bold (Jin and Elliott, 1993a). It was proposed that the L
polymerase slips backward after initiation of mRNA synthesis leading to a repeat of
the first two or three bases on the template (Jin and Elliott, 1993b).The same
mechanism (prime and realign model) was suggested for the initiation of HTNV
genomic and mRNA synthesis (Garcin et al., 1995a) (Figure1.10). In the latter model,
the 3’ end of hantavirus genome is AUC AUC AUC, but primers were observed with a
strong preference only for G at the 3’ end. As a result, transcription commences by
annealing the priming G to the C at +3 on the genome template, elongating a few
bases and then realigning back 4 bases, relocating the G to position -1. Both in vitro
and in vivo experiments showed that LACV transcripts terminated at nucleotide 175
(Raju and Kolakofosky, 1986 ; 1987a). When this termination site was disrupted
read-through was observed. Termination sequences of bunyavirus S segments were
also predicted. For instance, LACV and SSHV contain U-rich termination sequences
whereas BUNV and GERV have GU-rich termination sequences (Patterson and
Kolakofosky, 1984; Eshita et al., 1985; Bouloy et al., 1990; Jin and Elliott, 1992). The
transciption termination signal of BUNV S segment mRNA was identified (Barr et al.,
2007). A six nucleotide sequence (3’-GUCGAC-5’) within a 33 nt region upstream of
the 5’ NTR of the S segment was found to play a crucial role in transcription
termination. When the latter region was disrupted, a second region of five nucleotides
downstream, which overlaps with the 6 nt major termination signal, was identified to
be a minor functional termination signal in the absence of the major termination
signal. The pentanucleotide sequence was also identified in the 5’ NTR of the BUNV
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Figure 1.10. Prime and realign model for initiation of HTNV transcription and
replication.
Initiation of mRNA synthesis (a). The 3’ terminal G of a capped, host-derived primer
anneals to the C at the +3 position and the primer is extended by a few nucleotides.
The nascent mRNA then realigns on the template, skipping the priming G to the -1
position. Initiation of genome RNA synthesis (b). RNA synthesis begins with a GTP
bound to the C at the +3 position. After a short elongation the nascent transcript is
realigned to generate a 5’ overhang that is to be cleaved later, leaving a
monophosphorylated U at the 5’ terminus (adapted from Garcin et al., 1995).
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L RNA and other orthobunyaviruses. The coupling of BUNV transcription and
translation to prevent truncated mRNA synthesis was demonstrated (Barr, 2007).
After viral mRNA production, mRNAs derived from the L and S segments are
translated by free ribosomes to generate the L and N proteins. The mRNAs
synthesized from the M segment are translated by ER-bound cellular ribosomes to
produce the glycoproteins (and for some bunyaviruses NSm protein).
1.9.3. Replication of the viral genome
Replication of bunyaviruses involves synthesis of full-length antigenome and genome
RNAs. At some point, the L polymerase switches from mRNA transcription to
antigenome synthesis using the genome as template (Figure1.11). The mechanism
of switching from mRNA to antigenome RNA synthesis is not known, however, the N
protein might play a role in this respect. Studies on VSV suggested that there is a
biochemical difference between the polymerase (transcriptase) that drives mRNA
synthesis from that responsible for antigenome and genome production (the
replicase) (Qanungo et al., 2004). The latter hypothesis was supported by the finding
that in vitro TSWV replication was enhanced by the addition of purified transcription
factor (FoTF) but not viral transcription (de Medeiros et al., 2005). Subsequently, the
antigenome is used as a template for production of genome RNA that can be utilized
for a second round of transcription and replication. Priming of hantaviruses
replication is similar to that described for transcription initiation (prime-and-realign) of
HTNV. To date, no viral RNA polymerase starts RNA synthesis with a pyrimidine
residue (C or U) but the 5’ base of HTNV is U, hence, prime-and-realign is a possible
mechanism (Garcin et al., 1995).
1.9.4. Budding assembly,maturation and release
The bunyavirus packaging mechanism is not clear. In general, bunyaviruses extrude
through the Golgi membranes. However, RVFV and some hantaviruses have been
observed to bud through the plasma membrane (Anderson and Smith, 1987;
Goldsmith et al., 1995; Ravkov et al., 1997). Furthermore, tospovirus assembly
occurs in the ER (Goldbach and Peters, 1996). Both glycoproteins Gn and Gc
together with N protein of UUKV accumulated within the Golgi, with the RNPs
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Figure 1.11. Transcription and replication of bunyavirus.
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localized underneath the Golgi membrane (Kuismanen et al., 1984). Possible
interaction between the cytoplasmic domain of Gc and or Gn and RNPs was
suggested due to a lack of matrix protein in the bunyavirus particle. Hetero-
dimerization of the glycoproteins is thought to take place in the ER, and they are then
transferred to the Golgi (Pettersson and Melin, 1996). Studying the influenza virus
packaging process revealed that the ratio of infectious to non-infectious particles
produced during the infection support random packaging hypothesis (Lamb and
Choppin, 1983). The ability of influenza virus to package more than 8 segments was
reported (Enami et al., 1991). Likewise, packing of bunyavirus genome might occur
randomly since the three segments are rarely purified from virions in equimolar ratios.
The most predominant segment in bunyavirus virions is the S segment, usually with
two copies, which explains the abundance of S RNA in the infected cell (Bouloy et
al., 1973-4; Obijeski et al., 1976b; Gentsch et al., 1977).
It is not clear by which mechanism the genome RNPs can be distinguished from the
antigenome RNPs. However, TSW, LAC, UUK virions contained small amounts of
antigenome RNPs (Kormelink et al., 1992b; Raju and Kolakofosky, 1989; Simons et
al., 1990). Interestingly, the antigenome RNPs that were found to be incorporated in
UUKV and TSWV were from the ambisense segments. This suggested that the
packaging signal is linked to the promoter sequence which is present in both genome
and antigenome segments as they utilize ambisense strategy. Budding in the Golgi
apparatus results in virus particles being contained within a small vesicle; the vesicle
migrates to the plasma membrane and the two membranes fuse, releasing the virus
to the exterior.
1.10. Effect of bunyavirus infection on host cells
Members of Bunyaviridae generally cause cytopathic infection in vertebrates and
plant hosts. However, hantavirus does not cause cytopathic effects in infected
mammalian cells (Kraus et al., 2004; Meyer and Schmaljohn, 2000). In invertebrates,
bunyaviruses cause persistent infection (Beaty and Calisher, 1991; Carvalho et al.,
1986; Wijkamp et al., 1993).
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1.11. Protein shut-off
Orthobunyaviruses and phleboviruses encode NSs protein that inhibits cellular
protein expression. Recombinant BUNV lacking the NSs showed reduced shut-off in
infected cells while wt BUNV shut-off host cells protein synthesis efficiently (Bridgen
et al., 2001). In wt BUNV infected cells, phosphorylation of the C-terminal of cellular
RNA polymerase II was impaired. When BUNdelNSs was used the previous
observation did not occur (Thomas et al., 2004). Likewise, the NSs of RVFV inhibits
cellular protein expression through interaction with the P44 subunit of transcription
factor TFII H (Le May et al., 2004) resulting in inhibition of host mRNA synthesis. The
C-terminal region of BUNV NSs protein was found to be involved in interaction with
cellular MED8 protein causing the inhibition of host transcription and the interferon
response (Leonard et al., 2005).
1.12. Bunyavirus and its arthropod vector
The life cycle of a mosquito-transmitted bunyavirus begins when the female mosquito
bites infected or viraemic vertebrate host. The virus then establishes infection and
replication in eipithelial midgut cells (Schmaljohn, 1996a). Release of virus from the
midgut cells results in infection of the salivary glands and the ovaries. Virus can then
be transmitted horizontally or vertically to another host. Bunyaviruses establish
persistent infection in mosquitoes and some theories to account for this have been
suggested. One is that high level of N protein leads to encapsidation of mRNA
(Hacker et al., 1989). Another suggestion is that defective-interfering (DI) RNA drives
the maintenance of persistent infection (Schmaljohn and Hooper, 2001). So far, it is
not clear how persistent infection occurs but the obvious observations are reduction
in viral replication and transcription in parallel with the presence of DI RNAs in
infected mosquito cells (Newton et al., 1981).
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1.13. Defective-interfering (DI) RNAs
DI RNAs are internally-deleted RNA molecules having intact 5’ and 3’ non-coding
regions of the parental virus. They are encapsidated, replicated and packaged by
themselves. They take advantage by being shorter than viral genome in respect of
replication and as a result interfere with viral genome replication. Bunyavirus DI
RNAs have been identified as originality from the L segment (Inoue-Nagata et al.,
1998; Patel and Elliott, 1992; Scallan and Elliott. 1992). It has been suggested that DI
RNAs are produced when the RNA-dependent-RNA polymerase pauses during
replication of the L segment causing a switch from the transcription to replication
step. Secondary structure or short sequence repeats observed in deleted region of
the L segment were though to be involved in the L polymerase pausing (Resende
Rde et al., 1992). Meyer and Schmaljohn (2000) proposed a model for the
establishment of SEOV persistent infection. They observed the accumulation of
replication-incompetent, truncated genomes and antigenomes but not DI RNAs in
Vero-E6 cells. They suggested that the deletions were due to the endonuclease
activity of the viral L protein and the presence of these terminally deleted genomes
and antigenomes interfered with virus replication.
1.14. BUNV minigenome system
BUNV minigenome system is an artificial system which mimics BUNV transcription
and replication (Figure 1.12). It is a powerful tool for studying BUNV RNA synthesis.
Previously, Dunn et al. (1995) developed a BUNV minigenome. A negative-sense
chloramphenicol acetyltransferase (CAT) reporter gene was flanked by the authentic
viral 5’ and 3’ noncoding regions (NCRs) of the BUNV S segment. When cells which
express BUNV L and N proteins (either by recombinant vaccinia viruses or by the
vaccinia virus-T7 system) were transfected with BUNV minigenome (BUNVSCAT)
RNA, the activity of CAT could be measured, indicating that the negative-sense
reporter RNA is transcribed and mRNA is produced and translated. Similar systems
have been described for a number of negative-strand RNA viruses such as
rhabdoviruses, paramyxoviruses and influenza viruses (Garcia-Sastre and Palese,
1993). The similarity among all these systems is the template RNA is driven from a
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cDNA clone possessing authentic viral 5’ and 3’ NCRs sequences. However, several
differences have been reported. In some systems, the viral proteins are provided by
helper virus infection while some others via recombinant viruses. In influenza virus
system, the RNA template is delivered in RNP complex form while RV minigenome
transfected naked RNA. Different sequences are inserted between the authentic viral
5’ and 3’ ends sequences of the minigenome (reporter genes, authentic viral
transcripts, defective-interfering RNA or mutated RNAs) (Neumann et al., 2002).
A BUNV minigenome system was modified to utilize the Renilla lucifrase a reporter
gene instead of CAT (Kohl et al., 2004a).The Renilla gene was cloned in an
antisense orientation between the 3’ and 5’ NCRs sequences of the BUNV L, M, or S
segments under the control of T7 promoter. The minigenome cassette is inserted
between a T7 promoter and hepatitis δ ribozyme, facilitating the expression of a
virus-like genomic RNA by T7 RNA polymerase. Transfection of BSR-T7/5 cells,
which stably express T7 RNA polymerase (Buhholz et al., 1999), with pTM1-based
plasmids (encoding viral L and N proteins under the control of T7 promoters and an
internal ribosome entry site sequence (IRES) of the encephalomyocarditis virus
(EMCV) and BUNV minigenome expressing plasmid (pT7riboBUNMRen(-)).
Transfection efficiencies were normalized by cotransfection of the luciferase
expressing plasmid pTM1-FF-luc. If the minigenome is encapsidated and mRNA is
transcribed, Renilla luciferase activity can be measured. Analogous minigenome
systems have been reported for other bunyaviruses, such as LACV, UUKV, HTNV,
RVFV and CCHFV (Blakoqri et al., 2003; Flick & Pettersson, 2001; Flick et al.,
2003a, b; Lopez et al., 1995).
Further modifications to BUNV minigenome using pT7ribo-based plasmds expressing
viral L and N proteins instead of pTM1-based plasmids and using pT7-FF-luc rather
than pTM1-FF-luc as an internal control have been reported (Lowen et al., 2004).
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Figure 1.12. BUNV minigenome system.
BSR-T7/5 cells are transfected with a BUNV minigenome expression plasmid and
two viral L and N proteins expression plsmids. The minigenome RNA is then
encapsidated and the L protein starts transcription and replication. If mRNA is
produced and translated, the luciferase activity can be measured.
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1.15. BUNV minigenome packaging assay (virus-like
particles,VLPs)
Little is known about the assembly of BUNV genome segments into virions. A BUNV
minigenome packaging assay was developed to mimic BUNV assembly events
(Figure 1.13). BSR-T7/5 cells are cotransfected with pTM1BUNL and pTM1BUNN,
encoding viral L and N proteins, and a BUNV minigenome expressing plasmid (either
pT7riboBUNLREN(-), pT7riboBUNMREN(-) or pT7riboBUNSREN(-)). The cells are
then incubated for 24h to allow the formation of RNP structure. The cells are then
infected with wt BUNV as a helper virus to provide the remaining viral proteins (Gn,
NSm and Gc) required for VLP formation. 24h later, the growth medium is collected
and used to infect BHK-21 cells. At 24h postinfection cells are lysed and luciferase
assay carried out. If BUNV minigenome RNPs are packaged, released and the BHK-
21 cells become infected with VLPs, reporter gene activity will be detected (Kohl et
al., 2006).
Recently, BUNV minigenome packaging assay has been modified (Shi et al., 2006).
BSR-T7/5 cells are cotransfected with three pTM1-based plasmids encoding the viral
L, Gn, Gc and N proteins, BUN minigenome plasmid as well as pTM1-FF-Luc as
internal control. At 24h post-transfection cells are lysed and assayed for luciferase
activity as described by Kohl et al. (2004). The culture medium is cleared from cell
debris and 1.5ml is transferred onto new BSRT7/5 cells transfected with pTM1BUNL
and pTM1BUNN 3 - 5h earlier. Cells are incubated overnight and assayed for Renilla
luciferase activity.
Further modifications of BUNV minigenome packaging assay have been introduced.
First, rather than using pTM1-based clones to provide viral proteins, pT7-based
plasmids encoding viral proteins are used. Second, instead of transferring the growth
medium onto BSR-T7/5 pretransfected with pTM1BUNL and pTM1BUNN, the growth
medium is transferred onto untransfected BSR-T7/5 cells (Shi et al., 2007).
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Figure 1.13. BUNV minigenome packaging assay. BSR-T7/5 cells are
transfected with BUNV minigenome expression plasmid and three viral L, M
and N protein expression plasmids lead to encapsidation, transcription,
replication and packaging of the minigenome RNA into VLPs which be able to
infect a new cells and the luciferase activity is measured.
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1.16. Rescue of segmented negative-strand viruses
Recovery of several NSVs from cDNA clones has been reported (Table1.3). The first
attempt towards rescue of NSVs was achieved by Luytjes et al. (1989), using a
plasmid encoding influenza A minigenome (CAT gene negative-sense, flanked by
influenza A UTRs) which can be linearized and transcribed in vitro. Combination of
purified influenza A virus NP, PB1, PB2 and PA proteins with minigenome transcripts
enables the formation of RNPs in vitro. This complex was then transfected into cells
pre-infected with helper virus. Minigenome RNA was thus replicated and
incorporated into some of the new progeny virions (Figure 1.14). However, it was not
sustained in the genome beyond three passages. This obstacle was overcome using
selective pressures, which enabled the isolation of recombinant viruses from helper
viruses. Selection methods used include: neutralizing antibody selection (Enami and
Palese, 1991; Horimoto and Kawaoka, 1994), host-range restriction (Enami et al.,
1990; Subbarao et al., 1993), drug resistance (Castrucci and Kawaoko, 1995) and
temperature sensitivity (Enami et al., 1991; Li et al., 1995; Yasuda et al.,
1994).These methods allowed the generation of influenza viruses carrying a single
cDNA-derived genome segment. Neumann et al. (1994) recovered influenza A viral
RNPs using an RNA polymerase I expression system. Virus-like RNA (CAT gene
negative sense flanked by viral untranslated region) was cloned into a plasmid
contains RNA pol I promoter and terminator. Transfection of the latter plasmid into
mammalian cells lead to generation of minigenome in the nucleus. Cells were then
infected with helper virus to allow the encapsidation, transcription and packaging of
the minigenome.
Further improvement was reported when the minigenome RNA was produced
intracelluarly by using a T7 RNA polymerase–driven expression system. Importantly,
the recombinant RNA must contain the authenic viral 3’ end. This was achieved by
using hepatitis δ ribozyme which allows self-cleavage at the ribozyme sequence,
producing authentic viral 3’ ends (Pattnaik et al., 1992).
Bridgen and Elliott (1996) reported the first segmented negative sense RNA virus to
be rescued entirely from cDNA. In this system, HeLa cells were first infected with
recombinant vaccinia virus vTF7-3 to express T7 RNA polymerase. Three viral
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protein expression plasmids under control of T7 promoter were then transfected,
followed by a second transfection of three ribozyme-based plasmids encoding the
antigenome RNAs. In the latter constructs, BUNV sequences were flanked by the T7
promoter at the 5’ end and a hepatitis δ ribozyme followed by the T7 terminator at the
3’ end. Recoverd BUNV was purified by passaging the supernatant on C6/36 Aedes
albopictus cells allowing BUNV growth but not that of vaccinia virus (Figure1.15).
However, the yield was very poor with transfection of 107 cells only producing 10-100
infectious virus particles.
Recently, an improved and highly efficient BUNV rescue system has been developed
(Lowen et al., 2004). BSR-T7/5 cells constitutively expressing T7 polymerase were
transfected with three ribozyme-based plasmids expressing antigenome L, M and S
RNAs using DAC-30 (transfection reagent) for 5 h at 37˚C. Fresh medium (4ml) was
added and cells were incubated 4-5 days at 37˚C and supernatant was then used in
plaque assay (Figure1.16).
Using a different protocol from that of BUNV rescue system, the recovery of influenza
virus from cDNA has been reported (Fodor et al., 1999; Neumann et al., 1999). In
this system, RNA Pol I promoter and terminator sequences were used for synthesis
of viral RNAs while RNA Pol II promoters were also used for producing viral mRNA.
Moreover, genome expression plasmids were used instead of using antigenome
expression plasmids (Figure1.17). There are two reasons to explain the success of
this system. First, lack of processing of Pol I transcripts and secondly, influenza virus
replication takes place in the nucleus so no hybridization between the mRNAs and
the viral genome would occur. In the latter system, influenza virus was recovered
from transfection of either 12 or 17 plasmids. Cells were cotransfected with eight Pol I
based plasmids encoding the genome segments and either four or nine protein
expression plasmids. The yields was significantly higher (105 pfu/ml) when 17
plasmids were used compared to 103 pfu/ml obtained with 12 plasmids. Moreover,
Hoffmann et al. (2000a) simplified the system by using Pol I/Pol II expression system
which enables recovery of influenza virus from only eight plasmids. To produce a
cDNA which can be used for transcription of both negative sense genomic RNA and
mRNA, viral coding sequence was cloned in the positive sense between a pol II
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Table 1.3. Negative-strand RNA viruses recovered from cDNA
clones (adapted from Neumann et al., 2002).
Family Genus Species Abbreviation Reference
Vesiculovirus
Vesicular stomatitis
virus VSV
Lawson et al. (1995)
Whelan et al. (1995)Rhabdoviridae
Lyssavirus Rabies virus RV Schnell et al. (1994)
Henipavirus Nipah virus NiV Yoneda et al., 2006
Measles virus MV Radecke et al. (1995)
Rinderpest virus
RPV
Baron & Barrett (1997)Morbillivirus
Canine distemper
virus CDV Gassen etal.(2000)
Sendai virus SeV
Gassen et al. (1995)
Kato et al.(1996)
Human
parainfluenza virus
type 3
hPIV3
Durbin et al. (1997a)
Hoffman & Baneriee
(1997)
Respirovirus
Bovine
parainfluenza virus
type 3
bPIV3 Haller et al. (2000)
Simian virus type 5
SV5
He et al (1997)
Mumps virus Clarke et al. (2000)
Human
parainfluenza virus
type 2
hPIV2 Kawano et al. (2001)Rubulavirus
Newcastle disease
virus
NDV
Peeters et al.(1999)
Romer-Oberdorfer et
al. (1999)
Krishnamurthy et al.
(2000)
Human respiratory
syncytial virus hRSV Collins et al. (1999)
Paramyxoviridae
Peneumovirus
Bovine respiratory
syncytial virus bRSV Buchholz et al. (1999)
Filoviridae
Ebola-like viruses
Ebola virus EBoV
Volchkov et al. (2000)
Neumann et al. (2002)
Orthobunyavirus Bunyamwera,
LaCrosse BUNV, LACV
Bridgen & Elliott (1996)
Blakqori & Weber
(2005)Bunyaviridae
Phlebovirus
Rift valley fever
RVFV Ikegami et al (2006)
Influenzavirus A Influenza A virus Neumann et al. (1999)
Fodor et al.(1999)Orthomyxoviridae
Thogotovirus Thogoto virus THoV Wagner et al. (2001)
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Figure 1.14. Influenza A virus RNP in vitro transfection method for recovery of
viable virus. Influenza mini-genome RNA is transcribed in vitro. The influenza-
like RNA is then combined with purified, virion-derived, NP, PB1, PB2 and PA
proteins to allow RNP formation. The latter is transfected into cells pre-infected
with helper virus. Some of the off-spring contain the heterologous segment
(adapted from Luytjes et al., 1989).
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Figure 1.15. Bunyamwera virus rescue system.
HeLa cells were infected with recombinant vaccinia virus expressing T7 RNA
polymerase followed by transfection of three supported plasmids encoding the
viral L, Gn, Gc and N proteins. Second transfection includes three ribozyme-
based plasmids encoding the antigenome RNAs supernatant from transfected
cells. This was passaged onto C6/36 mosquito cells to isolate BUNV (adapted
from Bridgen and Elliott, 1996).
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Figure 1.16. BUNV rescue system.
BSR-T7/5 cells which stably express T7 polymerase, are cotransfected with
antigenomic expressing plasmids result in recovery of a viable virus.
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Figure 1.17. Influenza A virus rescue system utilizing 12 or 17 plasmids.
Cells are transfected with eight genome expressing plasmids followed by transfection
of cells with either four (RNP) proteins or all nine structural proteins (adapted from
Neumann et al., 1999).
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promoter and polyadenylation signal and the latter cassette was then inserted in a
negative sense between Pol I promoter and terminator sequences.
1.17. Rescue of non-segmented negative strand RNA
viruses
Sendai virus (paramyxovirus) was rescued from synthetic naked viral-like RNA when
transfected into cells pre-infected with helper virus (Park et al., 1991). Instead of
using helper virus during recovery of recombinant viruses, viral protein expression
plasmids have also been used. Pattnaik and Wertz (1990) reported using vTF7-3, a
recombinant vaccinia virus expressing T7 RNA polymerase, to produce VSV proteins
from cDNA clones under control of the bacteriophage T7 RNA polymerase promoter.
The first negative strand virus rescued was rabies virus (RV) from antigenome
expression plasmids (Schnell et al., 1994). The RV rescue system consists of cells
infected with vTF7-3. Transfecting these cells with a full length antigenome-
expression plasmid and three viral protein expression plasmids (L, P and N) under
the control of T7 promoter drives formation of active RNPs and produces viable virus
(Figure1.18). Using a similar approach, several non-segmented negative viruses
such as measles, SeV, respiratory syncytial virus (RSV) and VSV were recovered.
Several attempts have been made to recover negative strand viruses from genome
expression plasmids but not all were successful. Sendai virus was rescued from
genomic expression plasmids but with 100-fold less efficiency compared to using
antigenomic expression plasmids (Kato et al., 1996). This might be attributed to
hybridization of the genome and mRNA which could explain the deficiency of using
genome expression plasmids in recovery of negative strand viruses. However,
rescue of negative sense viruses from genome encoding plasmid was reported for
some viruses such as Ebola virus and human parainfluenza virus-3 with equivalent
virus yields from antigenome expression plasmids (Neumann et al., 2002).
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Figure 1.18. Rabies virus rescue system.
Transfection of four plasmids, three protein expression plasmids (encoding the viral
L, N and P proteins) and ribozyme-based plasmid encodes antigenome onto cells
preinfected with vTF7-3 ( adapted from Schnell et al., 1994).
Chapter 1. Introduction
51
1.18. Bunyavirus mutants
Three snowshoe hare virus temperature-sensitive (ts) mutants were generated using
5-fluorouracil. All mutant viruses grew well at 33˚C but not at 39.5˚C, showing a
greater than 1000-fold reduction in the yield (Gentsch and Bishop, 1976). Using the
same mutagen, a total of 77 ts mutant bunyaviruses belonging to Bunyamwera
serogroup (Batai, Bunyamwera and Maguari) viruses were generated (Iroegbu and
pringle, 1981). Group I mutant viruses were thought to be due to mutations in the S
segment while group II mutant viruses carried mutations in the M segment. A ts
mutant of Maguari virus designated MAGts23 (III), generated as above, was
restricted on BS-C1 cells and displayed reduction at least 100-fold in the yield
compared to wt virus (Pringle and Iroegbu, 1982). Nucleotide sequence analysis of
the S segment of MAGts23 (III) showed that the mutation occurred at residue V85A
in the N protein and F71L in the NSs protein (D.C.Pritlove and R.M.Elliott,
unpublished data). Using BUNV reverse genetics, a mutant BUNV lacking NSs gene,
called BUNdelNSs virus was generated (Bridgen et al., 2000). BUNdelNSs virus
displays small plaque size, reduction of 10-fold in titer, and high induction of IFN
compared to the wt BUNV. Recombinant mutant BUNV called BUN MLM, containing
the L segment coding sequence flanked by the M segment UTRs, was generated
using BUNV rescue system (Lowen et al., 2005). Characterization of BUN MLM virus
revealed that, in mammalian cells the virus was attenuated displaying reduction in
the L protein, L mRNA, L genomic and antigenomic RNA synthesis and produces
small plaques. Mutants BUNV carrying mutations at residue N624 or N1168 or at
both (sites for the attachment of N-linked glycans) on Gc were generated using
BUNV reverse genetics (Shi et al., 2005). The glycans on Gc play a role in infection
efficiency but are not important in virus replication. Two recombinant mutant viruses
contain Alanine substitutions in the cytoplasmic tail of BUNV Gc were generated (Shi
et al., 2007). They produce small plaque size and display more than 100-fold
decrease in their titers compared to the wt virus.
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1.19. Project Aim
The main objective of this project was to determine the linear domain map of BUNV
N protein (233 amino acids). This was to be achieved through the introduction of
single amino acid substitutions into BUNV S segment cDNA clone. The impact of the
mutations in N protein functionality was to be analyzed by introducing mutant N
genes into BUNV minigenome system to measure their activity compared to the wt
BUN N protein. A number of mutant N genes were then to be introduced to BUNV
rescue system in an attempt to recover viable viruses carrying mutations in the N
gene. To understand the impact of mutations in the N protein in viral growth
properties and determine any phenotypic differences, mutant viruses were to be
characterized via (i) titration, (ii) plaque phenotype, (iii) protein labeling and Western
blot, (iv) temperature sensitivity and (v) host-range. (vi) RNA synthesis by northern
blotting.
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Chapter 2. Materials and Methods
2.1. Materials
2.1.1. Cell culture
Six different mammalian cell lines were used, BHK-21, BSR-T7/5, Vero-E6, 293-V,
A549-V and 2FTGH-V. In general, BHK-21 cells were used for virus propagation,
Vero-E6 cells were used for virus purification, titration, protein labelling and western
blot. BSR-T7/5 cells were used for transfection purposes and virus rescue. BHK-21,
Vero-E6, 293-V, A549-V and 2FTGH-V cells were used in host-range experiment. A
full description of all cell lines and their maintenance shown in Table 2.1.
2.1.2. Plasmids
All plasmids are listed in Table 2.2.
2.1.3. Bacterial cultures
The bacterial strains used for plasmid propagation were:
(i) E.coli DH5α:Ø80d lacZΔM15, recA1, endA1, gyrA96,thi-1,hsdR17 (rk - ,mk +),
supE44,re1A1,deor, Δ (lacZYA-argF)U169,phoA.
(ii) E.coli JM109: endA1,recA1,gyrA96,thi-1.hsdr17(rk - ,mk +), re1A1,supE44, Δ (lac-
proAB),[ F`,traD36,ProAB,lacl9ZΔM15].
Chapter 2. Materials & Methods
54
Table 2.1. Mammalian cell lines.
Five different cell lines (BHK-21, Vero-E6, 293-V, A549-V and 2FTGH-V)
were used in host-restriction examination. The cell lines 293-V, A549-V and
2FTGH-V were modified to express Simian Virus 5 V protein which blocks
IFN signalling by targeting STAT1 for proteasome-mediated degradation
(Andrejeva et al. (2002). Vero-E6 cells do not produce IFN due to loss of the
IFN genes.
Cell line Description Reference
BHK-21
Baby hamster kidney cells were grown in
GMEM supplemented with 10% (v/v) NCS
and 20% (v/v) TPB.
Stoker and
Macpherson,
(1962)
BSR-T7/5
A modified BHK-21 cell line expressing T7
RNA polymerase constitutively. Cells were
maintained in GMEM supplemented with 10
% (v/v) FCS and 10% (v/v) TPB and 1mg/ml
G418-So4.
Buchholz
et al., (1999)
Vero-E6
An African green monkey cell line
maintained in DMEM supplemented with
10% (v/v) FCS.
ATCC
293-V
Human embryo kidney cell line interferon-
deficient maintained in DMEM containing
10% (v/v) FCS.
R.E Randall
unpublished
A549-V
Human lung cell line interferon-deficient
maintained in DMEM containing 10% (v/v)
FCS.
R.E Randall
unpublished
2FTGH-V
Human fibroblast diploid cell line interferon-
deficient were grown in DMEM containing
10% (v/v) FCS.
Andrejeva et al.
(2002)
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Plasmid Description Reference
pTM1
Vector contains a bacteriophage T7 promoter
followed by IRES :used for protein expression
Moss et al.,
(1990)
pTM1-BUNN
pTM1 plasmid contains the BUNN ORF. Point
mutations were introduced to prevent
expression of NSs protein
Weber et al.,
(2001)
pTM1-BUNS
pTM1 plasmid contains the coding sequence
of BUNV S segment; expresses both N and
NSs proteins.
Weber et al.,
(2001)
pTM1-BUNM
pTM1 construct contains the ORF of BUNV M
segment
Weber et al.,
(2001)
pTM1-FF-
luciferase
plasmid contains the firefly lucifrase ORF, was
used as internal control of cells transfection Weber et al.,
(2001)
pTM1-BUNL
pTM1 plasmid contains the coding sequence
of BUNV L segment
Weber et al.,
(2001)
pT7ribo
A vector containing bacteriophage T7
promoter, followed by StuI and Smal restriction
enzyme sites and the hepatitis δ ribozyme
sequence, is used for protein and antigenomic
RNA expression
Dunn et al.,
(1995)
pT7riboBUNL
(+)
pT7ribo encoding antigenomic BUNV L RNA Bridgen and
Elliott, (1996)
pT7riboBUNS
(+)
pT7ribo containing the BUNV S segment ORF
in positive sense allowing the expression of
antigenome RNA segment
Bridgen and
Elliott, (1996)
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Table 2.2. Plasmids used in this project.
Plasmid Description Reference
pT7riboBUNN
(+)
pT7ribo vector contains the full sequence of
the BUNV S segment encodes only BUN N
ORF, is cloned in the positive orientation
driving the expression of antigenomic S RNA
Bridgen and
Elliott, (1996)
pT7riboBUNM
(+)
pT7ribo vector contains the full sequence of
the BUNV M segment, cloned in the positive
orientation driving the expression of
antigenomic M RNA
Bridgen and
Elliott, (1996)
pT7riboBUNS
REN(-)
pT7ribo contains BUNV NCRs of the S
segment and Renilla luciferase gene in the
negative sense in place of the S segment
ORF
Weber et al.,
(2001)
pT7riboBUNM
REN(-)
pT7ribo contains BUNV NCRs of the M
segment and Renilla luciferase gene in the
negative sense in place of the M segment
ORF
Weber et al.,
(2001)
pT7riboBUNL
REN(-)
pT7ribo contains BUNV NCRs of the L
segment and Renilla luciferase gene in the
negative sense in place of the L segment
ORF
Weber et al.,
(2001)
pT7-FF-
luciferase
plasmid contains the firefly luciferase ORF,
was used as internal control of cells
transfection
R.M Elliott
pGEM-T Easy
vector
A linear vector containing a 3` terminal
thymidine at both ends. It was used for
ligation PCR product for sequencing
Promega
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2.1.4. Viruses
The wt BUNV supplied by RME and recombinant BUNdelNSs virus was rescued
using same plasmid (pT7riboBUNN) described by (Bridgen et al., 2001) and
recombinant vaccinia virus vTF7-3 that expresses the bacteriophage T7 RNA
polymerase (Fuerst et al., 1986) were used in this project.
2.1.5. Antibodies
(i) Anti-BUNV N poly-clonal antibody raised in rabbit against N protein expressed in
bacteria was provided by R.M.Elliott.
(ii) Anti-rabbit IgG horseradish peroxidase-linked antibodies were supplied by Cell
Signalling Technology.
(iii) Anti-Digoxigenin-AP,Fab fragment was purchased from Roche.
2.1.6. Synthetic oligonucleotides
All oligonucleotides were supplied by Sigma-Genosys and are listed in Table 2.3.
2.1.7. Reagents, chemicals and solutions
All chemicals and reagents were supplied by Sigma chemicals Co or BDH chemicals
Ltd unless otherwise stated.
2.1.7.1. Bacterial culture media
L-broth: 10g NaCl, 10g bactopeptone and 5g yeast extract/litre
LB agar: L-broth + 1.5% (w/v) agar.
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TSB: L-broth + 10% (w/v) PEG (MW3350), 5% (w/v) DMSO, 10mM MgCl2 and 10
mM MgSO4.
TSB+glucose: 380mg glucose/ 100 ml TSB.
YTB: 16g tryptone, 10g yeast extract, and 5g NaCl / litre.
Ampicillin 0.1% (w/v) (Promega).
2.1.7.2. Virus manipulation
Agarose type HSA 1.2% (w/v) (park scientific limited).
Neutral red stain 0.1% (w/v) (BDH).
PBS: 170mM NaCl, 3.4mM KCl, 10mM Na2 HPO4, 1.8mM KH2 PO4 , 0.68mM CaCl2,
49mM MgCl2.
Geimsa stain solution (BDH).
5% (v/v) formaldehyde PBS.
2.1.7.3. Enzymes
All enzymes are listed in Table 2.4.
2.1.7.4. Radiochemical
35S L- methionine (40µCi/µl) was purchased from Amersham.
2.1.7.5. Transfection reagent
Lipofectamine-2000 (Invitrogen).
2.1.7.6. DNA gel electrophoresis
Agarose 1% (w/v) MP (multi-purpose) (Roche).
Ethidium bromide (0.04mg/100ml) (Promega).
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DNA loading buffer: 2.5% (w/v) Ficoll 400; 11 mM EDTA; 0.017% (w/v) SDS; 0.015%
(w/v) bromophenol blue; 3.3 mM tris-Hcl.
10× Tris-borate EDTA buffer (TBE): 1.0M Tris, 0.9M boric acid; 0.01M EDTA
(Invitrogen).
2.1.7.7. RNA gel electrophoresis
Agarose 1.2% MP from (Roche).
Ethidium bromide (Promega).
RNA loading buffer: 25% (w/v) Ficoll 400; 0.4% (w/v) bromophenol blue; 0.4 % (w/v)
xylene cyanol.
10×TAE buffer: 400mM Tris-acetate; 10mM EDTA (Invitrogen).
2.1.7.8. Northern blotting
RNA loading buffer (as above).
Maleic acid buffer: 0.1M maleic acid, 0.15M NaCl, pH7.5.
50% formamide hybridization buffer: 50% (v/v) deionised formamide (Sigma); 25%
5×SSC; 1% (w/v) N-lauroyl-sarcosine (Sigma); 0.02% (w/v) SDS; 1% (v/v) blocking
solution.
20× Sodium chloride-sodium citrate (SSC): 3M NaCl, 0.3M sodium citrate, pH 7.0.
10× blocking buffer: 10g blocking reagent purchased from Roche were dissolved in
100ml maleic acid buffer.
Detection buffer: 0.1M Tris, 0.1M NaCl,pH 9.5.
Sodium dodecyl sulphate (SDS): 0.5% (w/v) in dH20.
Washing buffer: 0.1M maleic acid, 0.15M NaCl, pH7.5; 0.3 % (v/v) Tween-20.
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TRIzol reagent: a mono-phasic solution of phenol and guanidine isothiocyanate
(Invitrogen).
2.1.7.9. Polyacrylamide gel electrophoresis (PAGE)
Western blotting and co-immunoprecipitation reagents:
Acrylamide/bis-acrylamide stock solution: 30% (w/v) acrylamide, 0.8% (w/v) bis-
acrylamide (Biorad).
Ammonium persulfate 10% (w/v) (APS) (Biorad).
Blocking buffer: 10% (w/v) skimmed milk powder, 0.1% (v/v) Tween-20 in PBS.
HRP substrate supersignal west pico chemiluminescent substrate system (Pierce).
DMEM without methionine solution (Sigma).
Gel fixation buffer: 50% (v/v) methanol, 10% (v/v) acetic acid, 40% (v/v) dH20.
Phosphate buffered saline (PBS) : 170mM NaCl, 3.4mM KCl, 10mM Na2HPO4,
1.8mM KH2PO4, pH7.12-7.3,0.68mM CaCl2,0.49mM MgCl2 EnHance (Dupont).
Nitrocellulose membrane: Hybond-C extra (Amersham).
Coomassie blue stain: 10% (v/v) methanol, 10% (v/v) acetic acid, 0.1% (w/v)
coomassie blue.
Transfer buffer: 1×Tris-glycine, 20% methanol.
10×Tris-glycine running buffer: 2.4 M Tris, 1.9M glycine.
TEMED (N, N, N`, N` tetramethylethylenediamine) (Biorad).
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1.5M Tris-HCl pH8.8: 90.9g Tris, 400ml dH20, 7.3ml concentrated HCl, pH adjusted to
8.8 with HCl and volume made up to 500 ml with dH20.
1M Tris-HCl pH6.8: 60.6g Tris, 400ml concentrated HCl, pH adjusted to 6.8 with HCl
and volume made up to 500ml with dH20.
Protein A sepharose (Sigma).
Protein loading buffer (2x) : 100mM Tris-HCl pH 6.8, 4% (w/v) SDS, 200mM β-
mercaptoethanol, 20% (v/v) glycerol, 0.2% (w/v) bromophenol blue.
35S methionine (Amersham).
Non-denaturing RIP buffer: 50mM Tris-HCl pH 7.4, 1% (v/v) Triton X-100,300mM
NaCl, 5mM EDTA.
Complete protease inhibitor cocktail (Roche).
RIP wash buffer: 50mM Tris-HCl pH 7.4, 0.1% (v/v) Triton X-100, 300mM NaCl, 5mM
EDTA.
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Oligo Sequence (5’ → 3’)
Coordinate
Nucleotides
of BUNV S
L4A
1) Fw GCGGAATTTCATGATGTCGC
Rv TCAATCATTAAAGAGCCTT
95 → 113
94 → 76
F6A
Fw GCTCATGATGTCGCTGCTAACACC
Rv TTCCAACTCAATCATTAAAGAGCC
102 → 125
101 → 78
D8A
2) Fw GACGTCGCTGCTAACACC
Article II. Rv ATGAAATTCCAACTCAATC
1) 108
→ 
126
107 → 89
Y23A
Fw GCCGCTAACTTTAAGC
Rv TGCGACCTCTGGGTCA
152 → 168
151 → 136
R40A
Fw GCAATCTTCTACATTAAAGGACGC
Rv TATGTGGTCATAACTAAGCCCAGT
203 → 227
202 → 179
K50A
Fw GCAACTAGTCTCGCAAAAAGAAGTGAATGG
Rv AATCTCGCGTCCTTTAATGTAGAAGATTCG
233 → 263
232 → 203
T91A
Fw GCCCTCCACCGCCTCAGTGG
(b) Rv AAGACCATCGTCAGGAACTG
356 → 376
355 → 336
R94A
Fw GCCCTCAGTGGATTCCTTGCC
Rv GTGGAGGGTAAGACCATCGTC
365 → 386
364 → 344
L104A
Fw GCGGAGAAGATGCTGAAAGTC
Rv TAGGTACCTGGCAAGGAATCC
395 → 416
394 → 374
E105A
1) Fw GCGAAGATGCTGAAAGTC
2) Rv AAGTAGGTACCTGGCAAG
398 → 416
397 → 380
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Oligo Sequence (5’ → 3’)
Coordinate
Nucleotides
of BUNV S
E112A
Fw GCACCAGAGAAATTGATTA
Rv ACTGACTTTCAGCATCTTC
419 → 438
418 → 400
I118N
Fw AATAAATCAAAAATAATCAAC
Rv AATCAATTTCTCTGGTTCAC
437 → 458
436 → 417
A127G
Fw GGAGAAAAGAATGGGATCAC
Rv CAAAGGGTTGATTATTTTTG
464 → 484
463 → 444
E128A
Fw GCAAAGAATGGGATCACTTGGAA
Rv AGCCAAAGGGTTGATTATTTTTG
467→ 490
466 → 444
P125H
Fw CATTTGGCTGAAAAGAATG
Rv GTTGATTATTTTTGATTTAA
458 → 477
457 → 438
G131A
Fw TGGATCACTTGGAATGATG
Rv ATTCTTTTCAGCCAAAGGG
476 → 495
475 → 457
W134A
Fw GCGAATGATGGAGAGGAAG
Rv AGTGATCCCATTCTTTTCAG
485 → 504
484 → 465
G137A
3) Fw GCAGAGGAAGTTTATCTCTC
4) Rv ATCATTCCAAGTGATCCC
5) 494
→ 
514
493 → 476
Y141C
Fw TGTCTCTCTTTCTTCCCAG
Rv AACTTCCTCTCCATCATTCC
506 → 525
505 → 486
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Oligo Sequence (5’ → 3’)
Coordinate
Nucleotides
of BUNV S
G147A
Fw GCATCAGAGATGTTCTTAGG
Rv TGGGAAGAAAGAGAGATAAAC
524 → 544
523 → 503
M150A
Fw GCGTTCTTAGGAACTTTCAGA
Rv CTCTGATCCTGGGAAGAAAGA
534 → 555
533 → 513
Y158N
Fw AACCCCTTAGCAATCGGG
Rv GAATCTGAAAGTTCCTAAG
557→ 575
556 → 538
I162A
Fw GCCGGGATCTACAAAGTTCAGCGCAAG
Rv TGCTAAGGGGTAGAATCTGAAAGTTCC
569 → 596
568 → 542
V167A
6) Fw GCGCAGCGCAAGGAAATGGAAC
Rv TTTGTAGATCCCGATTGCTAAG
7) 584
→ 
606
583 → 562
M172A
Fw GCGGAACCAAAATACCTTGAG
Rv TTCCTTGCGCTGAACTTTGTAG
599 → 621
598→ 577
Y176A
Fw GCCCTTGAGAAAACAATGC
Rv TTTTGGTTCCATTTCCTTG
611 → 630
610 → 592
L177A
Fw GCGGAGAAAACAATGCGGC
Rv GTATTTTGGTTCCATTTCC
614 → 633
613 → 595
K179I
Fw ATAACAATGCGGCAGAGGTAC
Rv CTCAAGGTATTTTGGTTCC
620 → 641
619 → 639
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Table 2.3. The oligonuleotides were used in the mutagenesis of BUNV N
cDNA clone. Example: oligo L4A was used to substituted aa L4 to
Alanine. Fw: forward primer. Rv: reverse primer.
٭ Random primers were used to generate mutations in the BUNV N
protein randomly.
Oligo Sequence (5’ → 3’)
Coordinate
Nucleotides
of BUNV S
A190G
8) Fw
GAAGCAACTTGGACTGTTAG
9) Rv TTCTAGTCCCATGTACCTC
10) 653
→ 
673
652 → 634
W193A
Fw GCGACTGTTAGTAAATTGACAG
Rv AGTTGCTGCTTCTAGTCCCATG
662 → 684
661 → 640
L205A
Fw GCGACAGTTGTCTCTAGC
Rv TGCAGACTGAACTTCTGTC
697 → 715
696 → 678
V 208A
Fw GCCTCTAGCTTAGGTTGGAAG
Rv AACTGTCAGTGCAGACTGAAC
706 → 727
705 → 685
W213R
Fw CGGAAGAAAACCAATGTTAG
Rv ACCTAAGCTAGAGACAACTG
722 → 742
721 → 702
S219A
11) Fw
GCGGCAGCTGCCAGGGACTTC
12) Rv
AACATTGGTTTTCTTCCAACC
13) 740
→ 
761
739 → 719
A222G
14) Fw
GGCAGGGACTTCCTTGCTAAATT
CG
Rv AGCTGCACTAACATTGGTTTTCTTC
15) 749
→ 
774
748 → 724
L226A
Fw GCCGCTAAATTCGGAATCAAC
Rv GAAGTCCCTGGCAGCTGCAC
761 → 782
760 → 741
I 231A
Fw GCCAACATGTAAGCAGGGATG
Rv TCCGAATTTAGCAAGGAAGTC
776 → 797
775 → 755
Random٭
primers
Fw GACCATGATTACGAATTC
Rv CGATTAAAAATGCATCCC
219 → 236
1063 → 1045
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Table 2.4. The enzymes were used in this project
NEB: New England Biolab
Enzyme Usage Supplier
M-MLV reverse transcriptase Two-step RT-PCR Promega
AMV reverse transcriptase Reverse transcription and
amplification in one step
Promega
T4 DNA Ligase Ligation Invitrogen or
Roche
KOD Hot Start polymerase DNA amplification Invitrogen
EcoR 1 Restriction enzyme NEB
Nsi I Restriction enzyme NEB
Dpn I Restriction enzyme NEB
Taq DNA polymerase DNA amplification Promega
Calf intestinal phosphatase
(CIP)
Dephosphorylation NEB
Hind III Restriction enzyme NEB
PFU DNA polymerase DNA amplification Stratagene
Recombinant RNasin
ribonuclease inhibitor
Cellular RNA inhibitor Promega
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2.2. Methods
2.2.1. DNA manipulation and cloning procedures
2.2.1.1. Mini preparation of plasmid DNA
For small-scale plasmid preparation, miniprep Qiagen kit was used. Ten millilitres of
LB broth containing 0.1mg/ml ampicillin was inoculated with a single colony and
incubated in an orbital incubator overnight at 37ºC. The cells were pelleted and
resuspended in 250 μl of buffer P1 containing RNase. Then, 250 μl of P2 (lysis
buffer) containing SDS was added and mixed by inverting several times. A volume of
350 μl of N3 buffer was added and mixed gently. The sample was centrifuged for 10
minutes at 13,000 rpm. The supernatant was transferred to a miniprep column and
centrifuged at 13,000 rpm for 1 minute. The flow through was discarded and DNA
was washed and eluted with PBE buffer.
2.2.1.2. Maxi preparation of plasmid DNA
A 100 μl volume of overnight bacterial culture (above) was inoculated into 100 ml LB
medium containing 0.1mg/ml ampicillin and the culture incubated overnight with
shaking at 37ºC. The culture split into 50ml falcon tubes, centrifuged at 4000 rpm for
30 minutes and the supernatant discarded. The cells were resuspend in 10 ml buffer
P1. Ten ml of buffer P2 was added, the solution mixed gently and incubated for 5
minutes at room temperature. Ten ml of chilled P3 buffer was added, the mixture
transferred to a cartridge barrel and incubated for 10 minutes at room temperature.
At the same time QIAGEN-tip 500 tubes were equilibrated with 10 ml buffer QBT and
allowed tubes to empty by gravity flow. The supernatant was passed through the filter
of the syringe onto the QIAGEN-tip which was washed twice with 30ml QC buffer.
The DNA was eluted with 15ml buffer QF and precipitated by adding 10.5 ml
isopropanol followed by centrifugation at 4000 rpm for 1.5 hour. The pellet was
washed with 5 ml 70% ethanol, air-dried for 10 minute at room temperature and
resuspended in 1ml dH2O.
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2.2.1.3. Restriction endonuclease digestion of DNA
For the analysis of mini-prep plasmid DNA, restriction digests were performed in a 20
μl reaction volume containing 2μg DNA, 2 μl 10x reaction buffer, 1 μl 100 x BSA, 1U
of restriction enzyme and the volume was made up to 20 μl with dH2O.The reaction
was incubated as per manufacturers instructions.
2.2.1.4. Isolation of restriction fragments
Five μg DNA were digested with appropriate units of restriction enzyme in a 50 μl
reaction volume and incubated overnight at optimal temperature. The total reaction
volume was run out on an agarose gel and the desired fragment purified using a gel
extraction kit according to manufacturer’s instructions (Quigen).
2.2.1.5. Amplification of DNA by polymerase chain reaction (PCR)
Three DNA polymerases were used, KOD Hot start, Pfu turbo and Taq. Reactions
were performed in thin-walled 0.5 ml tubes using a thermal cycler with heated lid.
KOD Hot Start DNA polymerase reaction:
10× KOD reaction buffer…………..5µl
dNTPs (2 mM each)………………..5µl
MgSO4 (25mM)...............................2µl
Template DNA (25ng).....................1µl
Primer 1 (10µM)..............................1µl
Primer 2 (10µM)..............................1µl
DMSO..............................................2µl
KOD polymerase (1U/ µl)................1µl
dH2O………………………….…to 50µl
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PCR programme:
Initial denaturing………………...94°C……2mins
Strand separation……………….94°C…….30 s
Annealing……………………….variable…..30 s 18-35 cycles
Elongation………………………. 68°C…….variable
Final extension…………………..68°C…….10 mins
Pfu Turbo DNA polymerase reaction:
10× Pfu reaction buffer……………..5µl
dNTPs (10 mM)……………………...1µl
Primer 1 (10µM).............................. 1µl
Primer 2 (10µM)...............................1µl
Template DNA (50ng)......................1µl
Puf Turbo (2.5U/ µl)…………………1µl
dH2O…………………………… to 50µl
PCR programme:
Initial denaturing………………95°C………3mins
Strand separation……………..95°C………30s
Annealing…………………….variable…….30s 30 cycles
Elongation……………………...72°C……..3mins
Final extension……………….. 72°C……..10mins
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Taq DNA polymerase reaction:
10× Taq reaction buffer with MgCl2…………………5µl
dNTPs (25 mM)...............................................1µl
Primer 1(10µM)...............................................1µl
Primer 2(10µM)...............................................1µl
Template DNA (50ng).....................................1µl
Taq DNA polymerase (2U/ µl).........................1µl
dH2O.........................................................to 50µl
PCR programme is similar to Puf Turbo programme.
2.2.1.6. PCR random mutagenesis
PCR random mutagenesis was performed using Stratagene’s GeneMorph II random
mutagenesis kit. Low (0-4) mutations/1kb frequency was used to introduce point
mutations (substitution) in BUNV N cDNA clone. Briefly, pT7riboBUN N (template)
was linearized with HindIII and purified using PCR purification kit (Qiagen) and 100
ng target DNA was then used for amplification.
PCR reaction:
10× Mutazyme II reaction buffer………………….5µl
DNA template (100ng)…………………………….1µl
dNTPs mix (40mM)…….......................................1µl
Primer mix (250 ng).............................................1µl
Mutazyme II DNA polymerase (2.5U/µl)..............1µl
dH2O............................................................ to 50 µl
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PCR programme:
Initial denaturing………………95°C…………2mins
Strand separation……………..95°C…………1min
Annealing………………………48°C…………1min 30 cycles
Extension………………………72°C…………1min
Final extension………………..72°C…………10mins
The PCR product was gel extracted and double digested with EcoR I and Nsi I
restriction enzymes. In parallel, pT7riboBUN N (vector) was digested in the same
way and dephosphorylated using calf intestinal phosphatase enzyme (CIP).Vector
segment then was gel purified and ligated with desired PCR product and transformed
into competent E.coli.
2.2.1.7. Dephosphorylation of 5’ end
To prevent self-ligation of a linearized vector during cloning, CIP enzyme was used.
Addition of 20 U CIP directly to the digestion reaction and incubation for 2 hours at
37°C prevented self-ligation of the digested vector.
2.2.1.8. Quik-change PCR mutagenesis
The Quik-change protocol (Stratagene) was used to substitute single amino acids to
Alanine or Glycine in BUNV cDNA clone. Two primers (Sigma-Genosys), forward and
reverse were designed to anneal in both directions of the target site to generate
desired mutation.
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Quik-change reaction:
10× KOD Hot Start buffer…………………...5µl
dNTPs (2 mM)………………………………..5µl
MgSO4 (25mM)……………………………….2µl
DMSO…………………………………………2µl
Template DNA (25 ng)................................1µl
Primer 1(10µM)...........................................1µl
Primer 2(10µM)...........................................1µl
KOD polymerase (1U/ µl)............................1µl
dH2O…………………………………….. to 50µl
Quik-change PCR programme:
Initial denaturing…………………….94°C…………2mins
Strand separation…………………...94°C………….35s
Annealing…………………………..variable………...35s 18 cycles
Elongation……………………………68°C………….6 mins
Final extension………………………68°C………….10mins
The PCR reaction was digested with 5U of the restriction endonuclease Dpn1 for 1
hour at 37°C. This enzyme cleaves methylated parental DNA only. The PCR reaction
was purified using PCR purification kit and transformed into competent E.coli.
2.2.1.9. Agarose gel electrophoresis
Digested DNA fragments or PCR products were resolved by agarose gel
electrophoresis. One gram of agarose was melted in 100 ml 1x TBE buffer containing
0.04 µg/ml ethidium bromide. The mixture was poured into a horizontal gel tank
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(5.7×8.3×0.4 cm) and the gel submerged in 1xTBE buffer. Samples containing 1x
loading buffer were loaded into the wells and run at 100V for 30 minutes.
2.2.1.10. DNA ligation
2.2.1.10.1. Overnight ligation
Ligation reactions contained 100ng vector, 100ng insert DNA, 4µl 5x ligation buffer,
2U T4 DNA ligase and dH2O to final volume of 20µl. Ligation reactions were
incubated at room temperature overnight.
2.2.1.10.2. Rapid ligation
Roche’s rapid ligation kit was used. Ligation reactions contained 100ng of insert
DNA, 50ng of vector diluted in 1x DNA dilution buffer to a final volume of 10 µl. Ten
microlitres of ligation buffer was then added and mixed thoroughly. Three units of T4
DNA ligase were added and the reaction incubated for 5 minutes before
transformation into competent E.coli.
2.2.1.11. Competent E.coli preparation and Transformation
A single colony of E.coli strain DH5α or JM109 was used to inoculate 10ml LB and
incubated with shaking at 37ºC overnight. One millilitre of the overnight culture was
added to 100ml LB and incubated with shaking at 37ºC for 2 hours. The bacterial
culture was centrifuged at 3500 rpm for 20 min then resuspended in 9.5 ml TSB+0.5
ml DMSO and incubated on ice for 10 min. Approximately 1µg of DNA was added to
200µl competent cells and mixed by flicking. After incubation on ice for 30 minutes,
800 µl TSB + glucose were added and mixed by flicking. Cells were incubated at
37ºC for 1 hour with shaking. For intact plasmid transformation, 200µl cells were
plated onto LB agar + ampicillin.
For ligation, cells were pelleted by centrifugation at 13000 rpm for 3 minutes and 800
µl from the supernatant was removed and the cells were resuspended in the
remaining 200 µl LB and plated on LB agar +ampicillin. Plates were incubated at 37
ºC overnight.
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2.2.1.12. DNA gel extraction
Digested DNA was subjected to gel electrophoresis. The desired band was cut from
the gel and extracted using the Qiaquick gel extraction kit (Qiagen).
The digestion was performed according to the manufacturer’s instructions followed
by agarose gel electrophoresis.
2.2.1.13. T/A cloning
For sequencing purpose, 50ng cDNA obtained with Moloney Murine Leukemia Virus
(MMLV) reverse transcriptase was amplified using Taq DNA polymerase. The PCR
product was gel purified and cloned into pGEM-T Easy vector according to the
manufacturer’s instructions. The ligation reaction was set up as following:
pGEM-T Easy vector (50ng)………………….1µl
PCR product (100ng)………………………….1µl
2× ligation buffer……………………………...10µl
dH2O…………………………………………….7µl
T4 DNA ligase (3U/ µl)...................................1µl
The reaction was incubated overnight at room temperature and 1-5 µl transformed
into competent E.coli. If the PCR product generated with blunt ends, an A-tailing
procedure was carried out as following:
PCR product…………………………………………………………….. .1-7µl
Taq DNA polymerase 10× reaction buffer with MgCl2…………………. 1µl
dATP (2mM)………………………………………………………………….1µl
Taq DNA polymerase (5U/ µl)................................................................1µl
dH2O……………………………………………………………………....to 10µl
The reaction was incubated for 30 minutes at 70 ºC and 1-2 µl used in a ligation
reaction with pGEM-T Easy vector.
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2.2.1.14. Digestion of DNA
To confirm the insert, DNA was digested using EcoR1 restriction enzyme:
10× NEBuffer………………………………….2µl
DNA (300ng)…………………………………..1µl
10× bovine serum albumin (BSA)…………...2µl
EcoR1 restriction enzyme (3U/ µl)…………..1µl
dH2O………………………………………..to 20µl
The reaction was incubated at 37˚C for 1 h and 5µl was run in gel.
2.2.2. RNA manipulation
2.2.2.1. Total cellular RNA isolation using TrIzol
Total RNA was isolated from cell monolayers in 35mm dishes. First, the culture
medium was removed and 1ml TrIzol reagent (Invitrogen) was added to the
monolyers and incubated for 5 min before resuspension by pipetting several times.
The cell lysate was then transferred to a 1.5ml tube and left at room temperature for
5 min. 200µl chloroform was then added and mixed vigorously for 15s. The sample
was incubated for 3 min at room temperature and then centrifuged at 13000rpm for
15 minutes at 4ºC. The upper colourless aqueous layer was transferred to a new
1.5ml tube, 0.5ml Isopropanol added and mixed by gently inverting. The sample was
incubated at room temperature for 15 min and the RNA pelleted by centrifugation at
13000rpm for 15 min at 4ºC. The supernatant was removed and replaced with 1ml
75% (v/v) ethanol. RNA samples were stored at -70ºC, or pelleted by centrifugation
at 11000 rpm for 7 min at 4ºC. The ethanol was aspirated and the pellet allowed to
air dry for ½ hour. The pellet was resuspended in 30µl nuclease-free water.
Chapter 2. Materials & Methods
76
2.2.2.2. Viral RNA extraction from virions
At 20 h post-infection, growth medium was collected and centrifuged at 26,000 rpm
for 1.5 h in SW40 rotor at 4ºC. The supernatant was removed and virus pellet were
resuspended in 1ml Trizol reagent. The samples were treated as described above for
total RNA extraction.
2.2.2.3. RNA reverse transcription
For analysis purposes, viral RNA was converted to cDNA by using either the Avian
Myeloblastosis Virus (AMV) reverse transcriptase or Moloney Murine Leukemia Virus
(M-MLV) reverse transcriptase (Promega).
2.2.2.3.1. One-step RT-PCR (AMV)
After RNA extraction, RT-PCR reaction was prepared as follows:
AccessQuick Master Mix, 2x……………………25µl
Upstream primer (10µM)………………………….1µl
Downstream primer (10µM)………………………1µl
RNA template (1µg).............................................1µl
rRNasin RNase inhibitor (25U).........................0.5µl
AMV reverse transcriptase (5U)………………….1µl
Nuclease-free water…………………………...to 50µl
PCR programme:
Reverse transcription step……………..42ºC………….1h
Denaturation……………………………..94ºC………….5mins
Strand separation……………………….94ºC…………...30s
Annealing………………………………..variable…………30s 35 cycles
Elongation………………………………..72ºC………….1min
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Final extension…………………………..72ºC…………10mins
2.2.2.3.2. Two-step Reverse transcription (M-MLV)
After RNA extraction RT-PCR reaction was prepared as follows:
RNA sample (2µg)………………………….2µl
Forward primer (10µM)…………………….1µl
Reverse primer (10µM)…………………….1µl
Nuclease-free water……………………to 15µl
The reaction was mixed and heated at 70ºC for 5 min and cooled immediately on ice.
The following components were added to the annealed primer/template reaction:
M-MLV 5x reaction buffer…………………………5µl
dNTPs mix (10mM each)……………………...1.25µl
Recombinant rRNasin inhibitor (25U)…………0.5µl
M-MLV RT enzyme (200U).....….........................1µl
Nuclease-free water…………………………..to 50µl
The reaction was incubated at 42ºC for 1 hour and 50-100ng cDNA used for
amplification.
2.2.2.4. Northern blotting
2.2.2.4.1. Preparation of an agrose gel
Agarose gel 1.5% (w/v) was prepared by melting 1.5 g agarose in 85ml 1xTAE buffer
and cooled to 55ºC in a water bath. Agarose gel was then poured into a gel casting
tray with comb to produce an 11×15×0.6 cm slab gel with ×14 of 31 µl wells. Once
the gel had solidified, it was submerged in 750ml 1×TAE buffer (Masek et al., 2005).
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2.2.2.4.2 Preparation of RNA samples
3 to 5 µg total cellular RNA was diluted to 10 µl dH2O. Seventeen microlitres of
deionised formamide, was added and mixed. The samples were heated at 65ºC for
15 min, rapidly cooled on ice and then centrifuged briefly to collect the solution at the
bottom of the tube. Three microlitre RNA loading buffer was added and 30µl loaded
per well. The gel was run at 100V for 1½ hours for RNA genome detection or 2½
hours for antigenome/mRNA detection.
2.2.2.4.3 Capillary blotting
The gel was washed twice for 25 min with 10×SSC. A gel casting tray was placed
upside-down in a shallow tray. Two strips of 3MM (Whitman) paper (28 cm ×14 cm)
were placed on the top of the tray and were soaked with 20 ×SSC until the shallow
tray was full. The gel was placed on top of the wick on the upside-down gel casting
tray. The whole tray was then covered with cling film. A scalpel was used to cut a
window in the cling film around the gel. A positive charged nylon membrane (Roche)
was cut to the size of the gel, soaked in dH2O and then placed on top of the gel.
Three pieces of 3MM paper were cut to size of 14cm ×11.5cm, pre-soaked in
20×SSC and then placed on top of the nylon membrane. Bubbles were removed by
rolling with a plastic pipette. A Pad papers were placed on the top of the
chromatography paper. Finally, a 1kg weight was placed on the top stack overnight
to allow the capillary-driven transfer of RNA from the gel to membrane.
2.2.2.4.4. UV cross-linking of RNA to membrane
After blotting overnight, the orientation of the membrane was marked by cutting the
top, right corner. The membrane was removed, incubated for 10 min in 2×SSC, and
then hung to dry completely. The RNA was then cross-linked to the membrane using
2UV transilluminator (302 nm for 3 mins).The membrane was stored at 4ºC until used
for hybridization.
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2.2.2.4.5. Hybridization of DIG-labelled RNA probes
The membrane was placed in a cylindrical glass bottle (Techne FHB11) and 10ml
pre-warmed 50% formamide hybridization buffer at 68ºC added. The membrane was
incubated for 2 hours. Digoxigenin (DIG)-labelled RNA probe was denatured by
boiling for 5 min then cooling rapidly on ice. Approximately 150ng of each probe was
added to 10ml 50% formamide hybridization buffer at 68 ºC. The pre-hybridization
buffer was removed and replaced with the probe-containing hybrization buffer and
left at 68 ºC overnight, with rotation.
2.2.2.4.6 Washing
To remove excessive nonbinding probes, membrane was washed as following:
2×10min in 100ml 2×SSC, 0.1% (v/v) SDS at room temperature.
2×25 min in 100ml 0.1× SSC, 0.1% (v/v) SDS at 68 ºC.
2.2.2.4.7 Detection
As described by DIG Northern Starter kit (Roche) DIG-labelled probes were detected
with slight modifications in incubation times to reduce signals background:
10 min in 50ml washing buffer
45 min in 50ml 1×blocking buffer
45 min in 50ml 1×antibody solution
2×45 min in 60ml washing buffer
5min in 50ml detection buffer
The membrane was then transferred to translucent plastic sheet and 1ml CDP star
solution (Roche) was added drop-wise and incubated for 5 min at room temperature
before excessive liquid was removed. The plastic sheet was sealed and the
membrane was then exposed to x-ray film (18×24 MOL7016) for 10s-5min.
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2.2.2.5. Preparation of SDS-polyacrylamide gel
The resolving gel solution was prepared (below) then, poured into clean glass
cassette plates. A space equivalent to 2 comb-depths was left for the stacking gel. To
create a flat surface, drops of isopropanol were added. Once the resolving gel had
polymerized, the isopropanol was removed and washed with dH2O to remove traces
of isopropanol. The stacking gel was prepared (below) and poured on top of
resolving gel. Immediately, a comb was inserted and the gel was left to polymerize.
Resolving 12%
H2O……………………………………….5.0ml
30% Acrylamide mix……………………6.0ml
1.5M Tris-HCl (pH8.8)………………….3.8ml
10% SDS………………………………..150µl
10% APS………………………………..150µl
TEMED……………………………………6 µl
Stacking
H2O……………………………………….2.7ml
30% Acrylamide mix…………………....670µl
1M Tris-HCl (6.8pH)…………………….0.5ml
10% SDS………………………………….40µl
10% APS………………………………….40µl
TEMED……………………………………..4µl
The glass plates were then placed into a mini-gel tank (8×7.3cm) (Biorad) filled with
1×Tris-Glycine running buffer. The comb was removed gently and wells were washed
by syringe to be ready for use.
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2.2.2.6. In vivo protein labelling
Using 35mm-diameter dishes, Vero-E6 cells were infected at 0.01-1.0 MOI and
incubated at 33ºC overnight. Next day, the cells were starved of methionine by
replacing the culture medium with 1ml DMEM minus methionine and incubated for
1.5 hours at 37 ºC. Medium was then removed and replaced with 1ml fresh DMEM
containing 40µCi 35S-methionine/ml and cells were incubated at 37ºC for 2 hours.
The labelling medium was then removed and 200µl 1×protein dissociation buffer
added to each dish and cells were incubated 10 minutes at room temperature. Cells
were then harvested using a rubber policeman and transferred to 1.5ml tubes. The
samples were boiled for 5 mins and cooled on ice. Ten to 15 microlitres of samples
were loaded into 12% gel wells in parallel with protein marker (PageRuler prestained
protein ladder, Fermentase) .The samples were electrophoresed at 100V in 1×Tris-
Glycine running buffer until the bromophenol blue band reached the bottom of the
gel. The gel was incubated in fixation buffer for 1 hour at room temperature. The gel
was transferred to chromatography paper, covered with cling-film, dried and exposed
to x-ray film overnight.
2.2.2.7. Western blotting
Vero-E6 or BHK cells in 35mm-diameter dishes were infected at an appropriate MOI
for 1h at 37ºC and incubated at 33ºC overnight. Cells were lysed by adding 200µl
1×protein dissociation buffer/dish and incubated for 20 min at room temperature.
Cells were detached using cell scraper and the lysates collected into 1.5ml tubes.
Samples were boiled for 5min. Forty microlitres of the lysate was loaded onto a 14-
well, 12% acrylamide gel. The samples were electrophoresed at 100V in 1×Tris-
Glycine running buffer for 1 hour. The gel was incubated in transfer buffer for 10min,
as well as the nitrocellulose membrane and two blotting pads. First, a piece of paper
pad was placed on a semi-dry transfer cell (Bio-Rad Trans-Blot SD), the membrane
then replaced on top of first paper pad, and the gel on top of the membrane and
finally the second blotting pad on top. Bubbles were removed by rolling a pipette over
the stack. Transfer was carried out at 0.8mA/cm2 for 1 hour. The membrane was then
incubated 1 hour at room temperature in 100ml blocking buffer.
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The primary antibodies (anti-N) were added at a 1/1000 dilution and the membrane
incubated for 2 hours. The membrane was washed three times for 5 minutes with
blocking buffer. Secondary antibody HRP-linked anti-rabbit IgG (Cell Signalling
Technology) at a 1/1000 dilution in blocking buffer was added and membrane was
incubated for 1 h. The membrane was then washed 3 times for 20 minutes with
blocking buffer and once with PBS. The PBS was poured off and enhanced
chemiluminescent substrate were added to the membrane and incubated for 3
minutes at room temperature. Any excessive substrate was removed and the
membrane covered by a sheet of plastic and exposed to X-ray film.
2.2.2.8. Co-immunoprecipitation
2.2.2.8.1. Metabolic [35S] methionine radiolabeling of BUNV proteins
Sub-confluent BSR-T7/5 cells grown in a 35mm dish were transfected with 0.1µg of
pTM1BUNN or mutant, pTM1BUNL and 0.2µg of pT7riboBUNMRenilla (-) using
Lipofectamine-2000 (Invitrogene) for 4 - 5 hours at 37˚C with shaking every 15 mins.
Transfection mixture was removed and replaced with fresh medium. Cells were
incubated at 33˚C overnight. The culture medium was removed and replaced with
1ml methionine-deficient medium and cells incubated for 1½ hours at 37ºC. The
medium was removed and replaced with protein labelling medium containing
40µCi/ml [35S] methionine/ml and cells were incubated overnight at 33ºC.
2.2.2.8.2. Preparation of cell lysate for immunoprecipitation
The medium was removed from the previous dishes and cells rinsed once with 1ml
ice-cold PBS and 300µl RIP buffer containing protease inhibitor cocktail was added
and then cells incubated on ice for 10 min. The cell lysate was harvested with a cell
scraper and was collected into 1.5ml tube. The cell lysate was vortexed for 5
seconds and incubated on ice for 10 min. The samples were centrifuged at 16,000g
for 10 min at 4ºC to remove the cell debris and nuclei. The supernatant was
transferred to a new tube and placed on ice or stored at -20ºC.
Chapter 2. Materials & Methods
83
2.2.2.8.3. Preparation of antibody conjugated protein A-agarose beads
To prepare 50% (w/v) protein A-agrose beads, 100mg beads were mixed with 800µl
RIP buffer and incubated for at least 30 minutes at room temperature before use.
Thirty microlitres of 50% (v/v) protein A-agrose beads were combined with 1µl anti-
BUNV N poly-clonal antibody and 0.5ml ice cold PBS. The mixture was incubated
overnight at 4ºC with rotating. The beads were spun down for 5 sec at 16,000g, 4ºC
and washed 3 times with 1ml ice-cold RIP wash buffer and once with RIP buffer.
2.2.2.8.4. Immunoprecipitation
Ten microliters of 10% (w/v) BSA and 300µl of cell lysate were added to antibody
conjugated beads and incubated overnight at 4ºC on a rotating wheel. The samples
were centrifuged for 5 seconds at 16,000g and the supernatant was removed
carefully. The samples were washed 4 times with 1ml of ice-cold RIP wash buffer and
once with 1ml of cold PBS. Supernatant was removed and 30µl of 2x protein loading
buffer was added and samples were boiled for 3 min. The samples was
electrophresed in SDS-PAGE and the gel was subjected to same procedure
mentioned in 2.2.2.6.
2.2.3. Manipulation of higher eukaryotic cells
2.2.3.1. Maintenance of mammalian cell lines
Cells were grown in large (175cm2) or medium (80cm2) tissue flasks with regular
passaging: BHK-21, Vero-E6, 293T-V, A549-V and 2FTGH-V cells were split every 3
or 4 days. BSR-T7/5 cells were split every 2 or 3 days. The monolayer was first
washed with 10ml trypsin-EDTA solution (large flask) or 5ml (medium flask). Next,
2ml (large flask) or 1ml (medium flask) trypcine-EDTA solution was added and the
flask was incubated at 37ºC for 5min. Cells were resuspended by rigorously pipetting
in 10ml growth medium. Cells were spun down at 1700rpm for 3 minutes, the
supernatant discarded, and cells resuspended in 10ml fresh medium. Flasks were
seeded using 1ml of cell stock in 30ml medium for large flask or 0.5ml in 20ml
medium for a medium flask. Antibiotic G-418 So4 1mg/ml was added to BSR-T7/5
cells.
Chapter 2. Materials & Methods
84
2.2.3.2. Transfection of mammalian cells
Sub-confluent BSR-T7/5 cells were used for transfection, using Lipofectamine-2000
(Invitrogene) as transfection reagent. Thirty-five mm-diameter dishes were seeded
with 3.5×105 cells, 24 hours prior to transfection. All plasmids to be transfected were
diluted in 100µl Opti-MEM. In a separate tube, 2.5µl lipofectamine-2000 for each 1 µg
of DNA was diluted in 100 µl Opti-MEM, mixed and incubated for 5 min at room
temperature. The diluted Lipofectamine-2000 was added to the DNA solution mixed,
and incubated for 20 minutes at room temperature. The medium were removed and
200 µl of DNA/lipofectamine mixure added to a 35mm dish. Dishes were incubated at
37ºC for 4 hours with rocking every 15 min. The DNA/lipofectamine mixture was
removed, 2ml fresh growth medium added and cells were incubated at 33ºC
overnight.
2.2.3.4. BUNV minigenome assay
The BUNV minigenome system mimics BUNV transcription and replication. BSR-
T7/5 cells grown in 35mm-diameter dishes were co-transfected with a plasmid
expressing a luciferase based mini-genome pT7riboBUNS, M or LRenilla (-), two
pT7ribo-based plasmids encoding BUNV N and L proteins and pT7-FF-luciferase as
internal control of transfection efficiency. Transfection was performed as described in
section 2.2.2.8.2. Eighteen hours post-transfection cells were lysed and luciferase
assay performed (Weber et al., 2001).
2.2.3.5. Luciferase assay
Using the Renilla luciferase Assay Kit (Promega), the activity of BUNV minigenome
was measured. At 18 hrs post-transfection, BSR-T7/5 cells in 35mm-diameter dishes
were lysed by addition 200µl 1× passive lysis buffer and incubating for 20 minutes at
room temperature with rocking. The lysate was transferred to 1.5ml tube and
centrifuged for 1 min at 1700xg. Five microlitres lysate was diluted 1:20 in water.
Stop & Glo substrate (50x) was diluted to 1× in Stop & Glo buffer. Seventy microlitres
of luciferase assay buffer II (LARII) was added to a luminometer cuvette and
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combined with 5µl of diluted lysate and the first luminometer reading taken (the
firefly). Seventeen microlitres of Stop & Glo solution was added to the previous
combination, mixed and Renilla activity taken.
2.2.3.6. BUNV minigenome packaging assay
BSR-T7/5 cells were transfected with five plasmids: pTM1BUNL (0.1µg), pTM1BUNM
(0.1µg), pTM1BUNS (0.05µg), pT7riboBUNMRenilla (-) (0.1µg) and pTM1-FF-
luciferase (0.05µg) as internal control. At 24 h post-transfection, the supernatant was
used to infect new monolayers of BSR-T7/5 cells. Renilla luciferase activity was
measured after 24 h of incubation (Shi et al., 2007).
2.2.4. Bunyavirus manipulation
2.2.4.1. Rescue of BUNdelNSs
BUNV lacking NSs protein was rescued from cloned DNA by transfecting
approximately 107 BSR-T7/5 cells grown in 60 mm-diameter dishes with
pT7riboBUNL (1.0µg), pT7riboBUNM (1.0µg) and pT7riboBUNN (1.0 µg). Five days
post-transfection, culture medium was collected into 15 ml falcon tubes and
centrifuged at 1700 rpm for 3 minutes to remove cell debris. The supernatant was
aliquoted into 1ml virus storage tubes at -20ºC. One hundred microlitres were used in
a plaque assay on Vero–E6 cell line for virus isolation purpose. Vero-E6 cells were
infected using serial dilutions for 1 hour at 37ºC with rocking every 15 min. The virus
was removed and replaced with fresh medium and cells incubated at 33ºC for 6 days.
2.2.4.2. Plaque purification
Cells were stained with 1ml of 0.1% (w/v) neutral red/PBS and incubated for 1 hour
at 37ºC. Excessive stain was removed and cells incubated for 3-4 hours at 37ºC. A
single plaque was then picked by 1000 ml pipette tip and resuspended into 0.5ml
medium and used to inoculate BHK-21 cells grown in a medium flask for propagation
purpose.
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2.2.4.3. Plaque assay
Recombinant virus titres were determined using 100µl from the original stock which
was diluted 10-1 to 10-6 in 900µl PBS with 2% (v/v) FCS. A 200µl aliquot of each
dilution was used to infect 90% confluent Vero-E6 cells. Cells were then incubated at
37ºC for 1 h with rocking every 15 min. The virus aliquot was then removed and 2ml
agarose overlay was added, and left 10 min to solidify. The dishes were incubated at
33ºC for 6 days. To prepare agarose overlay, 1.2g of agarose type HSA was melted
in 100ml dH2O and autoclaved. Ten mililitres of FCS was added to 250 ml 2x MEM to
give 2% FCS. Before performing a plaque assay 1.2% agarose was melted in a
microwave oven and cooled to 55ºC in a water bath. Twenty five ml agarose was
added to 25ml 2×MEM containing 2% FCS, mixed and 2ml added to each dish.
Dishes were left 10 min at room temperature to solidify the agarose overlay. After 6
days of incubation at 33ºC, cells were fixed by adding 2ml 5% (w/v) formaldehyde in
PBS to each dish and incubated overnight at room temperature. The overlay was
then detached with a scalpel and cells were stained by adding 1ml Giemsa stain
solution per dish. The stain was incubated 20 min and washed with water. Plaques
were visualized as a clear circle area within blue monolayer surface.
2.2.4.4. Freeze-thawing
Freeze-thawing experiment was used for two purposes. First, to explore possibility of
some recombinant viruses were rescued but they were unable to be released from
cells. BSR-T7/5 cells were transfected with pT7riboBUNL (1.0µg), pT7riboBUNM
(1.0µg) and pT7riboBUNN or mut (1.0 µg). Five days post-transfection the
supernatant was used in plaque assay and cells detached in 1ml PBS using a cell
scraper. Cells were then subjected to 3 cycles of freeze-thaw (dry ice/waterbath
37ºC). The supernatant was cleared from cell debris and used in plaque assay.
Second, to compare the ratio between the intracellular and extracelluar virus
particles. 2FTGH-V cells were infected at MOI of 1 with the parental virus and mutant
virus. At 20h post-infection, supernatant was collected, cleared from cells debris and
used in plaque assay (extracellular particles).Cells were detached in 1ml PBS,
subjected to 3 cycles of freeze-thaw. The supernatant was used in plaque assay
(intracellular particles).
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2.2.4.5. Immunofluorescence
Approximately 8 ×104 BHK-21 cells were grown on coverslips placed in 24-well
dishes. After infection with 200µl rescue supernatant, the cells were incubated
overnight at 37ºC. Cells were washed twice with cold PBS and fixed with 100%
methanol for 5 minutes at room temperature. Cells were washed twice with PBS. The
coverslips were removed from dishes and incubated for 30 minutes at room
temperature in PBS containing the appropriate dilution of the primary antibody (Anti-
N antibody). The cover slips were then washed 5 times with PBS and incubated with
secondary antibodies (Anti-sheep IgG FITC) for 30 minutes at room temperature.
Cells were washed 5 times with PBS. The coverslips were then mounted face down
on a drop of moviol and tested using a confocal microscope.
2.2.4.6. Cross-linking of BUNV N protein
Subconfluent Vero-E6 cells grown in 35mm dishes were infected with vaccinia virus
vTF7-3 at MOI of 1 for 1 hour at 37ºC. The virus mixture was then removed and cells
were transfected with 2 µg of pT7riboBUNN or pTM1BUNN. Cells were incubated 3-5
hours at 37ºC. The transfection mixture was removed and replaced with fresh
medium. Cells were incubated over night at 37ºC. The cells were washed once with
0.5 ml PBS and treated with 200 µl of PBS containing 1mM Dithiobis
[succinimidylpropionate] (DSP) cross-linking agent (Figure 2.1) for 20 minutes. DSP
is water insoluble, creates a disulfide bridge between two reactive primary amines.
This bridge can be broken by β-mercaptoethanol. It is membrane permeable can be
used for intracellular and intramembrane cross-linking. Cells were detached with a
cell scraper and transferred to an eppendorf tube and incubated 20 minutes at room
temperature. The samples were then subjected to freeze-thaw 3 times. The samples
were then incubated 5 minutes at room temperature before adding 5µl of 1M Tris-
HC1 pH 7.5 to stop the cross-linking reaction. The samples were then incubated 15
minutes at room temperature. The samples were diluted in 2× protein loading buffer
without β-mercaptoenhanol (negative control). The samples were boiled and
electrophoresed by SDS-PAGE. Western blot was then carried out.
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Figure 2.1. Dithiobis[succinimidylpropionate] (DSP) cross-linking agent with
molecular weight of 404.42g/mol (Taken from Pierce instructions).
DSP is a water insoluble molecule that creates a disulfide bound between two
reactive primary amines. The x-links can be broken by β-mercaptoethanol since the
bridge contains thiol-thiol interaction.
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Chapter 3. Mutagenesis of Bunyamwera virus
(BUNV) N gene
3.1. Introduction
The orthobunyavirus N proteins sequenced to date range from 233-235 aa in length.
Alignment of 8 orthobunyavirus N proteins from the Bunyamwera serogroup shows
that at least 159 residues are conserved, too many to help in identifying the domain
map of N protein. The number of conserved amino acids decreases when 20 closely
related orthobunyavirus N proteins from the Bunyamwera and California serogroups
were aligned, showing 92 residues are well conserved, again still too many to be
mutated. A global alignment of 51 orthobunyavirus N proteins from four serogroups
(Bunyamwera, California, Group C and Simbu) showed that 58 residues are highly
conserved, and hence are more likely to be of functional significance (Figure 3.1).
To investigate the residues crucial for N protein functionality, several PCR-based
approaches were available to mutate the BUNV N gene including random or specific
site-directed mutagenesis. To minimize the scale of disruption of N protein function, it
was decided to produce mutants where single amino acids were substituted in the
BUNV N protein sequence. The two methods of substitution above were used. Lack
of sufficient data about the domain map of the orthobunyavirus N protein suggested
that the random approach should to be used first to make as many mutations across
the N ORF as quickly and cheaply as possible, then site-directed mutagenesis to
cover the whole region of the N protein and to fill in gaps.
Several differences between both approaches can be highlighted. Random
mutagenesis was performed using the GeneMorph II random mutagenesis kit
(Stratagene). It utilizes two error-prone DNA polymerases (Mutazyme I and Taq
mutant) that display increased misinsertion and misextension frequencies compared
to the wt Taq. They have been combined to minimise mutational bias and produce
equivalent mutation rates at A’s and T’s vs. G’s and C’s. The protocol can be
adjusted to give 3 levels of mutation frequency, low, medium and high, based on the
amount of the initial target DNA to be amplified and the number of cycles (Table 3.1).
Unique primers (forward and reverse) binding immediately upstream of the T7
promoter sequence and downstream of the N ORF sequence and containing two
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restriction sites, EcoRI and NsiI respectively (Figure 3.2), were used to ease
subcloning the insert (N gene) into the vector (pT7ribo) after mutagenesis. Site-
directed mutagenesis was performed using the Quik-change site-directed
mutagenesis kit (Stratagene). It was performed using KOD Hot Start DNA
polymerase which replicates both plasmid strands with high fidelity (Figure 3.3). Two
synthetic primers containing the desired mutation were designed, each
complementary to the opposite strand. Only 25ng of the template plasmid
(pT7riboBUNN) was amplified (18 cycles) and the product was treated with DpnI to
digest parental plasmid, the DNA self-ligated and transformed into competent E.coli
cells.
In both approaches, mutagenesis was performed using the pT7riboBUNN clone
rather than pT7riboBUNS. The reasoning behind this was that as BUNV S segment
encodes both N and NSs proteins in overlapping reading frames, a mutation in the N
ORF would likely also affect the NSs ORF in the overlap region, making it difficult to
determine whether any phenotype was due to an affect on the N or NSs protein.
Hence, a pT7riboBUNN clone expressing only the N protein gene was produced by
introducing a stop codon immediately after the first start codon of NSs protein gene
(Bridgen et al, 2001). Another vector expressing only the N protein, designated
pTM1BUNN, was also available. In pT7riboBUNN, the full length viral cDNA
sequence is cloned in the positive sense between T7 promoter and hepatitis δ
ribozyme sequences, followed by the T7 terminator immediately downstream,
allowing transcription of antigenome S by T7 RNA polymerase.
On the other hand, pTM1BUNN contains the N ORF cloned between the IRES
sequence and T7 terminator, and hence, it is a protein expressing plasmid only.
pTM1BUNN expresses about 10-fold more N protein than pT7riboBUNN due to the
IRES sequence. However, pT7riboBUNN supports BUNV minigenome activity
(Lowen et al., 2004).
It would be more appropriate to use pT7riboBUNN clone as a template for
mutagenesis of BUNV N gene as it could be used in the BUNV rescue system
without further modification.
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Figure 3.1. Alignment of orthobunyavirus N proteins.
(A) Alignment of 8 orthobunyavirus N proteins belong to Bunyamwera
serogroup shows at least 159 residues are conserved. (B) Alignnment of
20 orthobunyavirus N proteins from two closely related serogroups
(Bunyamwera and California) displays 92 conserved amino acids. (C) A
global alignment of 51 orthobunyavirus N protens from (Bunyamwera,
California, Group C and Simbu serogroups) shows 58 residues are highly
conserved. Each blue line indicates a conserved amino acid.
Chapter 3. Mutagenesis of BUNV N gene
93
Figure 3.2. PCR random mutagenesis was performed using GeneMorph II kit.
To ease the primers binding pT7riboBUNN was linearized using Hind III
restriction enzyme. The forward primer binds immediately upstream of T7
promoter (nucleotides 219 - 236 of the vector sequence), contains EcoR 1
restriction enzyme site and reverse primer binds immediately downstream of N
ORF (nucleotides 1063–1046 of the NCR), possesses Nsi 1 restriction enzyme
site.
N ORF
N ORF
N ORF
N ORF
Hind III
RF
Nsi 1
EcoR 1
Transformation
1- Digestion pT7riboBUNN
with Hind III to linearize the
plasmid
2- Amplification of the N ORF
3- Digestion with EcoR 1 and
Nsi 1 both PCR product and
the vector. This generates
sticky end.
4- Ligation of PCR insert
to the pT7ribo vector.
T7 promoter
Hepatitis δ ribozyme
T7 terminator
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Step 1
Plasmid Preparation
Step 2
Temperature Cycling
Step 3
Polymerization
Step 4
Digestion
Step 5
Transformation
KOD Hot Start DNA polymerase
Gene in plasmid with target
site( ) for mutation
Denature the plasmid and anneal the
oligonucleotide primers ( ) containing
the desired mutation(×)
Digest the methylated, nonmutated
parental DNA template with Dpn I
Mutation plasmid
(contains nicked circular strands)
Transform the circular, nicked dsDNA
Into E.coli JM109 competent cells
LEGEND
Parental DNA plasmid
Mutagenic primer
Mutated DNA plasmid
Figure 3.3. Quik-change PCR site-directed mutagenesis. Two designed
primers bind at the target site. Amplification of the new plasmid was performed
using KOD Hot Start polymerase. After the production of the nicked plasmid,
PCR reaction was treated with Dpn 1 to digest the methylated parental
plasmid. The mutant plasmid was then transformed into competent cells
(taken from Promega instruction manual).
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3.2. PCR random mutagenesis of BUN N gene
PCR random mutagenesis was performed using the GeneMorph II kit. According to
the manufacturer’s instructions, low mutation frequency (0 - 4.5 mutation/ kb) could
be achieved either by using high concentrations of the template (Table 3.1) or by
reducing the number of cycles (Table 3.2). The initial amount of target DNA required
to achieve a low mutation frequency refers to the amount of target DNA (N ORF), not
the total amount of plasmid DNA template (pT7riboBUNN) added to the reaction. As
the N gene is about 700 bases and the total construct is about 4300 bases, the target
DNA (N ORF) occupies ≈ 16% of the pT7riboBUNN. Accordingly, the amount of
target DNA was calculated from this perspective when PCR reaction was prepared.
When the manufacturer’s protocol was followed using 100ng target DNA and 20-25
cycles or 500ng target DNA and 30 cycles almost all the clones obtained were the
same as the input DNA and did not contain mutations. Therefore, slight modifications
were introduced to produce as many clones as possible carrying single mutations in
the N gene. When 100ng of target DNA was amplified for 30-35 cycles the result was
much better, and 2 in 10 clones carried single mutations.
To perform PCR random mutagenesis on the pT7riboBUNN clone, the plasmid was
first digested using HindIII restriction enzyme to linearize the template to ease primer
binding and prevent primer rotation. Then, 100ng of target DNA (N ORF) was
amplified for 30 – 35 cycles. The PCR product was then digested with EcoR1 and
Nsi1 restriction enzymes to facilitate insertion into the pT7ribo vector. pT7riboBUNN
plasmid was digested with EcoR1 and Nsi1 restriction enzymes, the pT7ribo fraction
gel purified and the insert ligated similarly into digested vector backbone of
pT7riboBUNN to generate mutant clones carry single mutations ready to be used in
BUNV minigenome and rescue systems for further investigation. This approach
overcomes an effects of mutations in non-coding sequences of the N clone as might
occur if the whole plasmid was used.To confirm the size of the insert (≈ 700 bases),
the clone was digested with EcoR 1 and Nsi1 restriction enzymes and
electrophoresed on an agarose gel. From 10 PCR reactions, three hundred and
twenty eight colonies were picked at random to generate as many single mutations in
the BUNV N gene as possible. Of the 328 miniprep clones sequenced, 72 were
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Table 3.1. Mutation frequencies VS. initial target DNA quantity using the
GeneMorph II kit.
The amount of template indicated is the amount of target DNA to be
amplified not the total amount of DNA (vector). Low mutation frequency can
be achieved by using higher amounts of target DNA (taken from
Stratagene’s instruction manual).
Mutation frequency
(mutation/kb)
Cycle number Initial target amount
20-25 100ng0-4.5
30 500ng-1000ng
Table 3.2. Alternative way of achieving low mutation frequency. Using fewer
cycle numbers (taken from manufacturer’s instruction manual).
Mutation
rate
Mutation frequency
(mutations/kb)
Initial target
Amount (ng)
Recommended
fold
Amplification
Low 0 - 4.5 500 -1000 1.5 -10
Medium 4.5 - 9 100 - 500 10 -100
High 9 -16 0.1 -100 100 -10,000
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found to carry single mutations (20 in the N-terminal region, 22 in the middle and 30
in the C-terminal region) of the BUNV N protein (Figure 3.4), 17 clones contained
double mutations and 2 clones carried triple mutations. Twenty-two single
substitutions occurred at globally conserved amino acids, 14 mutations occurred at
conserved residues between at least 20 orthobunyavirus N proteins, 10 single
mutations were at BUNV-specific and 26 mutations were Bunyamwera serogroup-
specific residues. The majority of clones carrying double mutations showed the same
pattern, carrying one mutation at a nonconserved residue and a second at a
conserved amino acid. Three clones contained mutations at two conserved residues.
Another 3 clones carried double mutations at nonconserved positions. Triple
mutations occurred at two nonconserved residues and the third mutation was at
conserved residue.
3.3. PCR specific site-directed mutagenesis of BUNV N
gene
Not all regions of BUNV N protein sequence were mutated by the random approach.
To produce further mutations in the N gene, targeted mutagenesis was performed.
Thirty globally conserved amino acids (6 residues in the N-terminal region, 11 amino
acids in the middle and 13 positions in the C-terminal region) were mutated to
Alanine or Glycine to minimize any disruption that could occur (Figure 3.5). Two
oligonucleotides were designed to each targeted site and the whole template
(pT7riboBUNN) was then amplified. The PCR product was then digested with
restriction enzyme Dpn1 to remove methylated template DNA (input plasmid), self-
ligated and used to transform competent E.coli. The desired mutation was confirmed
by sequencing.
3.4. PCR random and specific mutagenesis of BUNV N
gene
In total, 102 single mutations were generated randomly or deliberately covering the
whole region of BUN N gene sequence (Figure 3.6). Forty single mutations occurred
at globally conserved amino acids of orthobunyavirus N proteins, 26 single mutations
occurred at conserved residues among at least 20 orthobunyavirus N proteins, 26
single mutations were at Bunyamwera serogroup-specific residues and 10 single
mutations were at BUNV-specific residues.
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Figure 3.4. The BUNV N protein has been divided into three regions, the N-
terminus (aa 1-77), the middle (aa 78-154) and the C-terminus (aa 155-233).
Using random mutagenesis approach, 72 single mutations were generated in
the BUNV N protein, 20 mutations occurred in the N-terminus, 22 mutations
were generated in the middle and 30 mutations in the C-terminus.
Figure 3.5. Thirty globally conserved amino acids among orthobunyavirus N
proteins were substituted to Alanine or Glycine using PCR site-directed
mutagenesis approach. Six mutations occurred in the N-treminal region, 11
mutations in the middle and 13 mutations in the C-terminal region.
1 77 154 233
20 mutations 22 mutations 30 mutations
N-terminus Middle C-terminus
1 77 154 233
6 mutations 11 mutations 13 mutations
N-terminus Middle C-terminus
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CAR -MIELIFKDVASFTDNTFDPEAAYLRFESDYGSQLESAIVRVFYINAAKVKAYLRRSSEL
ORI -MIELIFNDVASFTDNTFDPEAAYLRFESDYGSQLESAIVRVFYINAAKVKAYLRRSSEL
MUR -MIELIFKDVASFTDNTFDPEAAYLRFESDYGSQLESAIVRVFYINAAKVKAYLRRSSEL
RES -MIELIFKDVASFTDNTFDPEAAYLRFESAYGSQLESAIVRVFYINAAKVKAYLRRSSEL
BRU -MIELIFKDVASFTDNTFDPEAAFLRFESAYGSQLVSAVVRVFYINAAKVKAYLSRSSEL
OSS -MIELIFKDVASFTDNTFDPEAAFLRFESAYGSQLVSAVVRVFYINAAKVKAYLSRSREL
ITA -MIELIFKDVPSFTDNTFDPEAAFLRFESAYGRQLVSAVVRVFYINAAKVKAYLSRSSEL
VIN -MIELIFKDEPSFTDNTFDPEAAFLRFESVYGQQLVAAVVRVFYINAAKVKAYLRRSREL
APE -MIELVFKDVASFTDNTFDPEAAYVRFKPAYGSELESSIVRVFYINAAKVKAYLRRSSEL
MAR -MIELVFKDVASFTDNTFDPEAAYVRFKPAYGSELESSIVRVFYINAAKVKAYLRRSSEL
NEP -MIELVFKDEASFTDNTFDPEAAYVRFKPAYGSELESAIVRVFYINAAKVKAYLRRSSEL
Gum -MIELVFKDETSFADNTFNPEAAFVAFKPTHGSELESSTVRIFYINAAKVKAYLRRSAEQ
MAD -MSELEFKDVPSFADNTFNPEAQYVTFIPRNGRVLEATIVRIFYINAAKVKAYLHRSSEQ
AIN MANQFIFQDVPQRNLATFNPEVGYVAFIAKHGAQLNFDTVRFFFLNQKKAKMVLSKTAQP
PEA MANQFIFQDVPQRNLATFNPEVGYVAFIAKYGAQLNFDTVRVFFLNQKKAKMVLSKTAQP
SHU MANQFIFQNVPQRNLATFNPEVGYVAFIAKHGAQLNFDTVRVFFLNQKKAKMVLSKTAQP
KAI MATHFIFQDVPQRNLATFNPEVGYVAFIAKHGAQLNFDTVRVFFLNQKKAKMVLSKTAQP
YAB MANQFVFNDVPQRNAATFNPDTGYVAFISKYGQHLNFSVARVFFLNQKKAKMVLHKTPQP
AKA MANQFIFNDVPQRNAATFNPDAGYVAFISKYGQQLNFTVARVFFLNQKKAKMVLHKTPQP
SAB MASQFIFDDVPQRNAATFNPDTGYVAFISKYGQHLNFTVARVFFLNQKKAKMVLHKTAQP
SIM MANQFIFEDVPQRNLSTFSPEAGYVAFIGRYGQQLNFSVVRVFFLNQKKAKMVLHKTAQP
SAT MSSQFIFEDVPQRNAATFNPEVGYVAFIGKYGQQLNFGVARVFFLNQKKAKMVLHKTAQP
SHA MSSQFIFEDVPQRNAATFNPEVGYVAFIGKYGQQLNFGVARVFFLNQKKAKMVLHKTAQP
DOU MSSQFIFEDVPQRNAATFNPEVGYVAFIGKYGQQLNFSVARVFFLNQKKAKMVLHKTAQP
BUT -MSEFIFNDVPQRSTSTFDPEAAYVAFEAQYRAXLSVSVARIFFLNQKKAKDRLRQTSQP
Fac -MTDFVFNDVPQRATSTFDPEAAYVAFENRFRANLTVDVARIFFLNQKKAKDRLAKTARA
ING MAEAIVFNDVPQRTQSTFDPEAQYVVFENTYRANLTVNTARIFFLNQKRAKDTLRQTPRP
MER MADAIVFNDVPQRAQSTFDPEAQYVVFENTYRANLTINTARIFFLNQKRAKDTLRQTPRP
ORO -MSEFLFNDVPQRTTSTFDPEAAYVAFEARYGQVLNAGVVRVFFLNQKKAKDVLRKTSRP
CV -MIELEFNDVAANTSSTFDPEIAYVNFKRIHTTGLSYDHIRIFYIKGREIKTSLTKRSEW
MAG -MIELEFNDVAANTSSTFDPEIAYVNFKRIHTTGLSYDHIRVLYIKGREIKTSLTKRSEW
NOR -MIELEFNDVAANTSSTFDPEVAYINFKRVYTTGLSYDHIRIFYIKGREIKTSLTKRSEW
BAT -MIELEFNDVAANTSSTFDPEVAYINFKRIYTTGLSYDNIRIFYIKGREIKTSLSKRSEW
BUN -MIELEFHDVAANTSSTFDPEVAYANFKRVHTTGLSYDHIRIFYIKGREIKTSLAKRSEW
MD -MIELEFHDVAANSSSTFDPEVAYASFKRVHTTGLSYDHIRIFYIKGREIKTSLSKRSEW
GER -MLELEFEDVPNNIGSTFDPESGYTNFQRNYLPGVTLDQIRIFYIKGREIKNSLSKRSEW
KAI -MSEIEFHDVTANTSSTFDPEAGYAAFKRRHTTGLNYDHIRIFFLNGKKAKDTLSKRSET
GUA -MAEIEFFDVAQNATSTFNPELQYATFKRTNTTGLNYDNIRIFYLNGKRSKDTLSKRSEQ
SSH -MSDLVFYDVASTGANGFDPDAGYMAFCVKYAESVNLAAVRIFFLNAAKAKAALSRKPER
LAC -MSDLVFYDVASTGANGFDPDAGYMDFCVKNAESLNLAAVRIFFLNAAKAKAALSRKPER
Cal -MSDLVFYDVASTGANGFDPDAGYVDFCAKHGESINLAAVRIFFLNAAKAKAALSRKPER
TAH -MSDLVFYDVASTGANGFDPDAGYVDFCIKHGEAINLHSVRIFFLNAAKAKAALARKPER
SA -MSELVFYDVASTGANGFDPDAGYLAFCVKHGESISLSSVRIFFLNAAKAKAALSRKPER
JS -MGDLVFYDVASTGANGFDPDAGFVAFMADHGESINLSAVRIFFLNAAKAKAALARKPER
Jam -MGDLVFYDVASTGANGFDPDAGFVAFMADHGESINLSAVRIFFLNAAKAKAALARKPER
INK -MGDLVFYDEASTGANGFDPDAGFVAFMADHGESINLAAVRIFFLNAAKAKAALARKPER
SR -MGDLVFYDVASTGANGFDPDAGFVAFMADHGESINLSAVRIFFLNAAKAKAALARKPER
SDN -MGDLVFYDVASTGANGFDPDAGFVAFMAGHGESINLTAVRIFFLNAAKAKAALSRKPER
KEY -MGDLVFYDVASTGANGFDPDAGYVAFMANHGESISLSTVRIFFLNAAKAKAALTRKPER
MEL -MGDLIFYDVASTGANGFDPDAGYLAFTIAHGEAINLSAVRIFFLNAAKAKAALSRKPER
TRI -MSELVFYDAPSTGANGFDPDAGYVAFIAAHAGSYDLSAVRIFFLNAAKAKNALSRKPEG
Con ------F-DV-------F-P------F-------------R-F-------K--L------
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CAR LVLLTLGGVNLAVLNTHFPGTQSIPLPDYGLTIHRLSGYLARWALYLIRPSP-ESDIGLV
ORI LVLLTLGGVNLAVLNTHFPGTQSIPLPDYGLTIHRLSGYLARWALYLIRPSP-ESDIGLV
MUR LVSLTLGGVNLAVLNTHFPGTQSIPLPDYGLTIHRLSGYLSRWALYLIRPSP-ESEIGLV
RES LVSLTLGGVNLAVLNTHFPGTQSIPLPDYGLTLHRLSGYLARWALYLIRPSP-ESDIGLV
BRU LVFLTLGGVNLAVLNTHFPGTQSIPLPDYGLTLHRISGYLARWALYLIRTNP-ESDIALV
OS LVFLTLGGVNLAVLNTHFPGTQSIPLPDYGLTLHRISGYLARWALYLIRTNP-ESDIALV
ITA LVFLTLGGVNLAVLNTHFPGTQSIPLPDYGLTLHRISGYLTRWALYLIKTNP-ESDIALV
VIN LVFLTLGGVNLAVLNTHFPGTQSIPLPDYGLTIHRISGYFSRWALYLIATNP-ESDIALV
APE LVLLTLGGVNLAVLNTHFPGTQSIPLPDYGLTIHRLSGYLARWALYLIYIIP-ESDIDLV
MAR LVLLTLGGVNLAVLNTHFPGTQSIPLPDYGLTIHRLSGYLSRWALYLIYIIP-ESEIDLV
NEP LVSLTLGGVNLAVLNTHFPGTQSIPLPDYGLTIHRLSGYLARWALYLICPIP-DSDIDLV
Gum LVSLTLGGVNLAVLNTHFPGTQSIPLPDYGLTIHRLSGYLARWALYLICPSP-DSSIGLV
MAD LVLLTLGGVNLAVLNTHFPGNQSIPLPDYGLTIHRVSGYLARWALYLIAPSP-YSDRDIV
AIN SVDLTFGGIKFTLVNNHFPQYTANPVPDTALTLHRLSGYLAKWVADQCKTN--QIKLAEA
PEA SVDLTFGGIKFTLVNNHFPQYTANPVPDTALTLHRLSGYLAKWVADQCKTN--QIKLAEA
SHU SVDLTFGGIKFTLVNNHFPQYTANPVPDTALTLHRLSGYLAKWVADQCKTN--QIKLAEA
KAI SVDLTFGGIKFTLVNNHFPQYTANPVPDTALTLHRLSGYLARWVADQCKTN--QIKLAEA
YAB SVDLTFAGVKFTVVNNHFPQYTANTVSDTAFTLHRISGYLARWVAEQCKGN--QIKLAEA
AKA SVDLTFAGVKFTVVNNHFPQYTANPVSDTAFTLHRISGYLARWIAEQCKAN--QIKFAEA
SAB SVDLTFGGVKFTVVNNHFPQYIANPVPDTALTLHRMSGYLARWVAELCRGN--QIKLAEA
SIM NVDLTFGGVKFTLVNNNFPQYTANPVPDNALTLHRLSGYLARWTAEQVKNN--QVKLAEA
SAT SVDLTFGGVKFTVVNNHFPQYVSNPVPDNAITLHRMSGYLARWVADTCKAS--VLKLAEA
SHA SVDLTFGGVKFTVVNNHFPQYVSNPVPDNAITLHRMSGYLARWIADTCKAS--VLKLAEA
DOU SVDLTFGGVKFTVVNNHFPQYVSNPVPDNAITLHRMSGYLARWVADTCKAS--VLKLAEA
BUT NVNLTFGQSVFPVVNNHFPQFQSNPVPDNGLTLHRLSGYLARWLMDQIXVGG-SVREAEI
Fac TVDITFGGVVFPVVNNHYPEYQRNPVPDDGLTLHRLSGYLARWLIDQCNAS--PVRMTEI
ING TVNLTFGQCTFPVVNNHYPQFQSNPVDDSALTLHRLSGYLARWVMTFYAQS--PVNQAAV
MER TVNLTFGQCTFPVVNNHFPQFQSNPVADTALTLHRLSGYLARWLMTFYSQS--PVNQAAV
ORO MVDLTFGGVQFAMVNNHFPQFQSNPVPDNGLTLHRLSGYLARWAFTQMRSP---IKQAEF
CV EVTLNLGGWKVTVFNTNFPGNRNSPVPDDGLTLHRLSGYLARYLLEKILKVS-DPEKVII
MAG EVTLNLGGWKVAVFNTNFPGNRNSPVPDDGLTLHRLSGFLARYLLEKILKVS-DPEKLII
NOR EVTLNLGGWKVTVFNTNFPGNRNSPVPDDGLTLHRLSGFLARYLLEKILKVS-EPEKLII
BAT EVTLNLGGWKVTVFNTNFPGNRNSPVPDDGLTLHRLSGFLARYLLEKILKVS-DPEKLII
BUN EVTLNLGGWKITVYNTNFPGNRNNPVPDDGLTLHRLSGFLARYLLEKMLKVS-EPEKLII
MD EVTLNLGGWKVAVFNTNFPGNRNSPVPDDGLTLHRLSGFLARYLLEKILKVS-EPEKLLI
GER EVTLNLGGWKVPVLNTNFPGNRNNAVPDYGLTFHRISGYLARYLLGKYLAET-EPEKLIM
KAI TITLNFGGWKIPVVNTHFLENRNMSVPDDGLTLHRVSGYLARYLLDRVYSAG-EPEKLKI
GUA SVVLNFGGWRIPVVNTHFPGNRNSPVLDDSFTLHRVSGYLARYLLERYLTVS-APEQAII
SSH KANPKFGEWQVEVVNNHFPGNRNNPINSDDLTIHRLSGYLARWVLEQYKENEDESRRELI
LAC KANPKFGEWQVEVINNHFPGNRNNPIGNNDLTIHRLSGYLARWVLDQYNENDDESQHELI
CAL KANPKFGEWQVEVVNNHFPANRNNPIGNNDLTIHRISGYLARWVLEQYKENEDESQRELV
TAH KASPKFGEWQVEVVNYHFPGNRNNPIDNNDLTIHRLYGYLARWVLEQFKENEDAAQRELI
SA KANPKFGEWQVEIVNNHFPGNRNNPIDNLDLTIHRLSGYLARWVLEQFIENEDESQRELI
JS KATPKFGEWQVEIINNHFPGNRNNPIGNNDLTIHRLSGYLARWVLEHFTADDDESQRELI
Jam KATPKFGEWQVEIVNNHFSGNRNNPIGNNDLTIHRLSGYLARWVLEHFNSDDDESQRELI
INK KATPKFGEWQVEIVNNHFPGNRNNPIGNNDLTIHRLSGYLARWVLEHFTEDDDESQRELI
SR KANPKFGEWQVEIVNNHFPGNRNNPIGNNDLTIHRLSGYLARWVLEHFTEDEDESQRELI
SDN KATPKFGDWQVEIVNNHFPGNRNNPIGNNDLTIHRISGYLARWTLEHFREGGDEAQKELI
KEY KATPKFGEWQVEIVNNHFPGNRNNPIGNNDLTLHRISGYLARWVLEHFGEGEDESQKELI
MEL KATPKFGDWQVEIVNNHFPGNRNNPIGNNDLTIHRLSGYLARWVLDLFKENEDESQKELI
TRI KVSIKFGEWSVEVVNNHFPGNRNNPIGNNDLTIHRISGYLARWVLEEFKGQDDEAQKDII
Con ------G-------N--FP-----P-----LT-HR-SGYLAR------------------
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CAR RSTFIVPLAEENGITWSDGVGMYLAFLPGAEMFMSTFTFYPLTIGMYRVRRWSMDPNCLE
ORI RSTFIVPLAEENGITWSDGVEMYLAFLPGAEMFMSTFTFYPLTIGMYRVRRWSMDPNCLE
MUR RSTFIVPLAEENGITWSDGVGMYLAFLPGAEMFMSTFTFYPLTIGMYRVRRWSMDPNCLE
RES RSTFIVPLAEENGITWSDGVGMYLAFLPGAEMFMSTFAFYPLTIGMYRVRRWSMDPNCLE
BRU RSTFVVPLAEENGITWRDGVEMYLAFLPGAEMFMSTFEFYPLTIGMYRVRRWSMDPNCLE
OSS RSTFVVPLAEENGITWRDGVEMYLAFLPGAEMFMSTFEFYPLTIGMYRVRRWSMDPNCLE
ITA RSTFVVPLAEENGITWRDGVEMYLAFLPGAEMFMSTFEFYPLTIGMYRVRRWSMDPNCLE
VIN RSTFVVPLAEENGITWRDGVEMYLAFLPGAEMFMSTFEFYPLTIGMYRVRRWSMDPNCLE
APE RTTFIVPLAEENGITWTDGVAMYLAFLPGAEMFMSTFKFFPLTIGMYRVRRWSMDPNCLE
MAR RTTFIVPLAEENGITWTDGVAMYLAFLPGAEMFMSTFKFFPLTIGMYRVRRWSMDPNCLE
NEP RTTFIVPLAEENGITWTDGVAMYLAFLPGAEMFMSTFTFFPLTIGMYRVRRWSMDPNCLE
Gum RATFVVPLAEENGITWCDGVAMYLAFLPGAEMFMSTFAFFPLTIGMYRVRRWTMDPQCLE
MAD RTTFIVPIAEKNGITWCDGVTMYLAFLPGSEMFMSTFRFFPLTIGMYKVQRWGMDPKCLE
AIN MEKIVMPLAEVKGCTWTEGLTMYLGFAPGAEMFLETFEFYPLVIDMHRVLKDGMDVNFMR
PEA MEKIVMPLAEVKGCTWTEGLTMYLGFAPGAEMFLETFEFYPLVIDMHRVLKDGMDVNFMR
SHU MEKIVMPLAEVKGCTWTEGLTMYLGFAPGAEMFLETFEFYPLVIDMHRVLKDGMDVNFMR
KAI MEKIVMPLAEVKGCTWTEGLTMYLGFAPGAEMFLETFEFYPLVIDMHRVLKDGMDVNFMR
YAB AATIVMPLAEIKGCTWNDGYTMYLGFAPGAEMFLETFEFYPLVIDMHRVLKDGMDVNFMR
AKA AATVVMPLAEVKGCTWSDGYAMYLGFAPGAEMFLETFEFYPLVIDMHRVIKDGMDVNFMR
SAB ATLIVMPLAEVKGCTWNDGYTMYLGFAPGAEMFLETFEFYPLVIDMHRVLKDGMDVNFMR
SIM TAAIVMPLAEVKGCTWNDGYTMYLGFAPGAEMFLETFEFFPLVIDMHRVLKDGMDVNFMR
SAT SAQIVMPLAEVKGCTWADGYTMYLGFAPGAEMFLDAFDFYPLVIEMHRVLKDNMDVNFMK
SHA SAQIVMPLAEVKGCTWADGYTMYLGFAPGAEMFLDAFDFYPLVIEMHRVLKDNMDVNFMK
DOU SAQIVMPLAEVKGCTWADGYTMYLGFAPGAEMFLDAFDFYPLVIEMHRVLKDNMDVNFMK
BUT RGAIVIPLAEIKGCTWNDGNAMYLAFAAGTEMFLQTFTFFPLAIEMQRVLKDGMDVNFMK
Fac RTKVIIPLAEVKGCTWNDGASMYLGFAAGAEMFLQSFTFYPLVIEMQRVLKDGMDVNFMR
ING REAVVIPLAEVKGCSWNDGPALYLGFAAGAEMFLQTFTFFPLVIEMHRVLKDGMEVNFMR
MER REAVVIPLAEVKGCSWDDGPPFYLGFASGAEMFLQTFTFFPLVIEMHRVLKDGMDVNFMR
ORO RATVVVPLAEVKGCTWNDGDAMYLGFAAGAEMFLQTFTFFPLVIEMHRVLKDGMDVNFMK
CV KSKIINPLAEKNGITWSDGEEVYLSFFPGSEMFLGTFKFYPLAIGIYKVQRKEMEPKYLE
MAG KSKIINPLAEKNGITWADGEEVYLSFFPGSEMFLGTFKFYPLAIGIYKVQKKEMEPKYLE
NOR KSKIINPLAEKNGITWTDGEEVYLSFFPGSEMFLGTFKFYPLAIGIYKVQRKEMEPKYLE
BAT KSKIVNPLAEKNGITWADGEEVYLSFFPGSEMFLGTFRFYPLAIGIYKVQRKEMEPKYLE
BUN KSKIINPLAEKNGITWNDGEEVYLSFFPGSEMFLGTFRFYPLAIGIYKVQRKEMEPKYLE
MD KSKIINPLAEKNGITWADGEEVYLSFFPGSEMFLGIFKFYPLAIGIYKVQRKEMEPKYLE
GER RTKIVNPLAEKNGITWESGPEVYLSFFPGAEMFLGTFRFYPLAIGIYKVQRKEMDPKFLE
KAI KTTIINPIAASHGITWDDGEEVYLSFFPGSEMYLTTFKFYPLAIGIYKVQRKLMDPKYLE
GUA RSKIINPIAASNGITWEDGPEVYLSFFPGTEMFLETFKFYPLAIGIYKVQKKMMEAKYLE
SSH KTTIINPIAESNGVRWDSGAEIYLSFFPGTEMFLETFKFYPLTIGIYRVKQGMMDPQYLK
La RTTIINPIAESNGVGWDSGPEIYLSFFPGTEMFLETFKFYPLTIGIHRVKQGMMDPQYLK
CAL KTTVINPIAESNGIRWENGAEIYLAFFPGTEMFLETFKFYPLTIGIYRVKNGMMDSQYLK
TAH KTTVINPIAESNGIRWDNGAEIYLAFFPGTEMFLETFNFYPLTIGIYRVKQGMMDPQYLK
SA KTTVINPIAESNGIKWENGAEIYLSFFPGTEMFLEIFKFYPLTIGIYRVKQGMMDPQYLK
JS RSTIINPIAESNGIHWNNGPEIYLSFFPGTEMFLEIFKFYPLTIGIYRVKHGMMDPQYLK
Jam RSTIINPIAESNGIHWNNGPEIYLSFFPGTEMFLEIFKFYPLTIGIYRVKHGMMDPQYLK
INK RSTIINPIAESNGIHWNNGPEIYLSFFPGTEMFLEVFKFYPLTIGIYRVKHGMMDPQYLK
SR RSTIINPIAESNGIHWNNGPEIYLSFFPGTEMFLEAFKFYPLTIGIYRVKHGMMDPQYLK
SDN RTTIINPIAESNGIHWANGAEIYLSFFPGTEMFLEAFKFYPLTIGIYRVKHGMMDAQYLK
KEY KSTVINPIAESNGIRWGNGVEIYLSFFPGTEMFLELFKFYPLTIGIYRVKHGMMDAQYLK
MEL QSTIINPIAESNGIHWANGVEIYLSFFPGTEMFLEAFRFYPLTIGIYRVKHGLMDPQYLK
TRI RSTIVNPIAESNGIHWDSGADAYLSFFPGTEMFLESFDFLPLAIGIYRVKNGMMDVQYLK
Con ------P-AE—G---W--G---YL-FFPG-EMF---F-F-PL-I----V----M------
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179 233
CAR KAIWQRYMGIGADQWITKETVAILTRFEDVEKLDWARTAFTSSAKEFVSRFGVRLA
ORI KAIWQRYMGIGADQWITKETVAILTRFEDVEKLDWAKTAFTSSAREFVSRFGIRLA
MUR KAIWQRYMGIGADQWITKETVAILTRFEDVEKLDWAKTAFTSSAREFVSRFGIRLA
RES KAIWQRYMGIGADQWITKETLAILTRFEDVEKLDWAKTAFTSAAREFVSSFGIRLA
BRU KAIWQRYMGIGADQWITKETVAILTRFEDVEKLDWARTAFTSAAREFVSRFGIRLA
OSS KAIWQRYMGIGADQWITKETVAILTRFEDVEKLDWARTAFTSAAREFVSRFGIRLA
ITA KAIWQRYMGIGADQWITKETVAILTRFEDVEKLDWARTAFTSAAREFVSRFGIRLA
VIN KAIWQRYMGIGADQWITKETVAILTRFDAVEKLDWARTAFTSAAREFVIQFGIRLA
APE KAIWQRYMGIGADDWITKETVTILARFEDVEKLDWARTAFTSSAREFVSQFGIKLA
MAR KAIWQRYMGIGADDWITKETVTILARFEDVEKLDWARTAFTSSAREFVSQFGIKLA
NEP KAIWQRYMGIGADDWITKETVTILARFEDVEKLDWARTAFTSSAREFVSQFGIKLA
Gum KAIWQRYMGIGADEWITKETVSILARFEDVEKLDWAKTAFTSAAREFVSKFGIRLA
MAD KAIWQRYAGIGADTWIQKEYADINARFSVVESLDWARTAFTSTAREFVAQFGIKLA
AIN KVLRQRYGTLTAEQWMTQKIDAVRAAFNAVGQLSWAKSGFSPAARAFLAQFGINI-
PEA KVLRQRYGTLTAEQWMTQKIDAVRAAFNAVGQLSWAKSGFSPAARTFLAQFGINI-
SHU KVLRQRYGTLTAEQWMTQKIDAVRAAFNAVGQVNWAKIRILPAARTFLAQFGINI-
KAI KVLRQRYGTLTAEQWMTQKIDAVRAAFNAVGQLSWAKSGFSPAARAFLAQFGINI-
YAB KVLRQRYGQLTAEEWMTTKVDAVKAAFGSVAQISWAKSGFSPAARAFLTQFGIQI-
AKA KVLRQRYGQLTAEEWMTSKLDAVKAAFGSVAQISWAKSGFSPAARAFLAQFGIQI-
SAB KVLRQRYGTLTAEEWMTTKIEAVRAAFNSVAQISWAKTGFSPAARAFFANFGIQI-
SIM KALRQRYGLLTAEQWMTQKIVEVKAAFDAVGQIAWAKSGFSPAARAFLQQFGFTG-
SAT KVLRQRYGTMTAEEWMTQKITEIKAAFNSVGQLAWAKSGFSPAARTFLQQFGINI-
SHA KVLRQRYGTMTAEEWMTQKITEIKAAFNSVGQLAWAKSGFSPAARTFLQQFGINI-
DOU KVLRQRYGTMTAEEWMTQKITEIKAAFKFVGQLAWAKSGFSPAVRTFLQEFGINI-
BUT KVIRQRYGTLTAEQWMRHEVTAVTAAFNAGGLLPWARSGFSSMARKFLRNFGINI-
Fac KVLRQRYGTKTAEQWMRDDIVAVKTAFEAINTISWARSGFSPAAREFLRQFGINI-
ING KVLRQRYGALTAEQWMRQEIVAIRAAFDAVGALPWAKSGFFPFAREFLAQFGIKI-
MER KVLRQRYGALTAEQWMRQELVAIRAAFEAVGALPWAKTGFFSAAREFLAQFGIRI-
ORO KVLRQRYGQKTAEQWMREEIVAVRAAFEAVGTLAWARTGFSPAGRDFLRQFGIGI-
CV KTMRQRYMGLEASTWTISKVNEVQAALTVVSGLGWKKTNVSAAAREFLAKFGISM-
MAG KTMRQRYMGLEAATWTVSKVNEVQAALTVVSGLGWKKTNVSAAAREFLAKFGINM-
NOR KTMRQRYMGLEASTWTISKVNEVQAALTVVSGLGWKKTNVSAAAREFLAKFGINM-
BAT KTMRQRYMGLEASTWTVSKLNEVQSALTVVSGLGWKKTNVSSAAREFLAKFGISM-
BUN KTMRQRYMGLEAATWTVSKLTEVQSALTVVSSLGWKKTNVSAAARDFLAKFGINM-
MD KTMRQKYMNMDAATWTVTQVSEVQAALTVVSGLGWKKTNVSAAAREFLAKFGINM-
GER KTMRQRYLGIDAQTWTTTKLGEVEAALKVVSGLGWKKTNVSSAAREFLSKFGIRM-
KAI KTMRQRYMNLDASQWTQKHFSDVNSALTVVAGLGWKKANVSIAAKDFLNKFGINI-
GUA KTMRQKYAGLDASQWTQQKYNEINAALSVVSSLGWKKANVSSAAREFLARFGISL-
SSH KALRQRYGSLTADKWMSQKVTAIAKSLKEVEQLKWGRGGLSDTARSFLQKFGIRLP
LAC KALRQRYGTLTADKWMSQKVAAIAKSLKDVEQLKWGKGGLSDTAKTFLQKFGIRLP
CAL KALRQRYGSLTAEKWMSQKTGMIAKSLKEVEQLKWGRGGLSDTARTFLQKFGIKLP
TAH KALRQRYGSLTADKWMSQKTTAIAKSLKDVEQLKWGRGGLSDTARTFLQKFGIRLP
SA KALRQRYGSLTADKWMSQKVGAIAKSLKDIEQLKWGKGGLSDTARTFLQKFGIKLP
JS KALRQRYGTLTAEKWMAQKTVLIAKSLKDVEQLKWGRGGLSDAARTFLIKFGVKLP
Jam KALRQRYGTLTAEKWMAQKTVLIAKSLKDVEQLKWGRGGLSDAARTFLIKFGVKLP
INK KALRQRYGTLTAEKWMAQKTVLIAKSLKDVEQLKWGRGGLSDAARTFLIKFGVKLP
SR KALRQRYGTLTAEKWMAQKTVLIAKSLKDVEQLKWGRGGLSDAARTFLIKFGVKLP
SDN KALRQRYGTLTADEWMAQKTVLITKSLKDVEQLKWGRGGLSDAARTFLSKFGVKLP
KEY KALRQRYGTLTADKWMAQKTSMITKSLKDVEQLKWGKGGLSDTARAFLAKFGVRLP
MEL KALRQRYGTLTADKWMAQKTTMIAKSLKDVEQLKWGKGGLSDAARTFLQKFGVRLP
TRI KALRQRYGTMTADKWMSTKTTVIAKTLKRVESFKWGKGGLSEAARAFLSKFNVKIP
Con K---QRY----A—W---------------V----W--------AR-F---FG----
Figure 3.6. Alignment of 51 orthobunyavirus N protein sequences. 102 residues
were substituted randomly or deliberately in the BUNV N protein and are
highlighted in red. “Con” indicates conserved amino acids.
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3.5. Activity of mutant N proteins in a BUNV minigenome
system
The BUNV minigenome replication system was described previously (see section
1.14). Briefly, a virus-like RNA (minigenome) containing the sequence of the reporter
gene (Renilla lucifrase) flanked by authentic viral 5` and 3` ends, is transcribed in
BSR-T7/5 cells expressing T7 polymerase. Provision of both BUNV N and L protein
leads to encapsidation of the minigenome and formation of virus-like RNP. The L
polymerase binds the RNP commencing transcription of the RNP and producing
mRNA. If the latter is produced and translated, the reporter gene is expressed and
luciferase activity can be measured (Kohl et al., 2004a).
3.5.1. Single amino acid substitutions
The mutant N genes were introduced to the BUNV minigenome system to measure
the activity of mutant N proteins compared to wt N protein. An example of the activity
of mutant N proteins is given in Figure 3.7. It seems that mutations at serogroup or
globally conserved residues are more disruptive than non-conserved residues.
Seventy-two mutant N proteins (Table 3.3) displayed 70 -100% of the parental N
activity, although 36 of these mutations occurred at conserved amino acids. Mutant
N proteins that showed 50% or less of parental N protein activity carry mutations in
the N-terminal region (E20G, G66R and W68R), in the middle of N protein sequence
(V85I, R94A, L104A, I118N, G131W, W134A, G137A, Y141C and M150A) and finally
in the C-terminal region (F157I, Y158N, I162A, L177A, K179I, W193A, W213R and
L226A), all of which are highly conserved residues in orthobunyavirus N proteins.
The most disruptive mutations occurred in the middle of N protein sequence at
globally conserved residues among all orthobunyavirus N proteins, R94A, I118N,
W134A, Y141C, L177A, K179I and W193A. Their activity in the BUNV minigenome
system was less than 15% of the wt BUNV N protein activity. In particular, mutations
R94A, W134A and Y141C were almost inactive in the BUNV minigenome system,
displaying 0.17, 1.9 and 1.8 % of the activity of the wt BUNV N protein respectively.
These residues are totally conserved among all orthobunyavirus N proteins. Overall,
mutant N proteins displayed a wide-range of activity, parental-like, moderate, or weak
or very low (Table 3.4).
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Figure 3.7. Examples of activity of mutant N proteins in the BUNV
minigenome system .
BSR-T7/5 cells were transfected with 0.2 µg pT7riboBUNN or mutant
clone, 0.2 µg pT7riboBUNL, 0.2 µg pT7riboBUNMRenilla (-) and 0.1 µg
pT7-FF-luc as internal control of the trasfection efficiency. Cells were
incubated overnight at 33˚C and luciferase activities were measured. The
transfection was performed in duplicate and luciferase activity was
normalised. For example, wt N protein produces 4042 light/units which is
considered as 100% and mutant N K50A produces 2643 light/units so
mutant K50A produces 2643/4043 × 100 = 65% of the wt N activity in
BUNV minigenome system.
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Clone Mutation
position
Nature of change Con* Activity
(%)
L4A 95,T → C
96,T → G
Nonpolar (hydrophobic) nonpolar (small) ++ 85
E5D 100
A → T
Polar -  Polar – - 97
F6A 101,T → G
102, T → C
Aromatic  nonpolar (small) ++++ 92
D8A 108
A → C
Polar -  nonpolar (small) ++++ 65
V9I 110, G → A  
112, C → A 
Nonpolar (hydrophobic)  nonpolar (hydrophobic ) ++++ 94
A10V 114,C → T
115,T → C
Nonpolar (small)  nonpolar (hydrophobic) - 100
T13A 122
A → G
Polar = (nucleophilic)  nonpolar (small) - 85
P19Q 141
C → A
Polar = (hydrophobic)  polar = (amide) ++++ 76
E20G 144
A → G
Polar -  nonpolar (small) ++ 55
V21I 146
G→A
Nonpolar (hydrophobic)  nonpolar (hydrophobic) - 95
Y23A 152, T →G
153, A → C
Aromatic  nonpolar (small) +++ 88
A24V 156
C → T
Nonpolar (small)  nonpolar (hydrophobic) - 92
K27E 164
A → G
Polar+  polar – - 95
R28G 167
C →G
Polar+  nonpolar (small) - 73
R40A 203, C →G
204, G → C
Polar+  nonpolar (small) ++++ 85
K45N 220
A →C
polar+  polar = (amide) - 93
K50A 233, A → G
234, A → C
polar+  nonpolar (small) ++++ 65
L53F 242
C → T
Nonpolar (hydrophobic) aromatic ++++ 90
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Clone Mutation
position
Nature of change Con* Activity
(%)
E58D 259
A → T
Polar -  polar – ++ 100
W59C 262
G → T
Aromatic  polar = (nucleophilic) - 82
E60V 263
A → T
Polar - nonpolar (hydrophobic) - 68
V61A 267
T → C
Nonpolar (hydrophobic) nonpolar (small) - 93
G66R 281
G → A
Nonpolar (small)  polar + ++++ 54
G67D 285
G → A
Nonpolar (small)  polar – - 90
W68R 287
T → C
Aromatic  polar + + 50
K69E 290
A → G
Polar +  Polar – - 80
I70V 293
A → G
Nonpolar (hydrophobic)  nonpolar (hydrophobic) - 68
I70T 293
T → C
Nonpolar (hydrophobic)  Polar = (nucleophilic) - 100
N74S 306
A → G
Polar = (amide)  polar = (nucleophilic) ++++ 99
P78H 318
C → A
Polar = (hydrophobic)  polar + ++++ 81
N80S 324
A → G
Polar = (amide)  polar = (nucleophilic) + 89
N82D 329
A → G
Polar = (amide)  Polar – + 71
V85A 339
T → C
Nonpolar (hydrophobic)  nonpolar (small) + 95
V85I 338
G → A
Nonpolar (hydrophobic)  nonpolar (hydrophobic) + 50
T91A 356
A → G
Polar = (nucleophilic)  nonpolar (small) ++++ 62
H93Q 364
C → G
Polar +  polar = (amide) ++++ 86
Chapter 3. Mutagenesis of BUNV N gene
107
Clone Mutation
position
Nature of change Con* Activity
(%)
R94A 365, C → G
366, G → C
Polar+  nonpolar (small) ++++ 0.17
S96G 371
A → G
Polar = (nucleophilic)  nonpolar (small) ++++ 100
A100V 384
C →T
Nonpolar (small)  nonpolar (hydrophobic) ++++ 100
L104A 395, C → G
396, T → C
397, T → G
Nonpolar (hydrophobic)  nonpolar (small) ++ 49
E105A 399
A → C
Polar -  nonpolar (small) + 79
M107I 406
G → A
Nonpolar (hydrophobic)  nonpolar (hydrophobic) - 100
L108M 407
C → A
Nonpolar (hydrophobic)  Nonpolar (hydrophobic) - 96
K109E 410
A → G
Polar +  Polar – - 100
V110A 414
T → C
Nonpolar (hydrophobic)  nonpolar (small) - 97
S111N 417
G → A
Polar = (nucleophilic)  Polar = (amide) - 92
E112A 420
A → C
Polar -  nonpolar (small) + 58
I118N 438
T → A
Nonpolar (hydrophobic)  polar = (amide) + 11
K121N 448
A → C
Polar +  polar = (amide) - 98
P125H 459
C → A
Polar = (hydrophobic)  polar + ++++ 66
A127G 465, C → T
466, T → A
Nonpolar (small)  Nonpolar (small) ++++ 100
E128A 468
A → C
Polar -  Nonpolar (small) ++++ 105
G131W 476
G → T
Nonpolar (small)  aromatic ++++ 40
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Clone Mutation
position
Nature of change Con* Activity
W134A 485, T → G
486, G → C
Aromatic  nonpolar (small) ++++ 1.9
N135Y 488
A → T
polar = (amide)  aromatic - 90
G137A 495
G → C
Nonpolar (small)  nonpolar (small) ++++ 36
Y141C 507
A → G
Aromatic  polar = (nucleophilic) ++++ 1.8
F145I 518
T → C
Aromatic  nonpolar (hydrophobic) + 93
G147A 525
G → C
Nonpolar (small)  nonpolar (small) ++++ 79
M150A 533, A → G
534, T → C
Nonpolar (hydrophobic)  nonpolar (small) ++++ 48
F155L 550
C → A
Aromatic  Nonpolar (hydrophobic) ++++ 75
F157I 554
T → A
Aromatic  nonpolar (hydrophobic) ++++ 33
Y158N 557
T → A
Aromatic  polar = (amide) ++++ 30
I162A 569, T → C
570, T → G
Nonpolar (hydrophobic)  nonpolar (small) ++++ 60
K166R 582
A → G
Polar +  polar + - 100
V167A 585, T → C
586, T → G
Nonpolar (hydrophobic)  nonpolar (small) ++++ 79
R169G 590
C → G
polar +  Nonpolar (small) - 78
R169H 591
G → A
polar +  polar + - 73
M172A 599, A → G
600, T → C
Nonpolar (hydrophobic)  nonpolar (small) ++++ 90
K175E 608
A → G
Polar +  Polar – - 100
Y176A 611, T → G
612, A → C
Aromatic  nonpolar (small) + 53
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Clone Mutation
position
Nature of change Con* Activity
(%)
L177A 613, C → G
614, T → C
615, T → G
Nonpolar (hydrophobic)  nonpolar (small) ++ 10
K179I 621
A → T
Polar +  nonpolar (hydrophobic) ++++ 4
T180S 623
A → T
Polar = (nucleophilic)  Polar = (nucleophilic) - 91
R184M 636
G → T
polar +  Nonpolar (hydrophobic) ++++ 100
M186L 642
A → T
Nonpolar (hydrophobic)  nonpolar (hydrophobic) - 100
G187E 644
G → A
Nonpolar (small)  Polar – - 105
A190G 654
C → G
Nonpolar (small)  nonpolar (small) ++++ 98
A191E 657
C → A
Nonpolar (small)  Polar – - 100
W193A 662,T → G
663, G → C
Aromatic  nonpolar (small) ++++ 3
T194I 666
C → T
Polar = (nucleophilic)  nonpolar (hydrophobic) - 61
T194A 665
A → G
Polar = (nucleophilic)  Nonpolar (small) - 74
K197T 675
A → C
Polar +  Polar = (nucleophilic) ++ 89
K197E 674
A → G
Polar +  Polar – ++ 91
L198M 677
T → A
Nonpolar (hydrophobic)  Nonpolar (hydrophobic) - 100
S203F 693
C → T
Polar = (nucleophilic)  Aromatic - 82
A204T 695
G → A
Nonpolar (small)  Polar = (nucleophilic) - 72
L205A 698, G → G
699, C → T
Nonpolar (hydrophobic)  nonpolar (small) - 75
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Table 3.3. Activity of mutant N proteins (carry single mutations) in a BUNV
minigenome system.
Clones highlighted in bold were generated using Quik-change site-directed
mutagenesis.
*Con: conserved aa, (-) non-conserved aa, (+) conserved aa among at least 20
orthobunyavirus N proteins, (++) conserved aa among at least 30 orthobunyavirus N
proteins, (+++) conserved aa among at least 40 orthobunyavirus N proteins, (++++)
highly conserved aa among all orthobunyavirus N proteins.
%: Activity of mutant N proteins compared to 100% activity of wt BUNV N protein.
Clone Mutation
position
Nature of change Con* Activity
(%)
T206I 701
C → T
Polar = (nucleophilic)  nonpolar (hydrophobic) - 84
V208A 708
T → C
Nonpolar (hydrophobic)  nonpolar (small) ++++ 100
S210N 714
G → A
Polar = (nucleophilic)  polar = (amide) - 87
W213R 722
T → C
Aromatic  Polar + ++++ 28
K215R 729
A → G
Polar +  polar + - 71
T216I 732
C → T
Polar = (nucleophilic)  nonpolar (hydrophobic) - 100
S219A 740, A → G
741, G → C
742, T →G
Polar = (nucleophilic)  nonpolar (small) ++ 61
A222G 750
C → G
Nonpolar (small)  nonpolar (small) ++++ 98
L226A 761, C → G
762, T → C
763, T → C
Nonpolar (hydrophobic)  nonpolar (small) ++++ 26
A227V 765
C → T
polar +  Nonpolar (hydrophobic) - 78
K228T 768
A → C
Polar +  polar = (nucleophilic) + 80
F229L 772
C → A
(ii) Aromatic  nonpolar (hydrophobic) ++++ 100
G230R 773
G → A
Nonpolar (small)  polar + ++++ 66
I231A 775, A →G
776,T → C
Nonpolar (hydrophobic)  nonpolar (small) +++ 95
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Table 3.4. Summary of the activity of mutant N proteins in the BUNV
minigenome system.
Four levels of activity were observed (parental-like, moderate, weak and
very low). The majority of mutant N proteins display parental-like activity
even though some mutations occurred at highly conserved residues.
Activity
(%)
70-100
Parental-like
50-69
Moderate
15-49
Weak
<15
Very low
72 clones 13 clones 10 clones 7 clones
Chapter 3. Mutagenesis of BUNV N gene
112
3.5.2. Double mutations
As low mutation frequency could generate 0-4.5 mutations/kb when random
mutagenesis was performed, double and triple mutations were generated in the
BUNV N gene. Seventeen N genes carried double mutations at different positions.
Mutant N proteins with double mutations showed a wide-range of activity in the
BUNV minigenome system. Although it was speculated that they might be
dysfunctional in the minigenome system, as several single mutations were shown to
disrupt the N protein function in the BUNV minigenome system previously, 6 double
mutant N proteins were functional even though some of the mutations were at
conserved residues. Four double mutant N proteins were weak, and 5 double mutant
N proteins were almost inactive (Table 3.5).
By targeting the conserved residue of these inactive double mutant N proteins, I was
able to explore whether the disruption was due to mutation at this residue or not. For
example, mutant N protein R94S/K109N, carries mutations in the middle of N protein
sequence. Mutant N protein K109E was generated previously and its activity in the
minigenome system was similar to parental N protein (Table 3.3). Therefore, Arginine
94 was targeted and substituted to Alanine. It was dysfunctional in the BUNV
minigenome which reflects the importance of the R94 residue. Similarly, mutant N
protein E105G/A204E was also inactive in the BUNV minigenome system. As mutant
N protein A204T was functional in the BUNV minigenome system, residue E105 was
mutated to Alanine to generate mutant N protein E105A. Its activity in the BUNV
minigenome system was almost like the parental, a result that was totally
unexpected. Not all N genes carrying double mutations and inactive in BUNV
minigenome were investigated in the same way since some genes were already
generated carrying single mutations and the activity of mutant N proteins was weak
or inactive.
3.5.3. Triple mutations
For the same reason mentioned above, the generation of mutant N protein with triple
mutations was expected. Two mutant N proteins carrying triple mutations were
produced and they were inactive in BUNV minigenome (Table 3.6). Mutant N protein
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Clone Mutation
position
Section 2.02 Nature of change Con Activity
(%)
I2N/H93R
89,
T → A
363,
A → G
Nonpolar (hydrophobic) polar = (amide)
Polar +  Polar +
-
++++
15
A11P/S15N
116,
G → C
118,
T → C
130,
G → A
Nonpolar (small)  Polar = (hydrophobic)
Polar = (nucleophilic)  polar = (amide)
-
-
60
A22T/K197R
149,
G → A
275,
A → G
Nonpolar (small)  polar = (nucleophilic)
Polar +  Polar +
-
++
35
E58D/N82S
259,
A → T
330,
A → G
Polar -  Polar -
polar (amide)  Polar = (nucleophilic)
++
+
91
T62A/P125L 269,
A → G
459,
C → T
polar = (nucleophilic)  Nonpolar (small)
Polar = (hydrophobic)  Nonpolar (hydrophobic)
-
++++
98
N74I/P113S
306,
A → T
422,
C → T
Polar = (amide) Nonpolar (hydrophobic)
Polar = (hydrophobic) Polar = (nucleophilic)
++++
-
25
V85A/L177I
339,
T → C
614,
C → A
Nonpolar (hydrophobic)  Nonpolar
(small)
Nonpolar (hydrophobic)Nonpolar (hydrophobic)
+
++
50
T206S/G212V
701,
A → T
720,
G → T
polar = (nucleophilic)  Polar = (nucleophilic)
Nonpolar (small) Nonpolar (hydrophobic)
-
-
0.11
E128K/L226R
467,
G → A
762,
T → G
Polar - Polar +
Nonpolar (hydrophobic)  Polar +
++++
++++
0.05
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Table 3.5. Activity of mutant N proteins (carry double mutations) in the BUNV
minigenome system.
Clone Mutation
position
Section 2.03 Nature of change Con Activity
(%)
D87E/K121N
346,
C → A
448,
A → T
Polar -  Polar -
Polar +  polar = (amide)
-
-
39
L92I/V208A
359,
C → A
708,
T → C
Nonpolar (hydrophobic) Nonpolar (hydrophobic)
Nonpolar (hydrophobic)  Nonpolar
(small)
-
++++
95
R94S/K109N
365,
C → A
413,
A → T
Polar +  Polar = (nucleophilic)
Polar +  polar = (amide)
++++
-
0.09
E105G/A204E
398,
A → G
695,
C → A
Polar -  Nonpolar (small)
Nonpolar (small)  Polar -
+
-
0.35
N67I/L99H
312,
A → T
381,
T → A
Polar = (amide)  Nonpolar (hydrophobic)
Nonpolar (hydrophobic)  Polar +
-
++++
100
G79S/L188V
320,
G → A
647,
C → G
Nonpolar (small)  Polar = (nucleophilic)
Nonpolar (hydrophobic)Nonpolar (hydrophobic)
++
+
97
V21D/K166E
147,
T → A
582,
A → G
Nonpolar (hydrophobic)  Polar -
Polar +  Polar -
-
-
90
E178G/A222T
618,
A → G
749, G → 
A
Polar -  Nonpolar (small)
Nonpolar (small)  polar = (nucleophilic)
-
++++
0.05
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Table 3.6. Activity of mutant N proteins (carry triple mutations) in the BUNV
minigenome system.
Clone Mutation
position
Nature of change Con Activity
(%)
A10T/K27M/
L226P
113 ,
G → A
115,
T → C
164,
A →T
762,
T → C
Nonpolar (small)  polar = (nucleophilic)
Polar +  Nonpolar (hydrophobic)
Nonpolar (hydrophobic)  Polar = (hydrophobic)
-
-
++++
0.07
A24T/E105V
/P113S
154,
G → A
398,
A → T
422,
C → T
Nonpolar (small)  polar = (nucleophilic)
Polar -  Nonpolar (hydrophobic)
Polar = (hydrophobic)  Polar = (nucleophilic)
-
+
-
0.05
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A10T/K27M/L226P carries two mutations at non-conserved residues in the N-
terminal region and a third mutation at a globally conserved residue in the C-terminal
region of BUNV N protein. All the three mutations above were already generated as
single substitutions in BUNV N protein. Mutant N proteins A10V and K27E were
functional in BUNV minigenome system, displaying 100% and 95% activity
respectively while mutant N protein L226A shows 26% of the wt BUNV N protein
activity (Table 3.3). Mutant N protein A24T/E105V/P113S contains a mutation in the
N-terminal region at a non-conserved residue and two mutations at conserved and
non-conserved residues in the middle of BUNV N protein. Both residues A24 and
E105 were obtained as single mutations and mutant N proteins carrying these
mutations were active in BUNV minigenome displaying 92% and 79% of the wt
BUNV N protein activity respectively (Table 3.3).
3.6. Effect of changing the amount of transfected DNA in
the activity and expression of N protein in BUNV
minigenome system
Mutant N protein Y141C was selected as an example of an inactive mutant N protein
in BUNV minigenome assay, displaying only 1.8% of the activity of wt N protein. To
investigate whether increasing the amount of transfected DNA would increase its
activity, BSR-T7/5 cells were transfected with different amounts (0.2, 0.4, 0.6, 0.8
and 1.0µg) of pT7riboBUNN or mutant pT7riboBUNN (Y141C). The amount of
pT7riboBUNL (0.2µg), pT7riboBUNMRenilla (-) (0.2µg) and pT7-FF-lucifrase (internal
control, 0.1µg) were fixed in the experiment. Cell lysates were used in both the
luciferase assay and western blot. The activity of wt N protein was not affected by
altering the amount of DNA (Figure 3.8). Moreover, the levels of BUNV N protein
expressed in the BUNV minigenome system seemed roughly equivalent despite the
use of different amounts of pT7riboBUNN (Figure 3.10A). It seems that using high
amounts of pT7riboBUNN does not increase the activity or expression of wt BUNV N
protein in the BUNV minigenome system. On the other hand, the activity of mutant N
protein Y141C was significantly increased by increasing the amount of transfected
DNA. The highest activity was obtained when 1.0 µg of the DNA was used,
displaying a 5-fold increase in activity compared to 0.2 µg DNA (Figure 3.9).
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Figure 3.8. Affect of changing the amount of pT7riboBUNN plasmid in the
activity of wt BUNV N protein in the BUNV minigenome system.
BSRT7/5 cells were transfected with 0.2 µg pT7riboBUNL, 0.2 µg
pT7riboBUNMRenilla (-) and various amounts of pT7riboBUNN (0.2, 0.4, 0.6,
0.8 and 1.0 µg). The highest activity was obtained when 0.4 µg of
pT7riboBUNN was used. In general, there were not considerable differences
in the activity of N protein.
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Figure 3.9. Affect of changing the amount of mutant pT7riboBUNN Y141C
plasmid in the activity of mutant Y141C N protein in the BUNV minigenome
system.
BSR-T7/5 cells were transfected with 0.2 µg pT7riboBUNL, 0.2 µg
pT7riboBUNMRenilla (-) and various amounts of mutant pT7riboBUNN
Y141C (0.2, 0.4, 0.6, 0.8 and 1.0 µg). The activity of mutant Y141C N
protein increased dramatically as the amount of DNA increased. The
highest activity was observed when 1.0 µg of DNA was used, displaying
greater than 3-fold increase compared to 0.2 µg.
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Figure 3.10. Western blot of wt BUN N protein and mutant Y141C N
protein using the minigenome cell lysate.
BSRT7/5 cells were transfected with 0.2 µg of pT7riboBUNL, 0.2 µg of
pT7riboBUNMRenilla (-) and various amounts (0.2, 0.4, 0.6, 0.8 and 1.0
µg) of pT7riboBUNN or pT7riboBUNN Y141C. It seems that using high
amount of pT7riboBUNN did not increase levels of expression (A).The
mutant Y141C N protein was not detected when 0.2 µg of DNA was
used. However, the levels of expression increased gradually as the
amount of DNA increased (B).
0.2 0.4 0.6 0.8 1.0
0.2 0.4 0.6 0.8 1.0
A
B
Chapter 3. Mutagenesis of BUNV N gene
120
No Y141C N protein was detected when 0.2 µg of mutant plasmid was used (Figure
3.10B). However, the total amount of mutant Y141C N protein was increased when
the amount of transfected DNA increased.
3.7. Discussion
Two PCR mutagenesis approaches, random and targeted, were used to mutate
BUNV N gene. First, PCR random mutagenesis was performed using low mutation
frequency (0 - 4.5 mutations/kb). To generate as many clones as possible carrying
single mutations, a slight modification of the manufacturer’s instructions was
introduced, using 100ng rather 500ng of the initial target DNA, and 30 - 35 cycles
rather than 20 - 25 cycles. The only explanation why the low mutation frequency did
not work efficiently when the manufacturer’s protocol was used, is the GenMorph kit
was designed to mutate fragments bigger than 1kb while the N target is about 700
bases.
In total, 328 clones were sent for sequencing. Of these, 72 clones carried single
mutations, 17 clones contained double mutations and 2 clones carried triple
mutations in BUNV N protein. The efficiency of this method to generate single
mutations is 79% when the number of double and triple mutations are taken into
account. However, if the total number of clones (328) sent for sequencing is
considered, the efficiency is 22% for clones carrying single mutations, 5% for clones
carrying double mutations, and 0.6% for clones containing triple mutations. Two-
hundred and thirty-seven clones (74%) had the same sequence as input parental
clone. Eighteen globally conserved residues between 51 orthobunyavirus N proteins
were substituted randomly. The remaining single mutations (10) occurred at BUNV-
specific, 26 mutations at Bunyamwera serogroup-specific residues, 18 mutations
occurred at closely related orthobunyaviruses N protein residues from two
serogroups (Bunyamwera and California).
To produce adequate mutational coverage along the BUNV N protein, 30 further
residues were targeted using PCR site-directed mutagenesis. Twenty-two residues
are conserved globally among 51 orthobunyavirus N proteins and 8 residues are
conserved between at least 20 orthobunyavirus N proteins. During both types of
Chapter 3. Mutagenesis of BUNV N gene
121
mutagenesis, 102 single mutations were generated in BUNV N protein covering the
whole region. Of these, 40 globally conserved amino acids were substituted and this
gives a percentage of 68% of global conserved amino acids of orthobunyavirus N
proteins.
A BUNV minigenome system was exploited by introducing all mutant N genes to test
the activity of mutant N proteins compared to the wt BUNV N protein. Four levels of
activity (parental-like, moderate, weak and very low) of mutant N proteins in BUNV
minigenome system were observed. Approximately 70% of mutant N protein
behaved like the wt BUNV N protein even though some mutations occurred at
globally conserved amino acids. This implies that such residues are not involved in
the functionality of N protein in this assay. In other words, the mutant N proteins are
able to encapsidate the BUNV minigenome, interact with the BUNV L polymerase
and produce mRNAs, indicating that transcription and replication of the BUNV
minigenome are competent. These data suggest that interactions of N-L, N-N and N-
RNA are intact. However, it is still possible that they may play a crucial role in other
steps in the virus life cycle e.g. entry, assembly, maturation or release.
Thirteen mutations caused moderate disruption (50-69%) of the N protein activity in
the minigenome system. It is possible that they could affect primary structure (linear
peptide) of the N protein. However, their activity can still be measured in the BUNV
minigenome system. The possibility that such residues affect other steps of the virus
cycle is higher than those functions like the parental N in the BUNV minigenome
system. All mutations resulting in high disruption (greater than 50%) occurred in the
middle (4 mutations) and in the C-terminus (7 mutations) of the N protein. Mutations
in the middle of N protein which caused high disruption might be involved in protein
folding while those in the C-terminal could be involved in multimerization of N protein
(Leonard et al., 2006).
The most important residues were R94A, I118N, W134A, Y141C, L177A, K179I and
W193A. All of these are globally conserved residues among 51 orthobunyavirus N
proteins, except I118N which is conserved between 22 orthobunyavirus N proteins
(Figure 3.4). Mutations I118N and L177A converted hydrophobic residues to a
hydrophilic and small nonpolar amino acids respectively. This would suggest strong
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disruption of its function. Mutations R94A and K179I occurred at positively charged
basic amino acids, and their function could be to interact with the RNA backbone.
The remaining disruptive mutations occurred at aromatic amino acids. Two residues
(W134A and Y141C) are in the middle of the N protein and W193A in the C-terminal
region. Alteration of the latter residues would definitely disturb protein structure since
they have a benzene-like ring. Coimmunopreciptation could reveal the intactness of
interaction between N and L proteins. On the other hand, cross-linking would show
failure in interaction of N protein molecules themselves. If there is no evidence of a
protein interaction failure, protein-RNA interaction might be examined.
Some clones carrying double mutations at conserved residues of the BUNV N protein
were still functional in the BUNV minigenome system. This could be explained via
either one mutation counteracts the impact of the other or both residues are not
crucial in the functionality of N protein in this assay. It seems that BUNV N protein is
very sensitive to triple mutations. Clones carrying double or triple mutations were
excluded from any further investigation as this project is concerned with the function
of individual residues and also more difficult to interpret.
The affect of changing the amount of DNA in the activity and expression of wt BUNV
N protein and inactive mutant Y141C as an example were studied. The wt BUNV N
protein displays no considerable differences in its activity and levels of expression in
the BUNV minigenome system when various amount of DNA were used. On the
other hand, the activity and expression of mutant N protein Y141C significantly
increased when high amount of DNA were used. No mutant N Y141C protein was
detected when 0.2 µg of mutant DNA was used. Its activity was 5-fold greater when
1.0 µg of the DNA was used. This is an indication of the impact of mutation at residue
Y141 on the activity and level of protein expression. Also mutagenesis strategy
reduced the possibility of introduction of mutations in the plasmid backbone or control
sequences, so that effects on N protein stability would be due to the mutation alone.
Residue Y141 might be involved in interactions with L polymerase during
transcription process. This would be investigated using coimmunopreceptation.
Otherwise, mutation Y141C might affects N protein stability.
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3.8. Summary
1- Using PCR random and targeted mutagenesis, 102 single substitutions were
generated in the BUNV N gene.
2- Mutant N genes were introduced to the BUNV minigenome to measure the activity
of mutant N proteins compared to the wt BUN N protein. They displayed a wide-
range of activity, parental-like, moderate, weak or inactive.
3- Mutations R94A, W134A and Y141C caused severe disruption in the activity of N
protein in the BUNV minigenome system.
4- In the BUNV minigenome system, the levels of activity and expression of BUNV N
protein was not significantly affected by changing the amount of DNA. However,
mutant Y141C, an example of an essentially inactive mutant N protein showed
dramatic increase in the activity and level of expression when the amount of DNA
increased which, reflects the impact of single mutation in BUNV N protein
functionality in this assay.
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Chapter 4. Rescue of recombinant viruses
carrying mutations in the N gene
4.1. Introduction
As mentioned previously, the BUNV S segment encodes the nucleocapsid and NSs
proteins in overlapping reading frames. A mutation on the BUNV S RNA could affect
the either N, NSs or both genes which would make it hard to distinguish whether the
phenotype of the resulting virus was due to mutation of the N or NSs ORF.
An attempt to recover a BUNV with 4 segments was carried out previously (Bridgen
et al., 2001). The purpose of that study was to rescue a recombinant BUNV which
encodes the N and NSs proteins from separate segments which offers the
opportunity to manipulate each gene individually. Two S-like segments were
constructed from pT7riboBUNS plasmid. To produce a plasmid which encodes only
the N protein (pT7riboBUNN), five silent point mutations were generated in
pT7riboBUNS to abrogate NSs protein expression. The first two start codons in NSs
ORF were both mutated to ACG, codon 3 was substituted from TCG (Ser) to TAG
(stop codon), and codons 4 and 5 were mutated from Leucine to Proline codons. The
second plasmid (pT7riboBUNNss) was constructed to encode only the NSs protein
ORF by introducing a single point mutation in the N protein initiation codon to be
converted to stop codon and 377 nucleotides were deleted at the 3’ end of the N
ORF. Hence, pT7riboBUNN expresses full length BUNV S segment (961bases) while
pT7riboBUNNSs encodes a smaller S-like RNA of 584 bases. However, only a 3
segment virus was recovered designated BUNdelNSs, indicating that NSs was not
essential for growth in tissue culture.
As it is possible to use only pT7ribo constructs in BUNV rescue system without any
support plasmids (Lowen et al., 2005), BSR-T7/5 cells grown in 60 mm-diameter
dishes were transfected with 1µg pT7riboBUNL, 1µg pT7riboBUNM and 1µg
pT7riboBUNN using lipofectamine-2000 transfection reagent. Cells were incubated
for 4 - 5 hours at 37ºC and the transfection mixture removed and replaced with 4 ml
fresh medium. Cells were incubated for 5 days at 33ºC. Cells were harvested and the
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supernatant was used in a plaque assay on Vero-E6 for isolation of recombinant
virus. The BUNdelNSs virus was then propagated on BHK-21 cells and titered.
4.2. Affect of mutations at conserved or non-conserved
residues of BUNV N protein in rescue of recombinant
mutant viruses
In the previous chapter I described the generation of 102 single mutations in BUNV N
gene. The first step was to study the impact of such mutations in the N protein by
measuring their activity in the BUNV minigenome system. However, limited
information can be obtained from this assay as it can only mimic virus transcription
and replication. To produce a better understanding of the impact of mutations in the
N protein functionality, it would be more instructive to attempt to rescue viable viruses
carrying mutations in the N gene. The activity of N protein in the BUNV minigenome
system was shown to be severely affected by mutations at highly conserved residues
while mutations at nonconserved residues had no affect in the functionality of N
protein in this assay.
To investigate this observation in the BUNV rescue system, five mutant N genes
(E5D, AI0V, G67D, N135Y and A227V) carrying single mutations at nonconserved
residues in parallel with 5 mutant N genes (F6, E20G, G66R, W134A and K228T)
carrying single mutations at well-conserved amino acids in orthobunyavirus N
proteins were first introduced to BUNV rescue system to explore whether mutations
at conserved or non conserved residues could affect virus recovery. Several
preliminary data supported focusing on mutations at conserved residues (Table 4.1).
Mutant viruses carrying mutations at nonconserved residues were recovered from the
first attempt like the parental virus while mutant viruses that contain mutations at
conserved residues were rescued after at least two attempts. Parental plaque size
(large) was produced by mutant viruses carrying mutations at non-conserved
residues and small plaque size was shown by mutant viruses carrying mutations at
conserved residues. Recovery of mutant viruses with mutations at nonconserved
residues took 4-5 days, similar to the parental virus, while mutant viruses containing
mutations at conserved residues took more than 5 days. The recovery of viruses
carrying mutations at nonconserved residues was between 105-106 pfu/ml, while
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Table 4.1. Preliminary data of the affect mutations at conserved or non-
conserved residues of BUNV N protein in recovery of viable virus.
BSR-T7/5 cells were transfected with 1.0 µg each of pT7riboBUNN or
mutant, pT7riboBUNL and pT7riboBUNM using lipofectamine-2000 for 4 –
5 h at 37˚C. Transfection mixture was then removed and replaced with
fresh medium. Cells were incubated at 33˚C for 4-5 days before plaque
assay was performed in Vero-E6 cells.
Clones highlighted in bold carry mutations at conserved residues
Clone Attempt Rescuable
Incubation
period
(days)
Plaque
size
Recovery
pfu/ml
Parental 1 + 5 large 107
E5D 1 + 5 large 105
F6A 2 + 8 small 102
A10V 1 + 5 medium 106
E20G 3 + 7 medium 102
G66R 3 + 8 small 100
G67D 1 + 5 large 105
W134A 3 - 13 - -
A227V 1 + 5 large 105
K228T 2 + 5 large 102
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mutant viruses with mutations at conserved residues yielded only 102 pfu/ml.
Moreover, mutant N gene W134A, a globally conserved residue, was nonrescuable
(Table 4.1). This suggests that it would be more appropriate to focus only on
mutations at conserved residues in BUNV N protein. A further 59 mutant N genes
carrying single mutations at conserved residues between 20 closely related viruses
(Bunyamwera and California) serogroups or between 51 orthobunyavirus N proteins
from 4 serogroups (Bunyamwera, California, Group C and Simbu) were introduced to
BUNV rescue system.
4.3. Attempt to rescue recombinant viruses carrying single
mutations in the N protein covering a wide-range of
minigenome activities
Of 64 mutant N genes spanning a range of minigenome activities introduced in
parallel with parental N genes as a (+ve) control into BUNV rescue system, 50
recombinant viruses were recovered and 14 mutant N genes were nonrescuable.
The efficiency of BUNV rescue system to recover recombinant viruses carrying
mutations in N gene is 78% if the total number of selected genes is to be considered.
The parental virus and mutant V85A plaques were picked up from dilution 10-7, 20
mutant viruses were purified by picking single plaques from dilution10-6, 6
recombinant viruses were purified from dilution 10-5, 5 mutant viruses were purified
from dilution 10-4, 7 mutant viruses plaques were picked from dilution 10-3, single
plaques of 7 recombinant viruses were picked from dilution10-2 and 3 mutant viruses
carrying mutations at conserved residues in N-terminal region of N protein (K50A,
G66R and W68R) were purified from undiluted supernatant (Table 4.2 and figure
4.1). Three individual plaques of each mutant virus were picked.
4.4. Recombinant viruses with single, double or triple
mutations in N gene
To confirm the input mutations in the BUNV N gene, a single plaque of each mutant
virus was grown up, RNA extracted and used in RT-PCR in order to determine the
sequence of the S segment. Forty mutant viruses were found to carry the input
mutations, 5 recombinant viruses (D8A, E20G, R40A, G66A and W68R) contained
the input mutations and as well as second mutations (Table 4.3). Two recombinant
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Table 4.2. Recovery of mutant bunyaviruses.
The titer of each virus presents the dilution from which single plaques were
picked. (100) indicates single plaque was picked from nondiluted
supernatant. Mutant viruses highlighted in bold carry mutations at
nonconserved residues.
Virus pfu/ml Virus pfu/ml Virus pfu/ml Virus pfu/ml Virus pfu/ml
Parental 107 K50A 100 V85I 106 F145I 106 V208A 103
L4A 102 L53 F 106 T91A 103 G147A 103 S219A 106
E5D 105 E58D 106 H93N 102 M150A 103 A222G 106
F6A 102 G66R 100 S96G 106 F155L 105 A227V 105
D8A 106 G67D 105 A100V 104 I162A 102 K228T 102
V9I 106 W68R 100 L104A 102 V167A 104 F229L 103
A10V 106 N74S 106 E105A 106 M172A 104 G230R 105
P19 Q 106 P78H 106 E112A 103 R184M 103
E20G 102 N80S 106 A127G 105 A190G 104
Y23A 106 N82D 106 E128A 106 K197T 104
R40A 106 V85A 107 N135Y 106 L205A 103
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Figure 4.1. Recovery of fifty recombinant viruses.
Different serial dilutions of rescue supernatants were used in plaque assay
to pick single plaques for each mutant virus. Three mutant viruses (K50A,
G66R and W68R) were purified from nondiluted supernatants (100).
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viruses (E112 and R184M) contained 2 mutations in addition to the input changes.
(Table 4.4). The second mutations in the N genes of recombinant viruses D8A, E20G
and W68R were at the same nonconserved residue with same substitution K109E. In
the N gene of mutant E112A, two additional mutations occured in the N-terminal
region at non-conserved residues K27E and T62A. Mutation R184M occurred in the
C-terminus and an extra two mutations were introduced, one in the N-terminus at
conserved amino acid D8G and the other in the middle at a non-conserved residue of
N protein.
4.5. Revertant viruses
Mutant genes R94A, I118N, P125H, G131W, W134A, G137A, Y141C, F157I Y158N,
Y176A, L177A, K179I, W193A, W213R, L226A and I231A contain changes at
globally conserved residues in the middle and the C-terminus of the N protein. No
viruses were recovered when plasmids containing these mutations were used in the
rescue system. Mutant F157I is an example of a nonrescuable gene that was used in
an immunofluorecent experiment to explore whether the recombinant virus had been
rescued but was unable to grow. The rescue supernatants of F157I and the parental
virus were used to infect BHK-21 cells. The mutant F157I N protein was detected by
immunofluorecent staining, however, the signal was very weak compared to wt N
protein (Figure 4.2). This result confirms the recovery of mutant F157I, however, the
recombinant virus seems to be very debilitated. The rescue supernatant was used to
infect BHK-21 cells in order to propagate the virus but without success. Such
observations suggest that extending the incubation period would give the virus a
better chance to grow. When the rescue experiment was performed again and the
cells incubated for 12 days, a virus was eventually rescued. However, nucleotide
sequencing showed that the recovered virus was the parental virus not F157I. All
nonrescuable mutations were subjected to the same incubation period. G137A was
rescued but nucleotide sequence analysis confirmed it had reverted to the parental
virus sequence.
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Table 4.3. Five recombinant viruses shown to carry double mutations
although the input mutation was single.
Recombinant virus Input mutation Second
mutation
Third mutation
E112A E112A K27E T62A
R184M R184M D8G F97S
Table 4.4. Two mutant viruses carry triple mutations .
Recombinant virus Input mutation Second mutation
D8A D8A K109E
E20G E20G K109E
R40A R40A T71S
G66A G66A R28H
W68R W68R K109E
Chapter 4. Rescue mutant viruses
132
F157I Parental virus
Mock
Figure 4.2. Immunofluorescent experiment .
BSR-T7/5 cells were transfected with 1.0 µg each of pT7riboBUNN or
mutant F157I N clone, pT7riboBUNL and pT7riboBUNM using
lipofectamine-2000 for 4-5 h at 37˚C. Transfection mixture was then
removed and replaced with fresh medium. Cells were incubated at 33˚C for
4-5 days. Cells were harvested and the supernatants were used to infect
8×104 BHK-21 cells. After overnight of incubation at 33˚C
immunofluorescent experiment was performed in the samples using Anti-
BUNV N antibody.
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4.6. New strategies to attempt to recover the nonrescuable
N genes
In addition to extending the rescue incubation period, several attempts to recover the
remaining nonrescuable genes were carried out. Previously, the activity and
expression of mutant Y141C (an example of an inactive mutant N protein) increased
dramatically in the BUNV minigenome system when higher amounts of DNA (1.0 µg)
was used. This suggests that if the amount of DNA of nonrescuable genes were
increased, it might help to recover the viruses. To explore these possibilities, BSR-
T7/5 cells were transfected with various amounts of pT7riboBUNN or mutant clone
(pT7riboBUNN Y141C) (0.2, 0.4, 0.6, 0.8, 1.0, 1.5 and 2.0 µg) and fixed amount (1.0
µg) each of pT7riboBUNL and pT7riboBUNM. The recovery of the parental virus was
108 pfu/ml for all combinations (Table 4.5). However, mutant virus Y141C was still not
recovered. The support plasmid (pTM1BUNN) which expresses wt N protein was
then included in the rescue mixture to overcome the possibility of low level of
expression of mutant N protein. In this experiment, BSR-T7/5 cells were transfected
with 1.0µg each of pT7riboBUNN, pT7riboBUNM and pT7riboBUNL and different
amounts of pTM1BUNN (0.01, 0.05, 0.1 and 0.5 µg). Massive CPE was observed but
no virus was recovered.
4.7. Discussion
The BUNV rescue system provides the opportunity to generate viable viruses
carrying desired mutations from cDNAs. 102 mutations were generated in BUNV N
protein and their activity measured in the BUNV minigenome system. The second
step was to introduce mutant N genes to the BUNV rescue system in attempt to
recover viable viruses carrying mutations in BUNV N protein. It was not feasible to
attempt to rescue all these mutations, so, 64 mutant N genes carrying single
mutations covering the whole region of BUNV N ORF and display a wide-range of
activity in BUNV minigenome were selected for further investigation. Preliminary data
from the activity of mutant N proteins in minigenome system suggested high and
severe disruption was caused by mutations at conserved residues in BUNV N protein
while mutations at nonconserved amino acids cause less or no disruption.
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pT7riboBUNNY141C DNA in the recovery of the parental virus and
mutant Y141C virus.
BSR-T7/5 cells were transfected with various amount of pT7riboBUNN
DNA (0.2, 0.4, 0.4, 0.6, 0.8, 1.0, 1.5 and 2.0 µg) and 1.0 µg each of
pT7riboBUNL and pT7riboBUNM. From all combinations virus yields are
within the same log
pT7riboBUNN
( µg)
Yield (pfu/ml) pT7riboBUNNY141C
( µg)
Yield (pfu/ml)
0.2 3.6 ×108 0.2 -
0.4 1.7 ×108 0.4 -
0.6 3.7 ×108 0.6 -
0.8 2.2 ×108 0.8 -
1.0 1.5 ×108 1.0 -
1.5 4.7 ×108 1.5 -
2.0 4.5 ×108 2.0 -
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To explore this observation in terms of the ability to rescue mutant viruses, 5 mutant
N genes carrying single mutations at nonconserved amino in parallel with 5 other
mutant N genes carrying single mutations at conserved residues were introduced to
BUNV rescue system (Table 4.1). Recombinant viruses carrying single mutations at
nonconserved residues of N protein displayed no phenotypic differences from the
parental virus while recombinant viruses with single mutations at conserved residues
in the N protein displayed phenotypic differences (small plaque, low titer,
nonrescuable).
It was clear that mutations at conserved amino acids of BUNV N protein affected
virus recovery. Hence, all mutant N genes (59) carrying single mutations at
conserved amino acid were introduced to BUNV rescue system.
Recombinant viruses were recovered at a wide-range of efficiecies (Table 4.2). This
could be used as evidence of the impact of mutations in BUNV N functionality. Some
viruses showed low or very poor recovery while others displayed high recovery. This
variation could be explained in a number of ways, some residues are not involved in
BUNV N functionality while other residues may affect some aspect of virus replication
and growth. In some cases the poor recovery (rescuable N gene cDNAs) could be
due to experimental conditions (e.g. DNA quality, cell viability, transfection reagent
etc). For example, mutant K228T showed recovery of 102 pfu/ml. When mutant
K228T was purified, the mutant virus grew to 108 pfu/ml. The S gene nucleotide
sequence of virus K228T was confirmed as only carrying the desired mutation.
The majority of recovered viruses contained the input mutations and hence such
mutations could be classified as tolerant mutations. However, they might be
conditional lethal when growth conditions e.g. temperature, cell line etc are changed.
Second and third site mutations were introduced into BUNV N gene of some mutant
viruses. RNA viruses have high rates of mutations due to lack of proof-reading
activity of their RNA polymerases. The manipulation of the BUNV N protein might
enhance the viruses to mutate further. A common feature was observed during
rescue of these mutant viruses. They were rescued after 7-9 days of incubation while
the parental requires a period of 5 days. The longer incubation period might give the
virus a chance, first to recover, and then to overcome the debilitating mutation by
introducing a second or third mutation to counteract the first mutation.
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Two mutant viruses, G137A and F157I, reverted back to the parental virus S RNA
sequence. Both residues are globally conserved (Figure 3.4). They are in the middle
of N protein within a cluster of conserved residues. The data obtained from the
immunofluorescence experiment suggests that the viruses had recovered but grew
poorly. When the incubation period was extended this might have given the virus
more chance to correct the input mutation culminating in the recovery of the parental
virus. Six mutant genes carrying mutations in the same region of N were
nonrescuable. It seems that this region therefore plays a crucial role in BUNV N
protein functionality.
4.8. Summary
1- 64 mutant N genes carrying single mutations were introduced into BUNV
rescue system in an attempt to recover viable viruses.
2- 50 recombinant viruses were rescued; 14 mutant N genes were nonrescuable.
3- Mutant viruses were recovered over a wide-range of efficiency.
4- In general, mutations at conserved residues severely affect virus recovery
compared to mutations at nonconserved residues of N gene.
5- Revertant viruses or viruses with additional mutations were also recovered for
some mutant N clones.
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5.1. Introduction
102 mutations were generated in the BUNV N protein randomly or specifically. The
activity of mutant N proteins was measured in the BUNV minigenome system. They
displayed a wide-range of activity. Sixty-four plasmids carrying single mutations (59
mutations at conserved residues and 5 at nonconserved residues) in the BUNV N
protein were used in the BUNV rescue system in an attempt to recover viable viruses
carrying mutations in the N protein gene. Fifty recombinant viruses were rescued; no
virus was recovered from the other 14 clones. These preliminary data indicate that
the recovery of recombinant mutant viruses from clones that carried mutations at
conserved residues was poorest. Mutations in the N protein gene could affect the
virus life cycle at any step (entry, uncoating, transcription, replication, assembly,
maturation or release).
The impact of such mutations in the N protein could be observed via virus growth
properties. It is possible that mutations in the N protein could produce an attenuated
virus with very low titre. Viruses carrying mutations in the N protein might show
different plaque phenotypes (small or large). Mutations in the BUNV N protein gene
could also affect N protein expression, however, it is also possible that mutations in
the N protein gene could affect expression of other viral genes as the N protein
encapsidates all the three segments. The generation of temperature-sensitive virus,
is another possibility from viruses carrying mutations in the N protein gene since the
N protein is involved in virus transcription and replication. Moreover, if the N protein
interacts with cellular proteins, mutations in the N protein might affect these
interactions and a new phenotype could be observed. All the above possibilities were
investigated through the characterisation of the mutant viruses by: virus titration and
plating efficiency, plaque phenotypes, protein labelling, western blotting, temperature
sensitivity and host restriction.
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5.2. Titration of mutant viruses
All mutant viruses were grown under the same conditions and stock viruses were
used in plaque assay on Vero-E6 cells. The mutant viruses grew to different titres
(Table 5.1). The majority of recombinant viruses (16) produced about 107 pfu/ml, 13
mutant viruses behaved like the parental virus yielding about 108 pfu/ml, 7 mutant
viruses showed about 106 pfu/ml, 8 mutant viruses displayed about 105 pfu/ml, 3
mutant bunyaviruses (R40A, A100V and V208A) released about 104 pfu/ml and 4
recombinant viruses (F6A, G147A, M150A and I162A) were debilitated and showed
titres of about 103 pfu/ml. The latter viruses carry mutations at universally conserved
amino acids, one in the N-terminus and the rest in the middle of N protein. Not all
conserved residues affected virus titration since 12 mutant viruses (L53F, N74S,
P78H, S96G, E105A, E112A, E128A, F145I, S219A, A222G, K228T and G230R)
carrying mutations at well conserved residues grew to titres similar to that of the
parental virus, about 107-108 pfu/ml. A summary of mutant virus titres is given in
Figure 5.1.
5.3. Plaque phenotypes of mutant viruses
In Vero-E6 cells mutant viruses showed 3 types of plaque size: large, medium or
small after an incubation of 6 days at 33ْ C (Figure 5.2). The majority of recombinant
viruses (22) produce parental plaque sizes (large, 4-5mm) even when mutations
occurred at conserved residues. Medium size plaques (2mm) were shown by 9
mutant viruses, and 11 recombinant viruses displayed pinpoint plaque size (<1mm).
Mixed plaque sizes were observed in 8 recombinant viruses. Nineteen mutant
viruses showed plaque size and titers similar to the parental virus. Mutant viruses
A100V and L205A produced large plaque sizes, however, their titres were 2.8  104
and 5.5  105 pfu/ml respectively. This means that they displayed a 10000 and 1000-
fold reduction, respectively, in virus yield compared to the parental virus.
Recombinant viruses Y23A and E128A showed pin point plaque sizes although they
grew to 107- 108 pfu/ml. Mutant viruses F6A, R40A, G147A, M150A, I162A and
V208A displayed pin point plaque sizes and poor titrations with reductions of 10000
or 100000-fold below the parental virus titre. Mutant viruses which displayed medium
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Table 5.1. Titres of recombinant viruses in Vero-E6 cells.
Recovery supernatants of mutant viruses were used in plaque assay in Vero-E6
cells. After 6 days of incubation at 33˚C, cells were stained with neutral red and
three single plaques for each mutant virus were picked and one single plaque
was inoculated into BHK-21 cells to grow a stock. After 6 days of incubation at
33˚C, the supernatants were used in plaque assay in Vero-E6 cells to determine
their titre.
Mutant viruses carry mutations at nonconserved residues are highlighted in
bold.
Virus
Titre
pfu/ml Virus
Titre
pfu/ml Virus
Titre
pfu/ml Virus
Titre
pfu/ml
Parental 7.4 108 E58D 3.5 108 A100V 2.8 104 M172A 2.0 106
L4A 1.0 107 G66R 2.0 107 L104A 6.0 105 R184M 4.5 105
E5D 2.5 107 G67D 9.0 107 E105A 6.5 107 A190G 2.5 106
F6A 4.0 104 W68R 3.5 107 E112A 1.5 108 K197T 1.0 105
D8A 8.0 107 N74S 4.0 108 A127G 2.0 106 L205A 5.5 105
V9I 1.0 107 P78H 3.3 108 E128A 1.1 108 V208A 1.5 104
A10V 6.7 108 N80S 2.8 108 N135Y 3.0 107 S219A 7.5 107
P19Q 1.4 106 N82D 1.0 108 F145I 2.5 108 A222G 4.0 108
E20G 5.0 107 V85A 1.5 108 G147A 2.0 103 A227V 1.5 107
Y23A 7.0 106 V85I 4.0 107 M150A 5.0 103 K228T 3.0 107
R40A 5.0 104 T91A 1.0 105 F155L 2 .0 105 F229L 9.5 105
K50A 6.0 105 H93Q 1.5 106 I162A 5.0 103 G230R 1.8 107
L53 F 4.8 108 S96G 5.5 107 V167A 2.0 106
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Figure 5.1. Summary of recombinant mutant virus titres.
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(A)
Parental G230R
V85IN82D
E105A
S96G R184M
N80S S219A
K228T
E58D P78H L205A N74S V85A
V9I A100V F145I L4A E5D
A227V A10V W68R
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(B)
Parental K50A E20G D8A
E112A A190G N135Y F155L
F229L K197T
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(C)
G147A
R40AF6A
L104A M150AE128A
Y23A
M172A V208A
Parental
A127G I162A
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(D)
Figure 5.2. Plaque phenotypes of mutant viruses.
After mutant viruses were purified, stock viruses were used in plaque assay.
Vero-E6 cells were infected with serial dilution (10-1 - 10-7) of stock virus for 1 h
at 37°C. The virus was removed and replaced with 2ml agarose overlay and
incubated at 33°C for 6 days. Cells were then fixed with 5% formaldehyde for at
least 2 hrs, stained with Geimsa and plaques were examined. The viruses were
classified into 3 size classes, large (A), medium (B) and small (C), while some
mutants produced mixed sizes of plaque (D).
Parental G67D L53F A222G
H93Q V167A T91A G66R
P19Q
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plaque sizes yielded titres of 106 -108 pfu/ml except recombinant viruses K50A,
F155L and F229L which produced titres of 105 pfu/ml, 1000-fold less than the
parental virus titre. Those recombinant viruses which displayed mixed plaques
produced 106 -108 pfu/ml, except mutant T91A which yielded 105 pfu/ml, 1000-fold
reduction compared to the parental virus.
5.4. Protein labelling and western blotting
Mutations in the N gene could affect not only N protein expression, they might affect
expression of other viral genes. To investigate the impact of mutations on N protein
expression as well as expression of the other viral proteins, protein labeling and
western blotting were performed (an example of a whole western blot is given in
Figure 5.3). Different MOI (0.01, 0.1 or 1.0) were used in the latter experiments due
to the poor titers shown by some mutant viruses which made it difficult to use a high
MOI. However, similar MOI of the parental virus was used with each group of viruses
(Figure 5.4). Several mutant viruses (F6A, R40, T91A, A100V, F155L, E112A,
K197T, V167A, M172A, and V208A) showed a dramatic decline in the level of N
protein expression. These results can be correlated to the titre of mutant viruses
since they displayed 1000 to 10000-fold reduction compared to the parental virus
(Table 3.10). In other cases, mutant viruses K50A, L205A, V208A and F229L
showed no deficiency in N protein expression which is consistent with results
obtained from the BUNV minigenome system; however, their titres showed significant
reduction 3 to 4 logs below the parental virus titre.
No significant differences in viral gene expression were observed. In general, it
seems that mutations in the N protein only affected the level of N protein expression
while the levels of other viral proteins were not affected. Some mutations in the N
protein affect protein mobility. This was observed in mutant viruses P19Q and L53F
(Figure 5.4A and B).
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Figure 5.3. An example of the whole blot (membrane size 11×7cm)
Using anti-N polyclonal rabbit antibody.
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Figure 5.4. Protein labeling and western blot of mutant viruses.
Since mutant viruses have different titres and some mutant viruses were
debilitated making it difficult to infect at high MOI, Vero-E6 cells were
infected at MOI 0.01 (a), 0.1 (b) or 1 (c) in duplicate, and incubated overnight
at 33ºC. Protein labeling and western blot were performed. Position of viral
Gc and N proteins are indicated.
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5.5. Temperature-sensitivity
As mentioned previously, all recombinant viruses were rescued at 33ºC. This would
increase the probability of recovering ts mutants which can grow only at lower
temperatures. The mutant viruses were tested for their ability to form plaques at
33ºC, 37ºC and 38ºC on Vero-E6 cells (Table 5.2). The parental virus behaved
similarly at all temperatures, producing almost the same titre and the same plaque
size (Table 5.2 and Figure 5.5). The majority of mutant viruses (23) displayed a
reduction of 10-fold in their titers at 37ºC or 38ºC or at both. Three mutant viruses
(F6A, G147A and V208A) functioned poorly at 33ºC, and displayed titers of 103-104
pfu/ml with pin point plaques size and did not grow at 37ºC or 38ºC. Another 4
mutant viruses (L104A, M150A, I162A and M172A) were debilitated, growing at 33ºC
and 37ºC only.
Using the titration data the reduction in virus titer (log10 pfu/ml) and the efficiency of
plating (EOP) of the mutant viruses were calculated (Table 5. 2). The parental virus
displayed reduction of ≥ 0.3 log10 pfu/ml in virus titre and plating efficiency of 0.5.
Twenty-nine mutant viruses showed reduction of ≤ 2.0 log10 pfu/ml and their plating
efficiency was 0.01-0.3, 13 mutant viruses displayed reduction of 2.1-2.6 log10 pfu/ml
and plating efficiencies between 0.003-0.009, 8 recombinant viruses showed greater
than 3.0 log10 reduction in titer and plating efficiency between 0.0-0.0004. Based on
the plaque phenotypes, titres and plating efficiency at various temperatures of mutant
viruses, temperature sensitivity was defined as production of large plaque size and
high titre (108 pfu/ml) at the permissive temperature (33°C) while at 38ºC (non-
permissive temperature) ts mutant virus produce small plaque size, reduction of >2.0
log10 in virus titre and plating efficiency ≤0.009. Hence, mutants N74S, S96G, K228T
and G230R are ts mutant viruses. Although mutant viruses F6A, K50A, L104A,
G147A, M150A, I162A, M172A and V208A displayed reduction of >2.0 log10 in virus
titer and plating efficiency <0.008, they were not classified as ts mutant either
because they displayed small plaque size and grew poorly at 33°C.
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Titre (log10 pfu/ml) Titre (log10 pfu/ml)
virus
33°C 37°C 38°C ∆ EOP
virus
33°C 37°C 38°C ∆ EOP
Parental 8.5 8.3 8.2 0.3 0.5 G66R 7.2 6.2 6.0 1.2 0.06
L4A 6.8 6.5 5.5 1.3 0.05 G67D 7.1 6.7 6.6 0.5 0.3
E5D 7.4 7.2 6.7 0.7 0.2 W68R 7.8 6.4 6.0 1.8 0.02
F6A 4.5 0.0 0.0 4.5 0.0 N74S 8.5 7.9 6.3 2.2 0.007
D8A 7.8 7.2 6.2 1.6 0.02 P78H 8.0 7.9 6.7 1.3 0.06
V9I 6.5 5.5 5.5 1.0 0.09 N80S 8.1 7.5 7.4 0.7 0.2
A10V 8.4 7.8 7.8 0.6 0.2 N82D 7.7 7.1 6.5 1.2 0.05
P19Q 5.9 3.5 3.3 2.6 0.003 V85A 7.9 7.2 6.5 1.4 0.04
E20G 7.0 5.7 5 2.0 0.01 V85I 6.7 6.5 5.9 0.8 0.2
Y23A 7.4 5.5 5.2 2.2 0.006 T91A 4.3 3.5 3.3 1.0 0.1
R40A 4.5 2.2 2 2.5 0.003 H93Q 5.8 3.5 3.5 2.3 0.005
K50A 5.7 4.4 2.3 3.4 0.0004 S96G 8.1 6.7 6.0 2.1 0.008
L53 F 8.4 8.1 7.2 1.2 0.06 A100V 3.9 2.6 2.5 1.4 0.04
E58D 8.5 7.2 7.2 1.3 0.06 L104A 5.5 5.1 0.0 5.5 0.0
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Table 5. 2. Temperature sensitivity and plating efficiency of mutant viruses
The ∆ indicates the reduction in virus titre (log10 pfu/ml) at 38°C compared to that
for the permissive temperature (33°C).
EOP: efficiency of plating determined via: titer at 38°C/titer at 33°C
Underlined values indicate a reduction of ≥2.0 log10 pfu/ml in virus titre at 38°C
compared to that of the titre at the permissive temperature (33°C).
Mutant viruses highlighted in bold display ts phenotype.
Titre (log10 pfu/ml)
virus
Titre (log10 pfu/ml)
virus
33°C 37°C 38°C ∆ EOP 33°C 37°C 38°C ∆ EOP
E105A 8.0 7.0 6.4 1.6 0.03 R184M 5.7 3.6 3.5 2.2 0.008
E112A 7.5 6.8 6.3 1.2 0.06 A190G 5.4 4.8 4.5 0.9 0.1
A127G 6.0 4.3 3.8 2.2 0.006 K197T 7.4 7.0 6.7 0.7 0.2
E128A 7.7 6.8 5.3 2.4 0.004 L205A 5.3 4.4 3.2 2.1 0.008
N135Y 6.6 6.0 5.9 0.7 0.2 V208A 3.7 0.0 0.0 3.7 0.0
F145I 8.3 7.2 7.2 1.1 0.08 S219A 7.9 6.2 6.1 1.8 0.02
G147A 3.4 0.0 0.0 3.4 0.0 A222G 8.0 7.2 6.5 1.5 0.03
M150A 3.9 1.7 0.0 3.9 0.0 A227V 7.5 5.7 5.7 1.8 0.02
F155L 6.4 5.0 4.3 2.1 0.008 K228T 8.4 7.7 6.3 2.1 0.009
I162A 3.7 2.8 0.0 3.7 0.0 F229L 5.3 3.6 3.6 1.7 0.02
V167A 6.5 6.3 5.3 1.2 0.07 G230R 8.3 7.2 6.2 2.1 0.007
M172A 5.0 3.7 0.0 5.0 0.0
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5.6. Characterization of ts mutant viruses
The four mutant viruses (N74S, G96S, K228T and G230R) designated as ts
displayed different behaviours. They grew only at 33°C while the parental virus grew
similarly at all temperatures, 33°C, 37°C and 38°C (Table 5.3 and Figure 5.5). They
displayed greater than 100-fold reduction in their titers, produced pinpoint plaque
sizes and showed plating efficiency ≤0.009 at 38°C compared to the parental virus.
Three stages in viral RNA synthesis could be ts: it could be a transcription step
(mRNA synthesis), early replication (antigenomic RNA synthesis) or late replication
step (genomic RNA synthesis).
To characterize these mutant viruses, protein labelling, western blotting and northern
blotting were performed at various temperatures, 33°C, 37°C and 38°C to test viral
gene expression, total amount of N protein expressed and RNA synthesis. Vero-E6
cells were infected with mutant viruses or parental virus at MOI of 1 for 1 hour at
37°C in triplicate, and incubated at 33°C, 37°C or 38°C overnight. The results
showed that none of the mutations (N74S, G96S, K228T and G230R) affected N
protein expression significantly (Figure 5.6). In other words, mRNA synthesis was
competent. This would suggest that these mutations could affect antigenomic or
genomic RNA synthesis.
To explore this possibility northern blotting is the best available technique. Total RNA
was extracted from infected cells using TrIzol reagent (Invitrogen). Between 3 - 5μg
of total RNA were run on an agarose gel using 1× TAE buffer (Masek et al., 2005) for
2 hrs (genome detection) or 3 - 4 hrs (antigenomic and mRNA detection). By using a
negative-sense DIG-labelled probe, mRNA and antigenome RNA can be detected
while a positive-sense DIG-labelled probe enables detection of the RNA genome
(Figure 5.7). The reasoning behind using probes for BUNV S segment rather for M or
L sgments is that it is possible to separate the S mRNA from the S antigenomic RNA
since the mRNA is 100 bases shorter than antigenomic RNA which represents 10%
of the size of antigenomic RNA. Two mutant viruses (N74S and S96G) were shown
to be deficient in genome-RNA synthesis (late replication step). Although both mutant
viruses were genome-synthesis deficient at 37°C and 38°C, they behaved slightly
differently. Mutant virus N74S showed decreased genomic RNA synthesis at 38°C
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Table 5. 3. Temperature sensitivity and platting efficiency of ts mutant
viruses. The ∆ indicates a reduction in virus titre (log10 pfu/ml) at 38°C
compared to that for the permissive temperature (33°C). EOP: efficiency of
platting.
Titre pfu/ml
virus 33°C 37°C 38°C ∆ EOP
Parental 6.0 × 108 3.5 × 108 3.0 × 108 0.3 0.5
N74S 3.0 × 108 7.5 × 107 2.0 × 106 2.0 0.007
S96G 1.2 × 108 5.0 × 106 1.0 × 106 2.1 0.008
K228T 2.5 × 108 4.5 × 107 2.4 × 106 2.0
0.009
G230R 2.2 × 108 1.5 × 107 1.2 × 106 2.2
0.006
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Figure 5.5. Plaque phenotypes of ts mutant viruses .
The same stock of virus was assayed at different temperatures. Vero-E6 cells
were infected with serial dilution (10-1 - 10-7) of stock virus for 1 h at 37°C. The
virus was removed and replaced with 2ml agarose overlay and incubated at
33°C, 37°C or 38°C for 6 days. Cells were then fixed with 5% formaldehyde for
at least 2 hrs, stained with Geimsa and plaques were examined.
wt BUN ×106
Parental ×106
N74S ×106
G96S ×106
33˚C 37˚C 38˚C
K228T ×106
G230R ×106
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Figure 5.6. Protein labelling and western blots of ts mutant viruses at various
temperatures.
Vero-E6 cells were infected in duplicate at MOI of 1 for 1 hour at 37°C and
incubated overnight at 33°C (lane 1), 37°C (lane 2) or 38°C (lane 3). Protein
labelling (A) and western blotting for N protein (B) were performed on the
samples. Viral Gc and N proteins are indicated. Mock (M).
Parental
21321321321
N74S G96S K228T
3 1 2 3
G230R
1 2 1 2 33 1 2 3 1 32 1 2 3
Parental G96S N74SK228T G230R
N
Gc
M
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Parental N74S
1 2 3 1 2 3
Figure 5. 7. An example of the whole blot of S segment genome RNA
detection using northern blotting at 33°C (lane 1), 37°C (lane 2) or 38°C (lane
3).
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Figure 5.8. RNA synthesis of ts mutant viruses.
Vero-E6 cells were infected with mutant virus at MOI of 1 at 37°C in triplicate.
Cells were then incubated overnight at 33°C, 37°C or 38°C. Total RNA was
extracted fron cells using TrIzol reagent and northern blotting was carried
out. To detect S genomic RNA positive DIG-labelled probe was used and
negative DIG-labelled probe was used for S mRNA and antigenome
detection.
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but also mRNA and antigenome synthesis declined. Recombinant virus S96G shows
no deficiency in mRNA and antigenome synthesis at all temperatures and only the
genome synthesis was deficient at 37°C and 38°C. Mutant viruses K228T and
G230R were ts at early replication step (antigenome-synthesis deficient). Mutant
virus G228T was early replication step strictly at 38°C while mutant G230R displayed
decreased antigenome-RNA synthesis at both 37°C and 38°C (Figure 5.8).
5.7. Host range restriction
In an attempt to detect host-restricted mutant viruses, plaque-forming ability of all
mutant viruses was tested on 5 different cell lines, Vero-E6, BHK-21, 2FTGH-V,
A549-V and 293T-V (Table 5.4). As BUNdelNSs virus was used in this project, it was
necessary to use interferon-deficent cell lines (for full details see Table 2.1). Host-
restriction could be defined as at least 100-fold reduction in titre on a specific cell line
compared to other cell lines. The parental virus displayed no differences in all cell
lines, showing titers of 8.5-8.8 log10 pfu/ml. Most mutant viruses followed this pattern.
The most permissive cell line was A549-V, even for those mutant viruses that
displayed poor titers in other cell lines. Mutant viruses F6A, M150A and G147A
produced pinpoint plaques in Vero-E6 and A549-V cells but did not plaque in 2FTGH-
V or 293T-V cells. In general, the parental virus produced smaller plaques in BHK-21,
2FTGH-V and 239-V than in Vero-E6 and A549-V cells (Figure 5.9) which could
explain the inability of the latter mutant viruses to form plaques in 2FTGH-V or 293-V
since they produced pinpoint plaque size in Vero-E-6 cells. Based on the definition
of host restriction above, mutant virus Y23A is defined to be host-restricted in
2FTGH-V cells. It displayed greater than a 100-fold reduction in virus titre compared
to other cell lines. In Vero-E6, BHK-21, A549-V and 293T-V cell lines, the mutant
virus yielded 7.3-8.1 log10 pfu/ml. Further investigations were carried out on mutant
virus Y23A to determine why it behaved differently only in 2FTGH-V cells.
Comparison of the ratio of intracellular and extracellular virus particles would reveal
whether the mutant virus Y23A had a deficiency in release from cells. 2FTGH-V cells
were infected with the parental or mutant virus at MOI of 1 overnight. The overnight
supernatant was collected and cell debris cleared by centrifugation. Cells were
harvested in PBS and subjected to 3 cycles of freeze-thaw. The lysate was then
Chapter 5. Characterization of mutant viruses
161
Titre (log10 pfu/ml)
virus
Vero-E6 BHK-21 2FTGH- V A549-V 293-V
Parental 8.5 8.7 8.5 8.8 8.5
L4A 7.0 6.8 5.8 7.3 6.9
E5D 7.3 7.9 6.7 8.0 7.5
F6A 3.7 4.5 - 5.0 -
D8A 8.2 7.7 7.6 8.6 8.0
V9I 7.9 7.7 7.3 8.3 7.7
A10V 8.3 7.7 7.0 8.3 8.2
P19Q 7.1 6.6 6.2 7.4 6.9
E20G 7.9 7.3 7.4 8.3 7.7
Y23A 7.7 7.0 6.0 8.2 7.3
R40A 7.2 5.3 3.2 5.0 5.5
K50A 5.8 5.3 5.5 6.7 6.3
L53 F 8.5 7.9 7.3 8.4 8.4
E58D 8.0 8.2 7.5 8.7 7.9
G66R 7.0 6.6 6.3 7.4 7.3
G67D 7.7 6.5 6.5 7.4 7.0
W68R 7.8 7.6 7.0 8.7 7.9
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Titre (log10 pfu/ml)
virus
Vero-E6 BHK-21 2FTGH- V A549-V 293-V
N74S 8.7 8.7 8.0 9.0 8.3
P78H 7.6 7.0 5.9 7.5 6.8
N80S 8.5 8.3 8.1 8.6 8.3
N82D 8.2 8.3 7.2 8.7 7.6
V85A 8.3 8.2 8.0 8.2 8.4
V85I 7.2 7.4 6.0 7.5 7.2
T91A 4.3 3.7 3.9 4.4 4.5
H93Q 7.4 7.2 6.6 7.5 7.7
S96G 8.0 8.3 7.5 8.5 7.6
A100V 4.5 4.0 4.0 4.7 4.7
L104A 5.9 6.5 3.3 6.4 5.9
E105A 7.6 7.7 6.4 7.5 7.0
E112A 7.8 7.5 6.7 7.8 7.7
A127G 5.9 6.0 4.7 6.7 5.0
E128A 7.7 8.1 6.7 8.2 7.8
N135Y 7.7 7.4 7.3 7.6 7.4
F145I 8.1 8.7 7.6 8.8 8.5
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Table 5.4. Host-restriction experiment
Stock of each mutant virus was assayed on five different cell lines (above) using
plaque assay technique. After an incubation of 6 days at 33°C, mutant virus titre was
counted. (-) indicates that mutant virus can not plaque even when undiluted stock
virus was used.
Titre (log10 pfu/ml)
virus
Vero-E6 BHK-21 2FTGH- V A549-V 293-V
G147A 3.0 - - 3.4 -
M150A 2.5 2.4 1.7 4.2 3.0
F155L 7.5 7.4 6.5 7.4 7.6
I162A 4.4 4.4 2.9 5.0 4.3
V167A 6.9 6.9 5.2 7.3 6.5
M172A 5.2 6.0 4.5 6.5 5.7
R184M 5.5 5.6 3.6 6.2 6.2
A190G 5.9 5.4 5.0 5.5 6.8
K197T 8.1 6.5 6.7 8.2 8.0
L205A 7.5 6.9 7.4 7.8 7.4
V208A 4.0 5.0 4.3 5.9 4.4
S219A 7.5 7.7 7.0 7.8 7.7
A222G 7.9 7.8 6.6 8.2 7.4
A227V 7.5 8.0 8.2 8.3 8.0
K228T 8.3 8.2 7.7 8.4 8.0
F229L 5.8 5.4 4.1 6.0 5.5
G230R 8.2 8.0 7.7 8.4 7.8
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Figure 5. 9. Parental virus plaque phenotypes in 5 different mammalian cell
lines.
Vero-E6 BHK-21 2FTGH-V A549-V 293-V
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Virus
Intracellular
particles pfu/ml
Extracellular
particles pfu/ml
Release
efficiency
%
Parental 3.5 × 107 1.5 × 107 30
Y23A 8.5 × 105 1.5 × 105 15
Table 5. 5. Comparison the ratio of the intracellular and extracellular virus
particles of mutant Y23A.
Vero-E6 cells were infected with parental virus or mutant virus Y23A at MOI of
1 and were incubated for 16 hrs at 33°C. The supernatants were collected and
cells were subjected to 3 cycles of freeze-thaw. The overnight supernatant
medium and freeze-thaw supernatant were used in a plaque assay.
The release efficiency was calculated via formula =
Extracellular titer
Total amount of virus x 100
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centrifuged to remove cell debris and both supernatants used in a plaque assay on
Vero-E6 cells. Mutant Y23A showed a 100-fold reduction in both intracellular and
extracellular virus particles compared to the parental virus (Table 5.5). These results
are consistent with the previous results obtained from host-range experiment (Table
3.14). Moreover, mutant virus Y23A not only had replication deficits but also showed
reduced release from cells. Comparison of the ratio of intracellular to extracellular
particles showed that only 15% of the total amount of mutant virus Y23A particles
were released compared to 30% of the parental virus particles.
5.8. Discussion
The growth properties of 50 recombinant viruses carrying mutations in the BUNV N
protein were characterized via titration, protein labelling, western blotting,
temperature sensitivity and host-restriction experiments. The majority of mutations
had little effect on virus growth properties. However, it was shown that single
substitutions in the BUNV N protein (e.g. G147A, M150A and I162A) reduced the
virus titer 100000-fold compared to the parental virus. These residues are highly
conserved in the middle of orthobunyavirus N proteins. Although mutant viruses
G147A, M150A and I162A were repropagated several times, they did not yield titres
more than 103 pfu/ml. The latter mutation might affect virus spread from cell to cell
since they produced pinpoint plaques. Overall, the titration of mutant viruses was a
good indication of the impact of mutations in the BUNV N protein which could affect
the virus life cycle at any step. Several mutant viruses (e.g. L4A, E20G and K228T)
showed poor recovery, about 102 pfu/ml (Table 4.2), however, when they were
purified they produced 105-107 pfu/ml (Table 5.1). The poor recovery could be
attributed to poor rescue conditions, DNA quality (e.g. purity, age, freez-thaw), cell
viability (e.g. passages) or high concentration of DI particles. Mutant viruses K50,
G66R and W68R displayed the poorest recovery and could only be isolated from
nondiluted rescue supernatant, but after they were purified and propagated, they
grew to titers 105-107 pfu/ml. Sequence analyses of the S segment of mutant viruses
G66R and W68R revealed second site mutations had been introduced at
nonconserved residue R28H and K109E respectively. In the latter case the poor
recovery might have been due to effects of the actual mutation rather than the rescue
conditions mentioned above.
Chapter 5. Characterization of mutant viruses
167
The recombinant viruses showed 3 types of plaque size, large, medium, and small
(Figure 5.2). Twenty-two mutant viruses produced parental-like plaque sizes (large)
(Figure 2.15A). These mutant viruses had no difficulty in spreading from cell to cell,
however, not all these mutant viruses produced high titers. Mutant viruses A100V
and L205A produced large plaques but their titers were 104 -105 pfu/ml more than a
1000-fold less than the parental virus. The latter residues affected virus replication
but not the spread from cell to cell. In contrast, mutant viruses Y23A and E128A
produced high titers of 107-108 pfu/ml but displayed pinpoint plaques (Figure 5.2C). It
seems that these mutations affected virus spread from cell to cell, but replication was
not affected. Mutant viruses F6A, R40A, G147A, M150A, I162A and V208A gave
pinpoint plaques and low titers (103-104 pfu/ml). Such mutations might affect both
virus replication and spread. Those mutant viruses which displayed mixed plaque
sizes (Figure 5.2D) might be due to the presence of DI particles or revertant viruses.
Protein labelling and western blotting results showed that mutations in the BUNV N
protein did not affect the expression of other genes specifically, but could affect N
gene expression in particular or all gene expression, as the N protein encapsidates
all three segments. N protein mobility in SDS-PAGE was affected by mutations
P19Q, L53F, G67D and N135Y. The latter substitutions increased the MW of BUNV
N by 31, 34, 58 and 45. As a result of the increase of the MW of mutant N proteins,
their migration in the polyacrylamyde gel was slower than the wt BUNV N protein
(Figure 5.4a, b).
Temperature-sensitivity experiments showed that 4 recombinant mutant viruses
(N74S, S96G, K228T and G230R) were ts, growing at 33°C, but not at 37°C or 38°C
while the parental virus grows at all temperatures. At permissive temperature (33°C)
they displayed large plaques and grew to titers of 108 pfu/ml. At nonpermissive
temperatures (37°C or 38°C) they showed pinpoint plaques, displayed a reduction of
>2.0 log10 pfu/ml in virus titer and plating efficiency ≤0.009 at 38°C (Table 5.3). Three
possible steps in RNA synthesis could be affected by these mutations at
nonpermissive temperature: mRNA, antigenome or genome synthesis. Protein
labelling and western blot analysis (Figure 5.6) shows no significant deficiency in N
protein expression in all ts mutant which is a preliminary indication of competent
mRNA synthesis.
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Using the northern blotting technique, the ts step of each mutant N protein was
determined. Two mutant viruses N74S and S96G were affected at a late replication
step (genome-deficient synthesis) with slight differences. Mutant N74S showed
genome-deficient synthesis strictly at 38°C but also mRNA and antigenome synthesis
declined compared to mutant virus S96G which displayed consistent production of
mRNA and antigenome (Figure 5.8). This could be explained by the fact N74S is
more sensitive at 38°C. Mutant viruses K228T and G230R are early replication step
(antigenome-deficient synthesis). While mutant G230R is early replication step at
both 37°C and 38°C, mutant K228T only at 38°C. These results demonstrate that
BUNV N protein plays a role in regulation of virus transcription and replication.
It is worth noting that only one ts mutant previously had been mapped to the S
segment of bunyaviruses designated MAGts23(III) (Pringle and Iroegbu, 1982). It
displayed plating efficiency of 0.001 (plaques at 38°C /plaque at 31°C). However,
nucleotide sequence analysis of the S segment of MAGts23 (III) showed that the
mutation occurred at residue V85A in the N protein (conserved residue) and F71L in
the NSs protein (conserved residue) (D.C.Pritlove and R.M.Elliott, unpublished data).
At this stage, it is not clear whether the phenotype of MAGts23 (III) was due to
substitution in N ORF or NSs ORF or both. Mutation at residue V85A of BUNV N
protein was generated randomly and viable virus carries this mutation was
recovered. Temperature sensitivity results showed that mutant V85A showed
reduction of 1.4 log10 pfu/ml in virus titer and plating efficiency of 0.04. These results
suggest that MAGts23(III) was not ts due to the mutation in the N ORF only but also
due to the mutation in the NSs ORF.
Host-restriction tests showed that the parental virus grew similarly in all cell lines with
titers of 8.5 - 8.8 log10 pfu/ml (Table 5.4). Mutant virus Y23A was host-restricted in
2FTGH-V cells. It displayed greater than 100-fold reduction in virus titer in 2FTGH-V
cells compared to the titers in other cell lines. The ability of mutant virus Y23A to be
released from 2FTGH-V cells was measured by comparing the ratio between the
intracellular and the extracellular particles (Table 5. 5). Only 15% of the total amount
of mutant virus Y23A particles were released as extracellular particles compared to
30% released by the parental virus. These results suggest that mutant Y23A grew
poorly in 2FTGH-V cells since it showed greater than 2.0 log10 pfu/ml reduction in titer
and also has particle release deficiency since 85% of the total amount of the virus
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was still trapped inside the cells. MAGts23(III) was host-restricted on BS-C-1 cells
displaying at least 100-fold reduction in virus plaque-forming ability compared to on
BHK-21 cells. Mutant V85A produced similar titers (8.0-8.4 log10 pfu/ml) in all cell
lines used. It is possible that the host-restriction of MAGts23(III) was due to mutation
at residue F71L of NSs ORF, however, unless the two ORFs of the N and NSs
proteins can be reconstructed separately it is hard to tell at this stage whether the
phenotypic changes displayed by MAGts23(III) was due to mutation in N or NSs
ORF.
5.9. Summary
1- Single substitutions (e.g. G147A, M150A, I162A) in the BUNV N protein gene
reduce virus titre 100000-fold below the parental virus titre.
2- Single substitutions (e.g. F6A, Y23A, and E128A) in the BUNV N protein gene
generate mutant viruses that display 3 plaque phenotypes: large, medium and
pinpoint.
3- Single substitutions (N74S, S96G, K228T and G230R) in the BUNV N protein
gene produce ts mutant viruses with different phenotypes.
4- Single substitution Y23A in the BUNV N protein gene produce host-restricted
mutant virus in 2FTGH-V displaying greater than 2.0 log10pfu/ml reduction in
virus titre compared to other cell lines.
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Chapter 6. Characterization of the
nonrescuable N genes
6.1. Introduction
Fourteen mutant N genes carrying single mutations at highly conserved residues in
the BUNV N protein were nonrescuable (Figure 6.1). Six of these involved residues
that are conserved in the middle of N protein while eight amino acids are conserved
in the C-terminal region of BUNV N protein. The mutant N proteins displayed a wide-
range of activity in the BUNV minigenome system (Table 6.1 and Figure 6.2). Mutant
N proteins P125H, G131W, Y158N, Y176A, W213R and L226A were functional,
displaying 66%, 30%. 25%, 53%, 28% and 26% of the wt N protein activity
respectively. Moreover, mutant I231A showed activity similar to wt N protein activity.
The other mutant N proteins were weakly active or inactive in the BUNV minigenome
system. The BUNV N protein is multifunctional and several interactions can be
speculated: interaction between N molecules to form a chain of N proteins,
interaction with L polymerase during virus transcription and replication, interaction
with the genomic and antigenomic RNA backbone and interaction with the C-tails of
the glycoproteins during virus assembly. Hence, it is possible that some of these
mutations could affect one or more of the above interactions making the recovery of
the virus unachievable.
Mutant N proteins which were weakly active (I118N and L177A) or inactive (R94A,
W134A, Y141C, K179I and W193A) in the BUNV minigenome system might be
affected in interaction with L polymerase, and hence coimmunoprecipitation could be
used to test N-L interactions. Another possibility was an affect on N protein
multimerization, that could be examined by cross-linking experiments. Mutant N
proteins P125H, Y176A and I231A, which displayed high activity in the BUNV
minigenome system, may have affected another step such as RNP packaging.
Therefore these mutant N genes were introduced into the BUNV packaging assay to
reveal whether the mutant N protein was able to package the BUNV minigenome into
virus-like particles.
Finally, any effect on RNA synthesis could be assayed by northern blotting of RNA
extracted from the cells transfected with plasmids for attempted rescue.
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Figure 6.1. Positions of nonrescuable mutations in the BUNV N protein
sequence. Six residues are conserved in the middle of N protein while eight are
conserved in the C-terminal domain. Black lines indicate the conserved residues
among 51 orthobunyavirus N proteins.
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Table 6.1. Activity of nonrescuable N genes in the BUNV minigenome system.
N genes highlighted in bold were mutated specifically.
“Con” indicates conserved residue. (+) conserved residue among at least 20
orthobunyavirus N proteins, (++) conserved residue among at least 30
orthobunyavirus N proteins, (+++) conserved residue among at least 40
orthobunyavirus N proteins, (++++) conserved residue among all orthobunyavirus N
proteins.
%: Activity of mutant N proteins compared to 100% activity of wt BUNV N protein.
N gene Mutation
position
Nature of change Con* Activity
(%)
R94A
365, C → G
366, G → C
Polar+  nonpolar (small)
++++ 0.17
I118N
438
T → A
Nonpolar (hydrophobic)  polar = (amide)
+ 11
P125H
459
C → A
Polar = (hydrophobic)  polar +
++++ 66
G131W
476
G → T
Nonpolar (small)  aromatic
++++ 30
W134A
485, T → G
486, G → C
Aromatic  nonpolar (small)
++++ 1.9
Y141C
507
A → G
Aromatic  polar = (nucleophilic)
++++ 1.8
Y158N
557
T → A
Aromatic  polar = (amide)
++++ 25
Y176A
611, T → G
612, A → C
Aromatic  nonpolar (small)
+ 53
L177A
613, C → G
614, T → C
615, T → G
Nonpolar (hydrophobic)  nonpolar (small)
++ 10
K179I
621
A → T
Polar +  nonpolar (hydrophobic)
++++ 4
W193A
662,T → G
663, G → C
Aromatic  nonpolar (small)
++++ 3
W213R
722
T → C
Aromatic  Polar +
++++ 28
L226A
761, C → G
762, T → C
763, T → C
Nonpolar (hydrophobic)  nonpolar (small)
++++ 26
I231A
775, A →G
776,T → C
Nonpolar (hydrophobic)  nonpolar (small)
+++ 102
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Figure 6.2. Activity of nonrescuable mutant N genes in the BUNV minigenome
system.
BSR-T7/5 cells were transfected with 0.2µg of pT7riboBUNN or mutant clone,
0.2µg of pT7riboBUNL, 0.2µg of pT7riboBUNMRenilla (-) and 0.1µg pT7-FF-
luciferase. Cells were incubated overnight at 33˚C and were lysed and luciferase
activity was measured.
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6.2. Quick-Change Directed mutagenesis on pTM1BUNN construct
As mentioned previously, both random and targeted mutagenesis were performed on
plasmid pT7riboBUNN rather than plasmid pTM1BUNN. The pT7riboBUNN construct
is an antigenome expression plasmid which contains the viral sequence cloned in the
positive sense between the T7 promoter and hepatitis δ ribozyme, followed by the T7
terminator immediately downstream. It is designed for use in the BUNV rescue
system to further investigate the functionality of the N protein. The pTM1BUNN
plasmid contains the N ORF cloned between the EMCV IRES and T7 terminator. It is
designed for protein expression and its expression is 10-fold higher than
pT7riboBUNN due to the IRES sequence. For protein-protein interaction studies the
pTM1BUNN plasmid was considered more appropriate, and hence a new series of
mutagenesis reactions was performed on pTM1BUNN to generate the same
nonrescuable N proteins.
6.3. Co-immunoprecipitation
Mutant N proteins R94A, W134A, Y141C, K179I and W193A were inactive in the
BUNV minigenome system, displaying less than 5% of the wt BUNV N protein
activity. One reason might be that these residues are involved in interaction with L
polymerase. To test this hypothesis, BSR-T7/5 cells were transfected with 0.1µg
each of pTM1BUNN or mutant clone, pTM1BUNL and 0.2 µg of pT7riboBUNMRenilla
(-) using Lipofectamine-2000 for 5 hours at 37˚C. The transfection mixture was
replaced with fresh medium, and the cells were incubated at 33˚C overnight.
Coimmunoprecipitation was performed using antibodies against N protein as
described in section 2.2.2.8. Two strong bands L and N were visualised in BUNV-
infected cells or cells transfected with wt BUNV N and L clones, indicating that N
protein interacts effectively with the L protein (Figure 6.3). The band above the L
band was observed in all transfected cells including the mock-transfected cells which
suggests it is a cellular band. In general, the mutant N proteins interacted less
effectively with L protein compared to the wt N protein. However, the weakest
interactions were observed when mutant N proteins I118N, W134A and Y141C were
used.
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Figure 6.3. Co-immunoprecipitation of BUNV L and N proteins.
BSR-T7/5 cells were transfected with 0.1 µg of pTM1BUNN or mutant clone,
0.1 µg of pTM1BUNL and 0.2µg of pT7riboBUNMRenilla (-). Cells were
incubated overnight at 33˚C and coimmunoprecipitation performed using anti
BUNV N protein antibodies.
Mock: mock transfected BSR-T7/5 cells
BUNV: BUNV -infected Vero-E6 cells was used as marker
Band above L is cellular band
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L band
density
AU/mm2
N band
density
AU/mm2
Ratio N/L
Amount of N
(%)
wt N 109461.6 335845.7 3.0:1.0 100
R94A 34957.5 303406.5 9.0:1.0 90
I118N 33960.4 210920.3 6.0:1.0 63
W134A 27863.6 162885 6.0:1.0 48
Y141C 24420.1 121062.6 5.0:1.0 36
W193A 67649.7 322747.5 5.0:1.0 96
K179I 69049.9 307746.6 5.0:1.0 91
Table 6.2. Ratio density of N to L bands and amount of mutant N proteins to wt N
protein using densitometry.
AU: absorbent units
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At this stage, it was not clear whether the poor interactions observed were due to low
amounts of mutant N proteins expressed or to binding deficiency to L. To determine
the latter hypothesis, the ratio of the density of N to L bands, and density of mutant N
protein bands to wt N protein band were measured (Table 6.2). The ratio of wt N to
wt L bands was 3:1. Overall, mutant N proteins displayed ratio ≥ 5:1. The highest
ratio was found when mutant N protein R94A was used. It displayed ratio 9:1
although the amount of mutant N protein R94A expressed represented 90% of the
amount of wt N protein. Mutant N proteins I118N, W134A and Y141C showed the
lowest amount of N protein expressed 63%, 48% and 36% respectively of the
amount of wt N protein. They showed almost similar ratios to L of 5-6:1. Conversely,
mutant N proteins K179I and W193A showed 91% and 96% of the amount of wt N
protein respectively but they displayed similar ratios to mutant N proteins I118N,
W134A and Y141C.
6.4. Multimerization of nonrescuable mutant N proteins
The ability of individual N molecules to form multimers was tested using a cross-
linking experiment (Leonard et al., 2005). Vero-E6 cells were infected with vaccinia
virus vTF7-3 at MOI of 1 for 1 hour at 37˚C. The virus was removed and cells were
transfected with 1 µg of pT7riboBUNN or mutant clone. The cells were treated with
1mM DSP, a cross-linking agent that creates a disulfide bridge between two reactive
primary amines. As the bridge contains thiol-thiol interactions it can be broken by the
addition of β-mercaptoethanol to the protein loading buffer.
Using the DSP cross-linking agent wt BUNV N protein shows a ladder of protein
bands, monomers, dimers, trimers, tetramers and higher multimers towards the top of
the gel, with molecular weights corresponding to multiples of 25kDa. Five mutant N
proteins (R94A, I118N, W134A and Y141C) were shown to be unable to form
multimers (Figure 6.4). In common, all of these are inactive in the BUNV minigenome
system so the multimerization results were expected. Mutant N protein W193A was
able to form multimers although it was inactive in the BUNV minigenome. Mutant N
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Figure 6.4. Cross-linking of nonrescuable mutant N proteins.
Vero-E6 cells were infected with vTF7-3 and transfected with 1 µg of
pT7riboBUNN or mutant plasmid. N proteins were cross-linked using PBS
containing 1mM DSP. The samples were then electrophoresed on a 12%
protein gel. To break down x-links, β-mercaptoethanol was added to the protein
loading buffer as negative control lane Wt N (-).
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Table 6.3. Relative expression levels of mutant N protein monomers using
densitometry.
N monomer band
density
AU/mm2
Mutant N / wt N
(%)
wt 435655 100
R94A 140246 32
I118N 73795 17
P125H 425701 98
W134A 197001 45
Y141C 102100 23
Y158N 400423 92
Y176A 296304 68
L177A 230255 53
K179I 370759 85
W193A 338177 77
W213R 35478 81
L226A 393326 90
I231A 356695 82
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proteins L177A, K179I and I231A were seen to be deficient in higher multimerization.
Mutant N protein L177A formed a decent monomer signal and a very weak signal of
dimmers, but no further multimers. Mutant N proteins K179I and I231A were not able
to form oligomers. All functional mutant N proteins in the BUNV minigenome system
were shown to be multimerization competent.
Measuring the density of the N monomer bands by densitometry as a measure of
expression efficiency (Table 6.3) showed that mutant N proteins R94A, I118N,
W134A and Y141C displayed 32%, 17%, 45% and 23% of the amount of the wt N
protein respectively. These mutant N proteins that failed to form high multimers
(L177A, K179I and I231A) showed no expression deficiency displaying 53%, 85%
and 82% of the amount of the wt N protein respectively.
6.5. RNA synthesis by nonrescuable mutant N genes
It is possible that some mutant N genes were not recovered due to RNA synthesis
deficiency during the rescue experiment. In the BUNV rescue system, the
pT7riboBUN-N, -M and -L constructs are transcribed by the T7 polymerase to
produce full length transcripts. The transcripts contain hepatitis δ ribozyme sequence
which promotes a self-cleave to produce the full length antigenomic viral RNAs. The
latter is encapsidated by the N protein and is used as a template to produce full
length genomic RNAs.
To investigate whether there was a deficiency in RNA synthesis, BSR-T7/5 cells were
transfected with 0.2 µg of each pT7riboBUNN or mutant clone, pT7riboBUNM and
pT7riboBUNL using Lipofectamine-2000 (Invitrogene) for 5 hours at 37˚C. The
transfection mixture was then removed and replaced with fresh medium. The cells
were incubated overnight at 33˚C. RNA extraction was performed using TrIzol
reagent and a northern blotting analysis was carried out. Using a positive-sense DIG-
labelled probe the S genomic RNA can be detected. In a separate blot a negative-
sense DIG-labelled probe was used to detect the S primary T7 transcript, and the
antigenomic RNA produced after processing by the ribozyme.
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Figure 6.5. RNA synthesis by nonrescuable mutant N genes.
BSR-T7/5 cells were transfected with 0.2 µg of each pT7riboBUNN or
mutant clone, pT7riboBUNM and pTriboBUNL. After an overnight incubation
at 33˚C total RNA was extracted using TrIzol reagent and northern blotting
analysis was performed. To detect the S segment primary transcript and
antigenomic RNA, a negative DIG-labelled probe was used. Using a
separate blot, a positive DIG-labelled probe was used to detect the S
genomic RNA. As a negative control of the genomic RNA synthesis, BSR-
T7/5 cells were transfected only with pT7riboBUNN. After an overnight
incubation at 33˚C total RNA was extracted using TrIzol reagent and
northern blotting analysis was performed. Using a negative DIG-labelled
probe primary T7 transcript and antigenome can be detected. Genomic RNA
can not be detected when a positive DIG-labelled probe was used since
there was no replication took place.
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All constructs produced both the unprocessed T7 transcript and the processed
antigenome RNA An additional band was detected, when the negative-sense DIG-
labelled probe was used, between the full length transcript unprocessed by ribozyme
and the full length genomic RNA; the origin of this band is unknown (Figure 6.5).
Six mutant N genes (I118N, P125H, G131W, Y158N, L226A and I231A) showed no
deficiency in genomic RNA synthesis. However, mutations at residues R94A,
W134A, Y141C, Y176A, L177A, K179I, W193A and W213R affected genomic RNA
synthesis in that the hybridization signal was weak or badly detectable.
6.6. Modification of a BUNV packaging assay
A BUNV packaging assay was described previously (Shi et al., 2007). Briefly, BSR-
T7/5 cells are cotransfected with three pTM1-based plasmids encoding the viral
structural proteins, pT7riboBUNMREN(-) (BUNV minigenome) as well as pTM1-FF-
Luc as an internal control. At 24h post-transfection, cells are lysed and assayed for
luciferase activity as described by Kohl et al. (2004). The culture medium is cleared
of cellular debris and 1.5ml is transferred onto new BSR-T7/5 cells transfected 3 - 5
hrs earlier with pTM1BUNL and pTM1BUNN. Cells are incubated overnight and
assayed for Renilla luciferase activity.
This assay was modified as follows; BSR-T7/5 cells were transfected with three
pT7ribo-based plasmids encoding L, M and N viral proteins, the BUNV minigenome
plasmid and pT7-FF-Luc as an internal transfection control. After 24h incubation at
33˚C, cells were lysed and assayed for luciferase activity. The culture medium was
cleared of cellular debris and 1.5ml used to infect naive BSR-T7/5 or BHK-21 cells
(i.e. cells that had not been pretransfected as in the original method). The cells were
incubated overnight at 33˚C and assayed for Renilla luciferase activity. Firstly, the
affect of using mock or pretransfected BSR-T7/5 cells on Renilla luciferase activity
was compared (Figure 6.6). Renilla luciferase activity was easily measured when the
infectious supernatant was transferred to mock BSR-T7/5 cells rather cells
pretransfected with L and N plasmids, giving about 40% activity obtained when viral L
and N proteins were previously expressed. The modified protocol was used as it
reduces the amount of plasmids needed and saves time.
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Figure 6.6. The affect of using mock or pretransfected BSR-T7/5
cells on the activity of BUNV minigenome.
BSR-T7/5 cells were transfected with 0.2µg of each pT7riboBUNN,
pT7riboBUNL, pT7riboBUNMREN(-), 0.1µg pT7riboBUNM and 0.1µg pT7-
FF-luc. At 24hr postinfection, the supernatant was clarified and 1.5ml was
transferred onto BSR-T7/5 cells pretransfected with pT7riboBUNL and N,
just pT7riboBUNL, just pT7riboBUNN or mock transfected. Luciferase
activity was measured 20 hrs later.
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6.7. Activity of nonrescuable mutant N proteins in BUNV packaging
assay (virus-like particle assay)
Only the functional mutant N proteins (P125H, G131W, Y158N, Y176A, W213R,
L226A and I231A) in the BUNV minigenome system were used in the BUNV
packaging assay to test their ability to form infectious virus-like particles (VLPs)
(Table 6.4 and Figure 6.7). Packaging activity was taken as 100% when the wt N
protein was used. The weakest packaging activity was observed when mutant N
proteins Y158N, W213R or I231A were used in this assay displaying only 12% of its
transcription and replication activity. Mutant N proteins P125H, G131W, Y176A and
L226A displayed packaging activity of 29%, 42%, 36% and 66% respectively.
6.8. Discussion
Fourteen mutant N genes were nonrescuable. Seven mutant N proteins (R94A,
I118N, W134A, Y141C, L177A, K179I and W193A) were very weak or inactive in
BUNV minigenome system, displaying between 0.17-11% of the wt N protein activity.
The remaining 7 mutant N proteins (P125H, G131W, Y158N, Y176A, W231R, L226A
and I231A) were functional in BUNV minigenome system, showing between 25-95%
of the wt N protein activity (Table 3.16 and Figure 2.24). The failure to rescue viruses
containing these mutations in the N protein could be due to deficiency in N-L
interaction, N-N molecules interaction, N-RNA interaction or N-glycoproteins
interaction.
The residues thought to be involved in interaction with BUNV L polymerase were
R94A, I118N, W134A, Y141C, K179I and W193A since they were almost inactive in
the BUNV minigenome system. Coimmunoprecipitation results (Figure 2.25) showed
the latter mutant N proteins have deficiency in interaction with L protein but to
different degrees. Interaction of mutant N proteins I118N, W134A and Y141C with L
protein was very weak. Two possibilities may explain this weakness, either these
mutations affected N-L interaction directly or the mutant N proteins were being
degraded which affected the amount of N protein which in turn affected N-L
interaction. The residues most probably affecting interaction of N-L were R94A,
K179I and W193A since the N bands of these mutant protein were almost equivalent
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Table 6.4. Normalized BUNV minigenome packaging activity
BSR-T7/5 cells were transfected with pT7riboBUNN or mutant clone,
pT7riboBUNM and pT7riboBUNL plasmids encoding BNUV N, M and L viral
proteins, pT7riboBUNMRenilla(-) (minigenome) and pT7-FF-luciferase as
internal control of transfection efficiency using Lipofectamine-2000 reagent for 5
hrs at 37˚C. Transfection mixture was then removed and replaced with 2ml fresh
medium and cells were incubated overnight at 33˚C. The supernatant was then
collected and cleared from cell debris by centrifugation. Luciferase assay was
performed on cells and the results represent BUNV minigenome transcription
and replication activity (a). The previous supernatant was transferred onto mock
BSR-T7/5 cells and incubated overnight at 33˚C. Cells were lysed and luciferase
assay was performed. The obtained results represent BUNV minigenome
packaging activity (b). The negative control of the packaging activity parental (-)
was transfection of all the above plasmids except pT7riboBUNM which encodes
BUNV glycoproteins so only BUNV minigenome transcription and replication
can be measured and no VLPs are produced.
Minigenome
transcription and
replication activity
Light units (a)
Minigenome packaging
activity
Light units (b)
N gene
Firefly Renilla Firefly Renilla (%)
wt (+) 2242 3258 2.0 2458 100
wt (-) 2239 3164 1.4 5.5 0.26
P125H 1723 1680 1.3 375 29
G131W 2290 810 1.7 258 42
Y158N 1860 736 1.1 69 12
Y176A 2313 915 1.4 256 36
W213R 1886 630 1.0 56 12
L226A 2303 639 1.2 321 66
I231A 2140 2390 1.1 213 12
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Figure 6.7. BUNV minigenome transcription and replication activity (a), BUNV
minigenome packaging activity (b).
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to the wt N band but the L protein bands were weaker than those produced when the
wt N protein was used . To confirm the above hypothesis, the ratio of the density of
the bands (N to L) calculated by densitometry and density of mutant N proteins
bands compared to wt N protein band, were determined (Table 3.17). The weakest
N-L interaction was observed when mutant N R94A was used, since the ratio of
mutant N protein R94A to L protein was about 9:1, that is three fold higher than the
ratio of wt N protein to L protein (3:1). The amount of mutant N protein R94A
presented 90% of the amount of the wt N protein. This suggests that residue R94A
affects interaction of N-L directly. Mutant N proteins I118N, W134A and Y141C
showed similar ratios 5-6:1, which is twice that shown by wt N protein, but the
amounts of mutant N protein were 63%, 48% and 36% respectively of the amount of
wt N protein. This could explain why weak interaction was observed between the
latter mutant N proteins and L protein. These mutant N proteins might be degraded
and further investigation needs to be done, for example using the proteosome
inhibitor MG-132 to find out whether the low amount of mutant N protein was due to
cellular degradation or expression deficiency in the first place. Residues K179I and
W193 apparently seem less involved in interaction with L protein than residue R94A,
and displayed ratio of 5:1 although expression of the mutant N proteins was almost
equivalent to wt N protein.
Using the cross-linking reagent DSP, Leonard et al. (2005) found that deletion of the
first 10 aa of BUNV N protein affected N multimerization. BUNNdel1-10 was unable
to form oligomers beyond dimers compared to the wt N protein. Furthermore, a
mutant BUNV N protein lacking the last 17 aa was generated. BUNNdel217-233
showed the ability to form dimers and weak signals of trimers but not higher
multimers. This study suggested that BUNV N protein molecules form head-head and
tail-tail interactions. The ability of the nonrescuable mutant N proteins to form
multimers was tested using cross-linking experiment (Figure 2.26). Mutant N proteins
R94A, I118N, W134A and Y141C were weakly active or inactive in BUNV
minigenome system and their ability to form oligomers was unlikely since they might
affect protein expression or stability in the first place. This was confirmed by
measuring the density of the N monomer bands of mutant N proteins as a measure
of expression efficiency. They displayed 32%, 17%, 45% and 23% of the amount of
the wt N protein respectively. Surprisingly, mutant N protein W193A was inactive in
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BUNV minigenome but still able to multimerize. Previously, coimmunoprecipitation
showed interaction of mutant N protein W193A with L was weak which could explane
the disfunctionality of mutant N protein W193A in BUNV minigenome system. Clearly
residue W193 is not involved in multimerization of BUNV N protein. Mutant N proteins
L177A, K179I and I231A were unable to form high multimers. The amount of mutant
N proteins expressed were 53%, 85% and 82% respectively. The failure of mutant N
protein L177A in multimerization could be due to low level of expression but this is
not the case for mutant N proteins K179I and I231A since they displayed more than
80% of the amount of the wt N protein.
RNA synthesis of the nonrescuable mutant N genes was carried out. It was though,
those mutant N proteins that fail to form multimers (R94A, I118N, W134A, Y141 and
L177A) were more likely to show deficiency in RNA synthesis since the antigenomic
RNA must be encapsidated by N protein to be used as a template for genomic RNA
synthesis, a finding that was subsequently confirmed with exception of mutant N
protein I118N (Figure 2.27). Although mutant N protein I118N showed an inability to
form multimers, it had no affect on genomic RNA synthesis. The latter residue might
affect mRNA synthesis since it was very weak in BUNV minigenome system. Despite
mutant N protein W193A being able to form multimers, mutant N gene carrying this
mutation was incompetent for genomic RNA synthesis. Moreover, mutant N proteins
Y176A and W213R were functional in BUNV minigenome, competent in
multimerization but they affected genomic RNA synthesis. As mutant N proteins
R94A, I118N, W134A, Y141C, L177A, K179I and W193A were inactive in the BUNV
minigenome system and affected genomic RNA synthesis , there was no need to
introduce them to the BUNV packaging assay since it was obvious that these
mutations affect the N protein functionality prior to the packaging step (transcription
or replication). On the other hand, the nonrescuable mutant N proteins (P125H,
G131W, Y158N and I231A) were functional in the BUNV minigenome system, able to
form multimers and had no impact on RNA synthesis. This suggested that these
residues might affect N protein functionality beyond transcription and replication.
In other words, these mutant N proteins encapsidate the BUNV minigenome RNA
and transcriptionally active RNP is produced. To test the ability of RNP to be
packaged into VLPs, the above mutant N proteins were used in the BUNV packaging
assay (Table 3.18 and Figure 2.29). BUNV minigenome showed a dramatic decline
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in its packaging activity when mutant N proteins Y158N, W213R and I231A were
used, displaying only 12% of the initial activity (transcription and replication activity).
The latter residues might be involved in interactions with the C-tails of the
glycoprotein. Residue L226 had no impact in BUNV minigenome packaging activity
since its packaging activity 3-fold higher than transcription and replication activity.
Likewise, residue G131W displayed no impact in BUNV minigenome packaging
activity. When mutant N protein G131W was used in this assay BUNV minigenopme
displayed packaging activity twice its transcription and replication activity. In general,
mutant N proteins G131W, Y176A and L226A did not affect BUNV minigenome
packaging activity since the minigenome displayed packaging activity higher than
transcription and replication activity. In common, mutant N proteins G131W, Y176A
and L226A behave almost similarly in BUNV minigenome system displaying 24%,
28% and 20% respectively of the wt N protein activity, were able to multimerize, did
not affect genomic RNA synthesis (except Y176A) and did not affect packaging of the
minigenome. Residues G131W and L226A might be involved in N-RNA interaction.
6.9. Summary
The nonrescuable mutant genes were characterized via their activity in the BUNV
minigenome system, their ability to form multimers, their ability to interact with L
protein, their impact in RNA synthesis and their impact in packaging of the
minigenome (Table 6.5).
1- Residues W134A and Y141C might affect N protein stability.
2- Residue I118N might affect mRNA synthesis
3- Residue R94A could be involved in interaction with L protein.
4- Residues Y176A, L177A, K179I, W193A and W213R are involved in genomic
RNA synthesis.
5- Residues G131W, Y176A and L226A might be involved in N-RNA interaction.
6- Residues Y158N, W213R and I231A might be involved in interactions with the
C-tail of the glycoproteins.
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N gene Con
(%)
Minigenome
transcription &
replication
Activity (%)
Ability to form
multimers
Genomic
RNA
synthesis
Mimigenome
packaging
activity (%)
R94A 100 0.17 - - -
W134A 100 1.9 - - -
Y141C 100 1.8 - - -
L177A 68 10 - - -
K179I 100 4.0 - - -
I118N 43 11 - + -
I231A 78 102 - + 12
Y176A 41 53 + - 36
W193A 100 3.0 + - -
W213 100 28 + - 12
P125H 100 66 + + 29
G131W 100 30 + + 42
Y158N 78 25 + + 12
L226A 72 26 + + 66
Table 6.5. Summary of characterization of nonrescuable mutant N proteins.
Con: Conservation among 51 orthobunyavirus N proteins
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Chapter 7. Conclusions
7.1. BUNV N protein functional domains in advance of its
3D structure
Previously, it has been demonstrated that the first 10 aa and the last 17 aa of BUNV
N protein are important for N molecule multimerization (Leonard et al., 2006). The
aim of this project was to determine the linear domain map of BUNV N protein in
advance of its 3D structure determination. The introduction of 102 single amino acid
substitutions in BUNV N protein sequence enabled me to determine some crucial
residues in BUNV N protein functionality (Figure 7.1). Using several established
techniques, this work demonstrates that single amino acid changes in the BUNV N
protein can cause:
• Disruption of BUNV minigenome transcription and replication (e.g. W134A, Y141C)
• Disruption of BUNV-like particle assembly (e.g. I231A).
• Disruption of BUNV genomic RNA synthesis (e.g. W193A, K179I).
• Reduction of virus titer 100000-fold (e.g. F6A, M150A).
• Production of distinct plaque phenotypes (small, medium or large).
• Generation of ts mutant viruses (e.g. N74S, K22T).
It is very clear from the above observations that the BUNV N protein is multifunction,
being involved in several interactions: N-N molecules to form chain of N molecules,
N-L polymerase during virus transcription and replication, N- RNA backbone and N-C
tail of the glycoproteins during virus assembly underneath the Golgi membrane.
It is possible that residues in the C-terminus of N protein come together with residues
in the middle performing the same function when the N protein is folded. The 3D
structure determination is only the way to demonstrate this hypothesis. So far,
residues in the middle of BUNV N protein (aa 94 -158) and the C-terminus (aa176-
231) appear crucial for N protein functionality with single mutations in these regions
causing marked disruption to several specific functions of BUNV N protein.
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Figure 7.1. Preliminarily BUNV N protein domain map
1 N-terminus 77 Middle 154 C-terminus 233
aa 1-10 and aa 216-233 N-N interaction
aa 94-141 N-L interaction (transcription or replication)
aa Y158N, W213R and I231A N-glycoprotein interaction
aa Y176A-W213R genomic RNA synthesis
Chapter 7. Conclusions
194
7.2. 3D structures of NSVs
The molecular design of all single-stranded, negative-sense RNA viruses is
essentially similar. Segmentation of the virus genome is a common, although not
universal, feature of such viruses. The RNA genome and a basic nucleocapsid (N)
protein condense together in the infected cell to form a helical structure. The
individual N protein monomer covers about nine nucleotides of the RNA genome and
protects it from chemical and physical injuries. An outer lipid envelope derived from
the host cell membrane surrounds the nucleocapsid core.
This category includes many of the best known human pathogens such as influenza
virus (Orthomyxoviridae), rabies virus (Rhabdoviridae), and measles virus
(Paramyxoviride). By comparing the nucleocapsid proteins of these infectious agents
we may finally speculate about the 3D structure of the BUNV N protein.
Influenza A virus is a segmented negative sense RNA virus. The N protein (55kDa) is
transported from the cytoplasm of infected cells to the nucleus via two nuclear
localization signals, residues 1-38 (Neumann et al., 1997) and residues 198-216
(Weber et al., 1998). Using electron microscopy, viral RNPs were observed as
supercolied structures containing a terminal loop (Compans et al., 1972; Heggeness
et al., 1982). The genome RNA is susceptible to RNase digestion (Baudin et al.,
1994). The three-dimensional reconstitution reveals that each ring consists of 9 N
protein molecules, and the viral polymerase was visualized as binding directly to two
subunits of the ring (Martin-Benito et al., 2001) (Figure 7.2). The N molecules of
influenza A virus interact through one point of contact (Figure 7.5a) which gives the
RNPs more flexibility (Schoehn et al., 2004).
RV is an enveloped, non-segmented negative-sense RNA virus. The N-terminus of N
is essential for N-N and N-RNA interactions while the C-terminus is involved in
interactions with phosphoprotein (P). The 3D structure of RV RNP (Figure 7.3)
shows that each ring consists of 10 N molecules (Schoehn et al., 2001). The N
molecules are bi-lobed in shape with two binding sites (Figure 7.5b) at the top and
bottom of each lobe while the middle of each monomer is not involved in N protein
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molecule interactions. They assemble into ring structures, each ring consisting of 9 to
11 monomers. 3D reconstruction of N-RNA complexes show the RNA is located on
the top of the rings, however, conformational change occurs in N which leads to
relocation of the RNA inside N protein. Major differences between N-RNA complexes
in infected cells and virions have been observed (Newcomb et al., 1982; Schoehn et
al., 2001). In the infected cells each ring consists of 15 monomers instead of 10, a
result of the longer RNA converting the shape to a loose helical structure. In virions,
condensation of the helix causes monomers to from tighter structures of 54
monomers per turn. The latter observation is though to be due to interaction of the
matrix protein with the RNP (Newcomb and Brown, 1981, Newcomb et al., 1982).
The RNP is resistant to RNase treatment and each N molecule covers 9 nucleotides.
Trypsin treatment of RNP caused removal of the C-terminal domain of N, but the
RNP structure shows major changes (Kouznetzoff et al., 1998) and does not linearize
(Iseni et al., 1998).
Measles virus (Paramyxoviridae) is an enveloped, nonsegmented negative-strand
RNA virus. It has been found that the N-terminus of N protein is crucial in N molecule
interactions and RNA binding (Buchholz et al., 1993). In measles virus N protein,
deletion of aa 189-373 disrupted N self-association while aa 240-303 were essential
for N protein stability (Bankamp et al., 1996). Furthermore, Liston et al. (1997) found
that two regions of measles N protein (aa 267-367 and the C-terminal 122 amino
acids) were involved in interactions with phosphoprotein (P). It has been speculated
that the presence of the P protein reduces the possibility of encapsidation of non-viral
RNA by N protein (Spehner et al., 1997). Study of measles virus N protein by
electron microscopy showed that each helical turn consists of 13 N protein molecules
(Figure 7.4). Two sites of interaction were detected between each two monomers of
N protein (Figure 7.5c). The N-RNA stoichiometry is 6 bases per N molecule
(Egelman et al., 1989). As for RV, the RNP of paramyxovirus is resistant to RNase
degradation.
It is possible that the 3D structure of BUNV has elements of both influenza virus and
rabies virus 3D structures since BUNV is segmented and the genome is wrapped by
the N protein. BUNV N protein has been preliminarily crystallised by sitting-drop in
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solution containing 0.1M acetate buffer pH 6.0, 20% PEG 4K and 0.2M ammonium
sulphate (Figure 7.6). Further optimisation for better X-ray diffraction quality crystals
is ongoing (P.Li and R.M.Elliott, personal communication). It will be more instructive
to map all mutations with new phenotypes in the 3D structure of BUN N protein to
produce a clear insight of the real position of such residues. Such data would confirm
several hypotheses such as interaction of N molecule by head-to-head and tail-to-tail
association (Leonard et al., 2005). Moreover, 3D structure determination of BUNV N
protein would provide information on the location of the RNA as well as the
mechanism of transcription and replication by viral L polymerase.
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9-mers ring L polymerase
Figure 7.2. Three-dimensional model of a recombinant influenza virus mini-
RNP. (A) Perspective view. (B) Side view. (C)Top view. (D) Bottom view
(taken from Martin-Benito et al., 2001).
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Figure 7.3. Rabies virus N-RNA complexes. 3D of N from the side (a), tilted
(b), from the bottom(c), and from above (d), helical structure side view with
an indication of the diameters (e) (taken from Schoehn et al., 2001).
10 mers ring
Loosely
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a
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Figure 7.4. 3D structure of recombinant measles virus nucleocapsid
protein. Helical structure from the surface with 54Å pitch nucleocapsid
comprising 13.04 subunits per turn (a), schematic representation of
measles RNP (b) (taken from Behlla et al., 2004).
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a b c
Figure 7.5 . Interaction domains of NSV N proteins. Influenza virus N
molecules interact through a single point of contact (a), there are two points of
contact between the N molecules of rabies and measles viruses (b and c)
(taken from Schoehn et al., 2004).
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Figure 7.6. BUNV N protein crystals (Courtesy of Dr. Ping Li).
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